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CHAPTER I 
 
ISOLATION, HYPOTHETICAL BIOSYNTHESIS AND BIOLOGICAL ACTIVITY 
OF APOPTOLIDINS  
 
 
1.1 Introduction 
As reported by the American Cancer Society, 7.6 million people died of 
various cancers in 2007 (http://www.cancer.org), cancer is one of the leading 
causes of morality worldwide. Clinically, cancer is defined as malignant 
neoplasm, a group of cells with uncontrolled growth properties and malignant 
behavior. The mechanism of cancer development is extremely complex, and is 
still not fully understood at the molecular or genetic level. However, it is widely 
accepted that genetic changes will disturb the balance between proliferation and 
apoptosis, activation of oncogenes leads to cell proliferation and resistance 
against programmed cell death, which initiates the development of cancers. 
During the progression of cancers, somatic alterations in oncogenes, tumor 
suppressor genes, and microRNA genes are observed.1  
Cancer chemotherapy is the use of cytotoxic drugs to kill cancer cells and 
currently one of the most effective methods to treat cancer. In a general sense, 
traditional chemotherapy acts by killing all quickly proliferating cells, either 
healthy or malignant. The major concern with conventional chemotherapy is 
insufficient selectivity, which causes severe side effects during the treatment. 
Today, cancer is viewed as a chronic disease. The goal of anticancer drug 
  2 
development is to find specific apoptosis inducing agents targeting only cancer 
cells with minimal effect on normal cells. 
Cells transformed with certain type of oncogenes can model key aspects 
of cancer. This provides a powerful screening system for the discovery of small 
molecules as specific anticancer drugs. Natural products continue to be one of 
the major sources for drug discovery.2 Screening natural products using cellular 
models is an effective strategy for discovery of a new generation anticancer 
agents for the treatment of specific types cancers. 
 
1.2 Isolation of Apoptolidin A-D and Hypothetical Biosynthesis 
In a screening program, initiated by Seto and coworkers in Japan, 
targeted to identify specific apoptosis inducing agents in E1A-transformed cells, 
an antinomycete secondary metabolite, apoptolidin A 1.1 (Figure 1.1), was 
isolated from the fermentation broth of Nocardiopsis. Sp. in 1997.3  
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Figure 1.1 Structure of Apoptolidin A (1.1) 
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Apoptolidin A 1.1 was isolated from the fermentation medium of producing 
microorganism Nocardiopsis. Sp. in the amount of 110 mg/L as reported by 
Seto’s group. The molecular formula of apoptolidin A 1.1 was determined to be 
C58H96O21 using high resolution FAB-MS.3 The two-dimensional structure and the 
stereochemistry were later elucidated by extensive NMR analysis and chemical 
degradation studies by the same group in 1998.4  Apoptolidin A 1.1 belongs to a 
family of macrocyclic polyketide type natural products. The structure of 
apoptolidin A 1.1 consists of a macrocylic aglycone and two α-linkaged sugar 
units located at C-9 and C-27. A novel sugar, 6-deoxy-4-O-methyl-L-glucose is 
connected to the aglycone at C-9.  A disaccharide located at C-27 consists of a 
D-oleandrose and a L-olivomycose interconnected through a β-glycoside linkage.  
The aglycone structure is composed of a highly unsaturated 20-membered 
macrolactone and a hemiketal pyranose populated with four stereogenic centers. 
The E geometry of all four tri-substituted olefins in the aglycone was assigned by 
COSY, HMQC, HMBC and ROESY analysis. The stereochemistry of the sugar 
units were used as an internal reference for the assignment of the absolute 
stereochemistry of apoptolidin A 1.1 by observed NOE correlations. 
Three minor congeners, apoptolidin B 1.2, apoptolidin C 1.3 and 
apoptolidin D 1.4 were later identified from the culture broth of the same 
microorganism by Wender’s group at Stanford University in 20055 and 2006, 
respectively (Figure 1.2).6 
Apoptolidin B 1.2 and apoptolidin C 1.3 were isolated from the culture 
medium in the amount of 2-5 mg/L.5 The molecular formulas for apoptolidin B 1.2 
  4 
and apoptolidin C 1.3 were determined to be C58H96O20 and C58H96O19 
respectively by high-resolution mass spectroscopy. Structure analysis reveals 
apoptolidin B 1.2 lacks one hydroxyl group at C-16 position, and apoptolidin C 
1.3 lacks two hydroxyl groups at the C-16 and C-20 positions. The remaining 
stereocenters of apoptolidin B 1.2 and C 1.3 were identical to apoptolidin A 1.1, 
established by extensive two-dimensional NMR data analysis (COSY, TOCSY, 
HMBC, HMQC, ROESY). 
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Figure 1.2 Structure of apoptolidin B (1.2), C (1.3), D (1.4) 
 
Apoptolidin D 1.4 is the most recent metabolite discovered in the 
apoptolidin family. The isolated yield of apoptolidin D 1.4 is 7 mg per liter of 
fermentation medium.6 Its molecular formula was determined to be C57H94O21 by 
high-resolution mass spectrometric analysis. Extensive NMR analysis revealed 
that apoptolidin D 1.4 lacks a C-6 methyl group in comparison to apoptolidin A 
1.1. The absolute stereochemistry of apoptolidin D 1.4 is identical to apoptolidin 
A 1.1. Once again, the four tri-substituted olefins present E-geometry. Apoptolidin 
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D 1.4 is the only apoptolidin that has a different carbon skeleton relative to 
apoptolidin A 1.1. 
The biosynthetic pathway leading to apoptolidin A 1.1 has not been 
elucidated. Hypothetically, either glycolate or its methoxy derivative may serve as 
a starter unit, which could be determined by examination of the PKS gene cluster 
of apoptolidin producer Nocardiopsis. Sp.7 The carbon chain is presumably 
extended with malonyl or methylmalonyl extender units, following reduction by 
ketoreductase and dehydratase in PKS and finally macrolactonization release the 
macrolide core from the PKS. Glycosylation is required to attach the sugar units, 
methylation of C-17 hydroxyl group, oxidation of C-16 and C-19 completes the 
unique structure of apoptolidin A 1.1. According to the above proposed 
biosynthetic pathway of apoptolidin A 1.1, apoptolidin B 1.2 and apoptolidin C 1.3 
are shunt metabolites, result of incomplete oxygenation. Apoptolidin D 1.4 is the 
biosynthetic product derived from incorporation of the malonyl extender unit in 
place of the methylmalonyl unit used for apoptolidin A 1.1 biosynthesis (Figure 
1.3).  
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Figure 1.3 Hypothetical Biosynthesis of Apoptolidins 
 
1.3 Discovery of Isoapoptolidin A, B, D 
In 2002, Wender and Sulikowski groups independently discovered an 
isomer of apoptolidin A 1.1 as the fermentation product of Nocardiopsis. Sp. 
Careful analysis of COSY and HMBC correlations revealed that this compound is 
the result of an acyl migration from the C-19 to C-20 hydroxyl group as shown in 
Figure 1.4.  This 21-membered macrolide was named as isoapoptolidin A 1.5.8,9 
The facile inter-conversion between apoptolidin A 1.1 and isoapoptolidin A 1.5 
produces an approximate 1:1 mixture in aqueous solution at ambient 
temperature. The isomerization of apoptolidin A 1.1 to isoapoptolidin A 1.5 could 
be catalyzed by triethylamine in methanol solution. Since apoptolidin B 1.2 and 
apoptolidin D 1.4 both feature a C-20 hydroxyl group, they can also establish 
equilibrium with their ring expansion isomers, isoapoptolidin B 1.6 and 
isoapoptolidin D 1.7 respectively.5  
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Figure 1.4. Stuctures of isopoptolidin A (1.5), B (1.6), D (1.7) 
 
The mechanism of ring expansion isomerization reaction can be 
rationalized as an intramolecular rearrangement through tetrahedral 
intermediates as shown in Scheme 1.1, a similar pathway was proposed for 
isomerization between bafilomycin  and isobafilomycin.10  
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Scheme 1.1 Isomerization between apoptolidins and isoapoptolidins 
 
1.4 Biological Activities of Apoptolidin A-D and Isoapoptolidin A 
Seto’s group used rat glia cells transformed with the adenovirus type 12 
oncogenes including E1A as an activity based screen leading to the identification 
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of apoptolidin A 1.1 from the extracts of Nocardiopsis Sp. The preliminary 
biological screening showed that apoptolidin A 1.1 induce programmed cell death 
only in E1A transformed glia cells with minimal effects on normal glia cells and 
other oncogenes transformed cells, such as 3Y-1 rat fibroblasts transformed with 
H-ras, v-src, and SV40 large T antigen. Seto’s group also observed that the 
apoptosis induced by apoptolidin A 1.1 was not suppressed by E1B gene 
products. The cytotoxicity of apoptolidin A 1.1 was observed over a 3-day cell-
assay as summarized in Table 1.1.3 
 
Table 1.1 Cytotoxicity of apoptolidin A (1.1) against transformed and normal cells 
 
Cell line Oncogene IC50 (ng/ml)
RG-E1A-7
RG-E1A19K-2
RG-E1A54K-9
RG-E1-4
Ad12-3Y1
Glia
E1A
E1A, E1B19K
E1A, E1B54K
E1A, E1B19K, E1B54K
E1A, E1B19K, E1B54K
            11
            10
            13
            10
            17
3Y1
HR-3Y1
SR-3Y1
SV-3Y1
H-ras
v-src
SV 40 large T antigen
> 100,000  
> 100,000
> 100,000
> 100,000
> 100,000  
 
 
Apoptolidin A 1.1 was discovered to be a highly selective and potent 
apoptosis inducing agent based on cell assays, which makes apoptolidin A 1.1 a 
very valuable candidate as an anticancer lead agent. The biological activity of 
apoptolidin A 1.1 was further evaluated against NCI-60 different human cancer 
cell lines, the results of this screening revealed that many cancer cell lines are 
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sensitive to apoptolidin A 1.1, and determined to be one of the most selective 
anticancer agents among more than 37,000 agents examined.11,12,13,14 
The cytotoxicity effects against H292 lung cancer cells showed that 
apoptolidin A 1.1, B 1.2, C 1.3 and D 1.4 can inhibit the cell growth in nanomolar 
range, among which, apoptolidin B 1.2 exhibited a slightly higher potency. 
Isoapoptolidin A 1.5 showed similar potency as apoptolidin A 1.1 in Ad12-3Y1 
transformed glia cells assay.5,6,15 
 
Table 1.2 Cytotoxicity of apoptolidin A-D and isoapoptolidin A 
 
Compounds             GI50(µM) (H292)         EC50(µM) (H292)            GI50(µM) (Ad12-3Y1)
Apoptolidin A (1.1)         0.032 + 0.003           0.050(0.025~0.100)                    0.0065
Apoptolidin B (1.2)         0.007 + 0.004               
Apoptolidin C (1.3)         0.024 + 0.005
Apoptolidin D  (1.4)                                         0.110(0.060~0.21)
Isoapoptolidin A (1.5)                                                                                          0.009
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CHAPTER II 
 
PREVIOUS SYNTHETIC STUDIES TOWARDS APOPTOLIDIN A AND 
APOPTOLIDINONE A 
 
 
2.1 Introduction 
Apoptolidin A 2.1, which can induce apoptosis in cancer cells with minimal 
effects on normal cells, is of potentially high significance in the treatment of 
cancers. Apoptolidin A 2.1 features a complex molecular architecture including 
25 stereocenters, a conjugated polyene system, and 3 carbohydrate units.  
These synthetically challenging attributes have attracted considerable interests 
from the synthetic community. Construction of this complex natural product in a 
convergent fashion poses an obvious challenge for synthetic chemists.  
Specifically, the acid and base labile nature of apoptolidin A 1.1 has to be 
carefully considered in planning the later stages of a total synthesis. To date, 
three total syntheses of apoptolidin A 2.116,17,18,19,20,21,22 and three total syntheses 
of apoptolidinone A 2.2 (the aglycone of apoptolidin A 2.1 as shown in Figure 
2.1) have been accomplished, including our group’s efforts directed towards the 
syntheses of apoptolidinone A 2.2.23,24,25 Several fragment syntheses have also 
been reported.26,27,28,29,30,31,32,33,34,35,36,37,38,39  
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Figure 2.1 Structure of apoptolidin A (2.1) and apoptolidinone A (2.2) 
 
2.2 Nicolaou’s Synthesis of Apoptolidin A 
 In 2001, Nicolaou’s group reported the first total synthesis of apoptolidin A 
2.1.16,17 As shown in Scheme 2.1, their synthetic strategy leading to apoptolidin A 
2.1 relied on the installation of sugar units at the later stage of the total synthesis. 
A Stille coupling reaction was used to install the C-11/C-12 bond, and Yamaguchi 
macrolactonization was utilized to form the 20 membered ring system. 
Retrosynthetic analysis indicates vinyl iodide 2.3, vinyl stannane 2.4, and 2 sugar 
units 2.5 and 2.6 as the key building blocks. In 2003, a second generation 
synthesis of apoptolidin A 2.1 was published, in which, more convergent 
synthetic routes for the construction of two of the major building blocks vinyl 
iodide 2.3 and vinyl stannane 2.4 was reported.18,19  
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Scheme 2.1 Strategic analysis in Nicolaou's syntheses of apoptolidin A (2.1) 
 
 The E-geometry in vinyl stannane 2.4 was realized by a palladium(0) 
catalyzed regioselective hydrostannylation from alkyne 2.7, which was originally 
prepared by a linear, iterative E-selective Wittig or Horner-Wadsworth-Emmons 
olefination-reduction-oxidation sequence on aldehyde 2.8, In the revised 
synthetic route, a Suzuki coupling strategy between vinyl bromide 2.10 and vinyl 
boronic acid 2.11 was employed. Vinyl bromide 2.10 was prepared from known 
vinyl bromide 2.12 by oxidation followed by E-selective Wittig olefination. Suzuki 
coupling partner, vinyl boronic acid 2.11 was prepared by chemoselective 
hydroboration with catecholborane on diyne 2.13 following an aqueous 
hydrolysis. Homologation with aldehyde 2.8 using the Ohira-Bestmann reagent 
followed by methylation of the terminal acetylene gave diyne 2.13. The 
stereochemistry at C-8 and C-9 in aldehyde 2.8 was set by Brown’s asymmetric 
crotylation with known propargylic aldehyde 2.9. 
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Scheme 2.2 Nicolaou's synthetic strategy for vinyl stannane (2.4) 
 
 The initial attempt to set the stereochemistry at C-19 and C-20 in the 
synthesis of vinyl iodide 2.3 depended on a chelation-controlled dithiane coupling 
reaction between dithiane 2.14 and aldehyde 2.15. However, the poor 
stereoselectivity prompted the evolution of a better strategy based on a late 
stage Sharpless asymmetric dihydroxylation of enone 2.19. Horner-Wadsworth-
Emmons olefination between phosphonate 2.20 and aldehyde 2.21 constructed 
the E-geometry in enone 2.19. The stereochemistry at C-16 in aldehyde 2.15 and 
2.21 were derived from commercially available pro-chiral starting material 2.16, 
the other stereocenter at C-17 in aldehyde 2.15 and 2.21 were established by 
Brown’s asymmetric allylation reaction. Both dithiane 2.14 and phosphonate 2.20 
were obtained from Weinreb amide 2.17, in which, the asymmetry was achieved 
by using pro-chiral epoxide 2.18, Brown’s asymmetric crotylation, and Evan’s 
asymmetric aldol reaction. 
  14 
O
MeO
OTBS
O
O
OMe
Me
OTBS
Me OMe
OTES
H
I
O
MeO
OTBS
Me
OH
I
O
OMe
OO
TBS TBS
OPMB
OMe
OTBSOTBSO
P
O
OMe
MeO
OTBS
OMe
H
O
OMe
S
S
Me Me
OPMBOTBSOTBS
OTBS
OMe
OH
O
OMe
O
OPMB
OMe
OTBSOTMSO
N
MeO
H
ODMB
O
2.3
2.14
2.15
2.16
2.17
2.18
2.19 2.20 2.21
16
17
17
16
19
20
 
Scheme 2.3 Nicolaou's synthetic strategy for vinyl iodide (2.3) 
 
 Two of the glycosyl building blocks 2.5 and 2.30 were synthesized starting 
from thioglycoside 2.25, which was prepared from L-rhamnose following known 
procedures. Glycosyl sulfoxide 2.5 was obtained after a series of protecting 
group manipulations and stereocenter inversion at C-2’ position by an oxidation-
reduction sequence. Phenylthioglycoside 2.30 was prepared from 2.25 over 12 
steps. The C-3’’ quatary methyl group in phenylthioglycoside 2.30 was introduced 
by chelation-controlled addition of methyl Grignard reagent. Phenylthioglycoside 
2.24 was synthesized from phenylthioglycoside 2.22 in two steps. Glycosylation 
between phenylthioglycosides 2.30 and 2.24 in presense of stannum (II) chloride, 
romoval of thiophenyl groups and benzyl protecting group provided a lactol 
intermediate 2.32, whch was converted to glycosyl fluoride 2.6 by treatment with 
DAST. Formation of the β-linkage in glycosyl fluoride 2.31 was directed by the C-
2’’’ phenylthio group in the glycosyl donor 2.24. 
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Scheme 2.4 Nicolaou's synthetic strategy for two sugar moieties 
 
 In the construction of apoptolidin A 2.1, the key coupling of fragment 2.3 
and 2.4 employed Stille reaction conditions to afford 2.33 in 86% yield. The C-9 
sugar moiety 2.5 was installed following the Kahne protocol. The ring-size 
selective macrolactone closing was realized under Yamaguchi conditions after 
hydrolysis of the corresponding methyl ester. The C-27 disaccharide moiety was 
installed by stannum (II) mediated activation of glycosyl fluoride 2.6 to afford the 
desired alpha stereochemistry. Finally, stepwise global deprotection gave the 
target molecule apoptolidin A 2.1. 
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Scheme 2.5 Nicolaou's Final Assembly of Apoptolidin A (2.1) 
 
2.3 Koert’s Synthesis of Apoptolidinone A and Apoptolidin A 
 In 2004, Ulrich Koert accomplished a total synthesis of apoptolidin A 2.1,20 
following their reported first total synthesis of apoptolidinone A 2.2 in 2001.23 The 
synthetic strategy adopted by Koert’s group was very similar to Nicolaou’s 
approach. However, in contrast to Nicolaou’s approach, the sugar moieties were 
introduced at an earlier stage of the syntheses, which increased the overall 
synthetic efficiency. A copper mediated cross-coupling reaction was selected to 
couple the two fully glycosylated northern building blocks 2.36 and southern 
building block 2.37 and form C-11/C-12 bond connection. Yamaguchi 
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macrolactionization was chosen to close the macrolide ring in a regio-selective 
fashion.  
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Scheme 2.6 Strategic analysis in Koert’s syntheses of apoptolidin A (2.1) 
 
The trienoate system in the northern building block 2.36 was prepared by 
iterative E-selective olefination. Vinyl iodide 2.39 was the glycosyl acceptor, and 
glycosylsulfoxide 2.38 was the glycosyl donor, coupling of these two partners, 
under Kahne’s glycosylation condition, gave the highest α–stereoselectivity. Vinyl 
iodide 2.39 was prepared from vinyl iodide 2.40. The stereocenters at C-8 and C-
9 in vinyl iodide 2.40 were derived from commercially available starting 
compound β-hydroxylactone 2.44. The southern building block 2.28 was 
prepared by an α–selective glycosylation of desilylated 2.42 with N-
iodosuccinimide activated disaccharide precursor 2.43, and a subsequent 
chelation-controlled Grignard addition of bromide 2.41. 
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Scheme 2.7 Koert's synthetic strategy for major building blocks 2.36 and 2.37 
 
 The stereochemistry at C-19 and C-20 in pyran 2.42 were set by 
substrate-controlled dihydroxylation on olefin 2.45, which was formed by addition 
of a vinyllithium reagent derived from vinyl iodide 2.47 to Weinreb amide 2.46, 
followed by a spontaneous ketal formation after protodesilylation. The C-17 
stereocenter was derived from chiral epoxide 2.51, a similar chiral epoxide used 
by Nicolaou’s group to introduce chirality at other centers in the apoptolidin 
backbone structure. Noyori’s asymmetric hydrogenation of β-keto ester 2.50 was 
employed to set the stereocenter at C-27. Evan’s dienolate addition and anti-
selective reduction were adopted to introduce the stereocenters at C-23, C-24 
and C-25 in Weinreb amide 2.46. 
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Scheme 2.8 Koert's synthetic strategy for vinyl iodide 2.40 and pyran 2.42 
 
The Koert’s group reported a total synthesis of apoptolidinone A 2.2 in 
2001. In which, vinyl iodide 2.40 was converted to vinyl iodide 2.52 following a 
reduction-oxidation-olefination sequence. Pyran 2.42 was transformed into vinyl 
stannane 2.53 by reductive debenzylation, Dess-Martin oxidation and chelation-
controlled addition of a Grignard reagent derived from bromide 2.41. The 
northern 2.52 and southern halves 2.53 were coupled together under copper 
promoted cross-coupling conditions, the following hydrolysis of the corresponding 
ethyl ester under basic condition, macrocylization under Yamaguchi’s condition, 
and global deprotection completed the total synthesis of apoptolidinone A 2.2. 
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Scheme 2.9 Koert's synthesis of apoptolidinone A (2.1) 
 
 Two carbohydrate units 2.38 and 2.43 were required in the synthesis of 
apoptolidin A 2.1. The glycosyl sulfoxide 2.38 was prepared from acetonide-
protected L-rhamnose thioglycoside 2.25, which was the same starting material 
used in Nicolaou’s preparation of C-9 sugar residue. Methylation of the 
secondary alcohol, removal of the acetonide protecting group, selective 
protection 4-hydroxyl as a TBS ether and Dess-Martin oxidation provided ketone 
2.26. Reduction of the ketone in 2.26 with NaBH4 and desilylation generated an 
intermediate diol, which was protected emplying a new protecting group, 1,1,4,4-
tetraphenyl-1,4-disilabutyl (SIBA). Then m-CPBA was used to convert the 
corresponding phenylthiol to glycosylsulfoxide 2.38. 
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Scheme 2.10 Koert's synthetic strategies for two sugar building blocks  
 
The C-27 disaccharide precusor 2.43 was prepared starting from L-
rhamnose 2.54 and D-glucal 2.57. Treatment of benzylidene protected methyl 
acetal with excess MeLi afforded diol 2.55 via a cyclohexenone intermediate.  
Selective acylation of the secondary alcohol, TES protection of the tertiary 
alcohol followed by cleavage of the acetate protecting group furnished olivomycal 
building block 2.56. The precursor of the glycosyl donor 2.59 was prepared from 
D-glucal 2.57. A 5-step protecting group manipulation provided a tosylate 2.58, 
which was converted to trichloroacetimidate 2.59 via a three-step reaction 
sequence. β-Selective glycosylation of 2.56 with 2.59 in presence of TMSOTf 
produced a disaccharide, which was reduced to give C-27 disaccharide building 
fragment 2.43.  
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Scheme 2.11 Koert's assembly of apoptolidin A (2.1) 
 
Copper (I) mediated cross-coupling conditions optimized by Koert’s group 
in the total synthesis of apoptolidinone A 2.2, worked well in the coupling reaction 
between fully glycosylated northern half 2.36 and southern half 2.37. 
Cyanomethyl ester 2.60 was then subjected to hydrolysis and Yamaguchi 
macrolactonization to produce the 20-membered macrolide. Global deprotection 
with H2SiF6 accomplished the total synthesis of apoptolidin A 2.1.  
 
2.4 Crimmins’s Syntheses of Apoptolidinone A and Apoptolidin A 
 In early 2009, Crimmins’s group claimed a total synthesis of apoptolidin A 
2.1 following their previously published total synthesis of apoptolidinone A 2.2 
and individual sugar units.22,25,32 Both Nicolaou and Koert divided the carbon 
backbone of apoptolidin A 2.1 into northern and southern halves at C-11/C-12 
bond and C-1/O-19 bond. Crimmins disconnected the macrolide skeleton at C-
  23 
10/C-11 and C-1/O-19 bonds, which was formed via a regio- and stereoselective 
cross metathesis reaction and a regio-selective Yamaguchi macrolactonization. 
As previous attempts to couple fully glycosylated northern half with fully 
glycosylated southern partner resulted unsuccessful, glycosylation of the C-9 
oxygen was performed after the cross metathesis, This completed syntheses 
established 12 of the 24 sterocenters of apoptolidin A 2.1 via diastereoselective 
aldol reactions with Crimmins’s thiazolidinethione chiral auxiliaries. 
 
Me
Me
Me
O
O
MeO
OH
Me
O
O
HO
HO
OMe
Me
HO
O
OH
OH
Me OMe
O
H
O
Me
O
OH
Me
O Me
OH
OMe
1
9
2721
16
12
Cross 
Coupling
Yamaguchi 
macrolactonization
Me
Me
Me
O
Me
HO
OEt
S(O)Ph
O
TBSO
TBSO
OMe
Me
Glycosylation
O
MeO
OTBSMe
O
O
OMe
Me
OTBS
Me OMe
H
O
O O
Me
O
OTES
Me
O Me
OTBS
OMe
2.1
2.61
2.622.5
 
Scheme 2.12 Strategic analysis in Crimmins’s synthesis of apoptolidin A (2.1) 
 
The diene unit in the southern part 2.61 was incorporated by two 
sequential Wittig olefinations, and the C-27 dissaccharide 2.6 was attached 
directly to ketal 2.64 or at a later stage after installation of diene unit. The C-20 
and C-21 stereogenic centers in ketal 2.64 were introduced by Sharpless 
asymmetric dihydroxylation on olefin 2.65, which was generated from Horner-
Wadsworth-Emmons olefination between aldehyde 2.66 and ketophosphonate 
2.67 under Sinisterra and Paterson modified conditions. This strategy was initially 
developed by Nicolaou’s group in the total synthesis of apoptolidin A 2.1. Both C-
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17 stereocenter in 2.66 and C-27 stereocenter in 2.67 were set by glycolate 
alkylations with Evan’s chiral auxiliaries. Chelation controlled nucleophilic 
addition was used to establish the stereocenter at C-16 in 2.66. All stereocenters 
at C-22, C-23, C-24, C-25 in 2.67 were constructed by iterative chlorotitanium 
enolate aldol reactions. To prepare the northern half building block 2.62, the 
known syn-aldol adduct 2.63 was chosen as the starting point, the following three 
iterations of reduction-oxidation-Wittig olefination sequence provided trienoate 
2.62.  
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Scheme 2.13 Crimmins's synthetic strategy for building blocks 2.61 and 2.62 
 
 In Crimmins’s total synthesis of apoptolidinone 2.2, cross metathesis 
between trienoate 2.62 and ketal 2.68 in the presence of Grubbs’ ruthenium 
carbene catalyst, and the following TBS protection of secondary alcohol 
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intermediate provided E-polyene intermediate 2.69. Hydrolysis of the ethyl ester 
and C-19/C-20 carbonate, regio-selective Yamaguchi macrolactonization yielded 
a lactone intermediate.  Finally, treatment with H2SiF6 removed the methyl ketal 
in addition to all the silyl protecting groups, which completed the total synthesis of 
apoptolidinone A 2.2.  
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Scheme 2.14 Crimmins's synthesis of apoptolidinone A (2.2) 
 
 To prepare the carbohydrate fragments of apoptolidin A 2.1, both Nicolaou 
and Koert groups chose natural carbohydrates as starting materials and used 
chemical methods to modify and transform the known carbohydrates into the 
desired glycosyl donors. As Crimmins’ group employed the same stereoselective 
glycosylation strategy used by Nicolaou’s group, the same glycosyl donors 2.5 
and 2.6 were required. In contrast, Crimmins’ group developed de novo synthetic 
routes to prepare the three monosaccharides. An asymmetric anti glycolate aldol 
addition with oxazolidinethione chiral auxiliaries was utilized to establish the C-4 
and C-5 stereocenters in each of the monosaccharides. In the synthesis of C-9 
glycosyl donor 2.5, a Sharpless asymmetric dihydroxylation was executed to set 
the C-2’ and C-3’ stereocenters. In the synthesis of the C-27 disaccharide 2.6, 
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both of the carbinol centers C-3’’ and C-3’’’ were established by a chelation-
controlled allylation, and the β–glycoside linkage in C-27 disaccharide precursor 
2.6 was formed by the coupling of in situ generated glycosyl donor 2.77 with 
glycosyl recepter 2.82 using Binkley’s conditions. 
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Scheme 2.15 Crimmins's synthetic strategy for two sugar units 
 
 In the final construction of apoptolidin A 2.1, exposure of trienoate 2.62 
and fully glycosylated ketal 2.61 to the Grubbs heterocyclic carbene catalyst 
yielded E-isomer 2.83 as the major cross metathesis product. Glycosylation with 
sulfoxide 2.5 resulted glycoside 2.84 in decent yield and high stereoselectivity. 
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Finally, regio-selective Yamaguchi macrolactonization following hydrolysis of the 
ethyl ester and C-19/C-20 carbonate, and global deprotection with H2SiF6 
released the synthetic target apoptolidin A 2.1. 
 
O
MeO
OTBSMe
O
O
OMe
Me
OTBS
Me OMe
H
O
O O
Me
O
OTES
Me
O Me
OTBS
OMe
Cl2(PCy3)(Imes)Ru=CHPh
Me
Me
Me
O
Me
HO
OEt
CO2Et
HO
O
MeO
OTBSMe
O
O
OMe
Me
OTBS
Me OMe
H
O
O O
Me
O
OTES
Me
O Me
OTBS
OMe
S(O)Ph
O
TBSO
TBSO
OMe
Me
Tf2O
CO2Et
O
O
MeO
OTBSMe
O
O
OMe
Me
OTBS
Me OMe
H
O
O O
Me
O
OTES
Me
O Me
OTBS
OMe
O
HO
HO
OMe
Me
1) LiOH,MeOH/H2O
2) Yamaguchi conditions
3) H2SiF6
Me
Me
Me
O
O
MeO
OH
Me
O
O
HO
HO
OMe
Me
HO
O
OH
OH
Me OMe
O
H
O
Me
O
OH
Me
O Me
OH
OMe
60%, >20:1 E:Z 40%
30%
2.62
2.61
2.83
2.5
2.84
2.1
 
Scheme 2.16 Crimmins's assembly of apoptolidin A (2.1) 
 
 
2.5 Sulikowski’s Synthesis of Apoptolidinone A   
 Our group accomplished the total synthesis of apoptolidinone A 2.1 in 
2004.40 The synthetic strategy used by our group was different from other groups’ 
approaches in the following aspects: firstly, all other groups’ syntheses toward 
either apoptolidin A 2.1 or apoptolidinone A 2.2 relied on a linear approach to 
assemble the seco acid and which was subjected to a Yamaguchi 
macrolactonization to provide the macrocycle in apoptolidin A 2.1. Whereas, in 
our approach to apoptolidinone A 2.2, a Suzuki-Miyaura cross-coupling reaction 
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was employed to form C-5/C-6 bond connection and close the macrocycle at late 
stage. We also explored closure of the macrocycle at C-5/C-6 conjuncture by 
using ring-closing metathesis and Horner-Wadsworth-Emmons reactions, but all 
attempts resulted in failure. It was later reported in Roush’s apoptolidin fragment 
synthesis that C-5/C-6 bond formation via intermolecular Horner-Wadsworth-
Emmons olefination was unsuccessful for an unkown reason.41 To our 
knowledge, utilizing a cross-coupling reaction to close macrocycle has been 
rarely reported in the synthesis of the macrolide in polyketide natural products. It 
was only reported by Toshima’s group that they successfully constructed the 
apoptolidin macrolactone ring via an intramolecular Stille coupling reaction to 
form C-12/C-13 bond.42 Secondly, other groups have employed a Sharpless 
asymmetric dihydroxylation strategy to establish the stereocenters at C-19 and 
C-20 wothout exclusion.16,17,18,19,20,21,22,23 Alternatively, our group employed a 
Mukaiyama aldol condensation reaction to build the syn relationship between C-
19 and C-20. 
In our synthetic strategy, apoptolidinone A 2.2 was generated from 
macrolactone 2.85 by in situ formation of the pyran ring after removal of the 
protecting groups. In a more convergent fashion, we divided macrolide 2.85 into 
7 small building fragments 2.41, 2.86, 2.87, 2.88, 2.89, 2.90 and 2.91 by a 
combination of one chelation-controlled Grinard addition, two diastereoselective 
aldol reactions, one Grubbs cross-metathesis reaction, one intermolecular and 
one intramolecular Suzuki-Miyaura coupling reaction.  
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Scheme 2.17 Strategic analysis in Sulikowski’s synthesis of apoptolidinone A 2.2 
 
The synthesis began with the preparation of 7 small building fragments 
2.41, 2.86, 2.87, 2.88, 2.89, 2.90 and 2.91. Fragment 2.90 was synthesized from 
(R)-glycidyl methyl ether 2.92. Epoxide opening with the lithium anion of 1,3-
dithiane, TBS protection of the resulting secondary alcohol, and hydrolysis of 
dithiol acetal with MeI provided adehyde 2.94. The following Crimmins syn aldol 
reaction with chlorotitanium enolate derived from 2.95 established the C-24 and 
C-25 stereocenters and TES protection of the newly formed alcohol gave aldol 
adduct 2.96. Reductive removal of oxazolidinethione chiral auxiliary followed by 
oxidation of the corresponding alcohol under Swern conditions completed the 
synthesis of aldehdye 2.90.  
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Scheme 2.18 Sulikowski's synthetic strategy for aldehyde 2.90 
 
The preparation of bromide 2.41 started from dihyrofuran 2.97 following 
Kocienski’s procedure as described in Koert’s total synthesis of apoptolidinone A 
2.2.20 Alcohol 2.98 was then transformed into bromide 2.39 via a standard two-
step Finkelstein reaction sequence. 
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Scheme 2.19 Sulikowski's synthetic strategy for bromide 2.41 
 
The synthesis of carboxylic acid 2.89 began with 2-methyl diethyl 
malonate 2.99, which was converted to allylic alcohol 2.101 via basic hydrolysis, 
decarboxylation and lithium aluminum hydride reduction. PCC oxidized and E-
selective Wittig olefination afforded the trans-dienoate 2.103.  The methyl ester in 
2.103 was then hydrolyzed to provide desired carboxylic acid 2.89.  
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Scheme 2.20 Sulikowski's synthetic strategies for carboxylic acid 2.89 
 
 Our final route to aldehyde 2.86 began with β-hydroxy lactone 2.105, 
which was originally prepared from (S)-malic acid 2.104 by 3-step reaction 
sequence including Fisher esterification, NaBH4 effected regioselective reduction 
and in situ acid mediated cyclization. Since β-hydroxy lactone 2.105 became a 
commercially available material at a relatively cheap price, it was used as starting 
compound for the synthesis of aldehyde 2.86. Methylation of β-hydroxy lactone 
2.105 followed by reduction with DIBAL-H and in situ condensation with 1,3-
propanedithiol provided dithiane 2.107. At last, Swern oxidation of the primary 
alcohol afforded aldehyde 2.86. So the only stereocenter in aldehyde 2.86, 
corresponding to the C-17 carbon in apoptolidin A 2.1 was derived from chiral 
starting material 2.105.  
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Scheme 2.21 Sulikowski's synthetic strategy for aldehyde 2.86 
 
 There  are two stereocenters in fragment 2.87, and we planned to 
establish these centers by using an asymmetric crotylation reaction. The 
aldehyde 2.110 was prepared from acrolein 2.108, which was subjected to 
bromination, aldehyde protection and elimination sequence to afford acetylene 
2.109. Then a Hall’s procedure was utilized to convert diethyl acetal 2.109 to 3-
boronoacroein 2.110. Addition of the Z-crotylboronate reagent 2.111 to aldehyde 
2.110 followed by in situ TES protection of the newly generated secondary 
alcohol gave syn homoallylic ether 2.87 with modest enantioselectivity (80% ee) 
and fair yield (40-43%).  
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Scheme 2.22 Sulikowski's synthetic strategy for boronate 2.87 
 
The assembly of these small synthetic fragments began with the 
construction of C(6)-C(19) large fragment. Grignard reagent generated from 
bromide 2.41 was added to a solution of aldehyde 2.86 in Et2O. The addition 
proceeded through a chelation-controlled process as described in Koert’s 
synthesis of apoptolidin, and gave syn-addition product 2.112 as a single isomer. 
Sequential iodine-tin exchange and in situ silylation of the secondary alcohol 
delivered vinyl iodide 2.113 in 90% yield over 2 steps.  Effective hydrolysis of 
dithiane 2.113 using the Fetizon-Jurion procedure gave aldehyde 2.114 in 64-
74% yield. Suzuki coupling between vinyl iodide 2.114 and vinyl boronate 2.87 
under Roush modified coupling conditions (Pd(PPh3)4, TlOEt, THF(aq)) 
accomplished the synthesis of C(6)-C(19) fragment 2.115 in 71% yield 
consistently. Mukaiyama aldol condensation between advanced intermediate 
2.115 and enol silane 2.88 afforded ketone 2.116 as the major diastereomer, the 
ratio of the two major isomers was 4:1. The relative stereochemistry of C(17)-
C(20) was assigned based on the observed coupling constant between H(19) 
and H(20) (J19,20=3.5 Hz) and the 1,3-asymmetric induction model proposed by 
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Evans and coworkers for β–methoxyaldehydes. Yamaguchi esterification of 
Mukaiyama aldol product 2.116 with carboxylic acid 2.89 provided ester 2.117. A 
matched double diastereoselective aldol reaction between aldehyde 2.90 and 
lithium enolate generated from ketone 2.117 under kinetic deprotonation 
condition, afforded syn aldol adduct 2.118 as a single stereoisomer in 41% yield 
(57% yield based on recovered starting material). The C-23 hydroxyl group was 
protected as TES ether 2.119, which was then subjected to cross metathesis with 
propenyl boronate 2.91 in the presence of Grubbs secondary generation catalyst 
2.120 and furnished vinyl pinacol boronate 2.121 in 30% yield (E:Z=10:1). The 
geometric byproduct could be detected by HPLC, however, it couldn’t be 
completely isolated from other byproducts. Using the same Grubbs catalyst, we 
switched the solvent from CH2Cl2 to toluene, which allowed us to alleviate the 
reaction temperature to 50 °C. Under these optimized conditions, the amount of 
the geometric isomer was significantly reduced. Subjection of vinyl pinacol 
boronate 2.121 to Roush modified Suzuki coupling condition afforded the 
macorlide 2.85.  Finally, exhaustive global desilylation with HF.Pyridine and in 
situ pyran cyclization achieved apoptolidinone A 2.2 in 61% yield.   
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Scheme 2.23 Sulikowski's assembly of apoptolidinone A 2.2  
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CHAPTER III 
 
PREVIOUS STUDIES ON THE MECHANISM OF ACTION OF APOPTOLIDIN A 
AND APPLICATION OF A PROBE DERIVED FROM APOPTOLIDIN A TO 
TARGET IDENTIFICATION  
 
 
3.1 Introduction 
Cancer, which is characterized as uncontrolled cell growth, is an example 
of a disorder in which genetic disruption of the normal mechanism of cell 
proliferation/death leads to cell accumulation. Some types of cancers exhibit an 
over-proliferation of cells while others display decreased elimination of cells. 
Apoptosis and autophagy are two major types of programmed cell death, which 
are mediated by genes or their protein products involved in various signaling 
pathways required to execute cell killings (i.e. elimination of cells). Programmed 
cell death is different from necrotic cell death, which is the result of acute tissue 
injury, infection, cancer, infarction, poisons and inflammation. These different 
forms of cell death can be differentiated by distinctive cell morphological 
changes. 
Historically, cancer chemotherapy has primarily utilized anticancer drugs 
that inhibit the cell division of fast growing cancer cells at different stages of the 
cellular cycle, which results in disruption of vital metabolic functions. It is now 
generally accepted that programmed cell death plays an important role in the 
expressed cytotoxicity of anticancer drugs. Information about the correlations 
between dysregulation of programmed cell death and the development and 
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progression of cancers, and understanding of the molecular mechanisms of the 
cell death and molecular switches between different cell death pathways have 
unraveled the mechanisms of drug action and paved the way for more novel cell-
selective therapeutic approaches which may increase the effectiveness of cancer 
treatment.43,44,45, 
 
3.2 Apoptosis and Autophagic Cell Death 
 The concept of apoptosis was first postulated in 1972 to describe 
programmed cell death. Apoptotic cells are morphologically characterized by 
chromatin condensation, nuclear fragmentation, plasma membrane blebbing, cell 
shrinkage and finally formation of apoptotic bodies.46 The morphological changes 
associated with apoptosis are directly or indirectly caused by a proteolytic 
cascade activation of caspases, which are a group of intracellular cysteine-
aspartic-acid-proteases.47   
The mechanism of apoptosis is extremely complex and sophisticated. To 
date, two different apoptosis mechanisms have been well defined: the intrinsic or 
mitochondrial pathway and the extrinsic or death receptor pathway. However, 
these two pathways are linked and some effectors in one pathway can also 
influence the other. In the death receptor pathway, death factors (TNF-α or Fas) 
bind to death receptors (TNF-R-1) on the cell surface, which recruit multiple pro-
caspase-8, leading to the activation of caspase-8. Regarding the mitochondrial 
pathway, internal signals (such as oxidative stress, DNA damage, p53 activation 
and hypoxia) cause the release of pro-apoptotic factors leading to the release of 
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cytochrome c from mitochondria inter-membrane space, which then activate 
caspase-9 by binding to Apaf-1 and pro-caspase-9.  The release of cytochrome c 
is controlled by Bcl-2 family proteins, which include pro-apoptotic members (such 
as Bax, Bak, Bad) and anti-apoptotic members (such as Bcl-2, Bcl-x, bcl-w).  Bcl-
2 family proteins can regulate mitochondria membrane permeability by an 
unknown mechanism.47,48,49 
 Autophagic cell death was initially described by Schweichel and Merker in 
1973.50 However, it was neglected for the following three decades by the majority 
of the scientific community because of the dominant concept of apoptosis versus 
necrosis. Recently, increasing evidence indicates that autophagic cell death 
plays an important role in tumor development. There are many literature reviews 
on the topic of autophagic cell death and its role in anticancer therapy.44,45,48,51 
The distinctive morphological change of autophagic cell death is the formation of 
double membrane autophagic vacuoles in the cytoplasm. An autophagic vacuole 
or autophagosome is derived from part of the endoplasmic reticulum or from the 
cytoplasmic lipid pool. The autophagosome fuses with lysosome to form 
autolysosome in which the cytoplasmic contents are degraded by lysosomal 
hydrolytic proteases. The degraded materials are then released into cytosol for 
recycling.50 
 Many signaling pathways have been implicated in the mechanism of 
autophagic cell death. However, the mechanism details are not well understood. 
Anticancer treatment and low nutrient conditions are thought to be the initial 
signals needed to induce autophagic cell death in cancer.44,45,48,51 
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 Apoptosis and autophagic cell death are not completely separate.48 It’s 
been observed that inhibition of apoptosis can trigger autophagic cell death, and 
inhibition of autophagic cell death can induce, delay or antagonize apoptosis. 
However, the molecular mechanisms underlying the interaction between 
apoptosis and autophagic cell death are not known till now.  
 
3.3 Stanford Group Studies on The Action Mechanism of Apoptolidin A 
In the preliminary biological tests, Seto’s group observed condensed 
chromatin and fragmented nuclei by staining with Hoechst Dye. 33258 when E1A 
transformed rat glia cells (RG-E1A-7) were treated with 1 µg/mL of apoptolidin A 
3.1 for 24 hours. This observation led Seto’s group to conclude that the cell death 
induced by apoptolidin A 3.1 is resulted from apoptosis. This led Khosla and co-
workers at Stanford University to compare the structure of apoptolidin A 3.1 with 
other cytotoxic macrocyclic polyketides with known action mechanism of action, 
and conducted a series of experiments utilizing molecular and cell-based 
pharmacological assays to propose a mechanism of action of apoptolidin A 3.1 
leading to apoptosis.52,53,54  
Since the molecular mechanisms of apoptosis are well understood, the 
Khosla group first examined knockouts of key apoptosis related proteins, such as 
p53, BCL-2 and caspases, on apoptolidin induced cell death using sensitive cell 
lines including mouse B cell lymphoma cells and human colon cancer cells 
HCT116. These experiments showed that the cell death induced by apoptolidin A 
3.1 was independent of p53 status, inhibited by BCL-2 and dependent on the 
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action of caspase-9. These results suggested that the biological responses of 
apoptolidin A 3.1 were associated with a target within the mitochondria pathway. 
Next, the Stanford group identified structurely related natural products of known 
mechanism of action that demonstrated a high correlation in the cytotoxic profile 
with apoptolidin when evaluated against the NCI 60-cell line panel. To this end, 
the Khosla group searched chemical database for polyketides with similar 
structure features to the apoptolidin A 3.1. This structural search led to the 
identification of ossamycin 3.3, cytovaricin aglycone 3.4, and oligomycin A 3.5. 
Interestingly, this group of polyketides are all inhibitors of mitochondrial F0F1-
ATPase, and all display a similar pattern of cytotoxicity against NCI-60 human 
cancer cell line panel. These results prompted the Khosla group to evaluate the 
ability of apoptolidin A 3.1 to inhibit mitochondrial F0F1-ATPase, which led to the 
conclusion that apoptolidin A 3.1 was an inhibitor mitochondrial F0F1-ATPase (Ki 
= 5 µM).52,53 
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Figure 3.1 Structures of apoptolidin A (3.1), truncated apoptolidin A (3.2), 
Ossamycin (3.3), cytovaricin aglycone (3.4) and oligomycin (3.5)  
 
 Examination of the pattern of cytotoxicity of macrolides shown in Figure 
3.1 against the NCI-60 human cancer cell line panel shows leukemia cell lines 
including HL-50, K-562, MOLT-4, RPMI-8226, CCRF-CEM and SR are 
particularly sensitive to those structurely similar macrolides. In contrast, a small 
group of cell lines including HCT-116, HT-29, IGR-OV-1, M14, SN12C, 780-0 
and SF-539 do not respond to the same group of macrolides. The common 
characteristic of the latter group of cells is that they have low ATP demand, and 
all exhibit a high level of anaerobic carbon metabolism by the Embden-Meyerhof 
pathway even in the presence of oxygen, a phenomenon known as the Warburg 
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effect, while the leukemial cells have high ATP demand from mitochondria and 
do not exihibit Warburg effect. 55,56,52,53  
Oxmate is an inhibitor of lactate dehydrogenase and 2-deoxyglucose is an 
inhibitor of Embden-Meyerhof pathway. Theoretically, these inhibitors can 
modulate the carbon flux from Embden-Meyerhof pathway to mitochondria, and 
increase the cell demand for ATP biosynthesied aerobically from mitochondria. 
Further experiments revealed that apoptolidin A 3.1 non-sensitive cells that 
exhibit the Warburg effect indeed became sensitive to apoptolidin A 3.1 when 
incubated with either oxmate or 2-deoxyglucose. These results provided 
additional evidence on the close correlations between the mitochondria pathway 
and apoptolidin A 3.1 induced cell death.52 
 In Khosla’s structure comparison study, the truncated apoptolidin A 3.2 
was obtained by acidic methanolysis of apoptolidin A 3.1. The biological activity 
of this degradation product 3.2 and apoptolidin A 3.1 were compared in a yeast 
ATPase assay and cell assays. The truncated apoptolidin 3.2 retained 
substantial activity against yeast mitochondrial ATPase (Ki = 10 µM) comparing 
to apoptolidin A 3.1 (Ki = 5 µM); whereas, the apoptolidin derivative 3.2, without 
C-27 disaccharide, only retained 1% cellular toxicity relative to apoptolidin A 3.1 
using apoptolidin sensitive cell lines (a human breast tumor cell line MCF-7 and a 
murine B cell lymphoma cell line LYas). To explain the significant drop in cellular 
cytotoxicity of 3.2 Khosla proposed that the missing sugar units of 3.2 are 
important in facilitating the transportation of the apoptolidin structure to its cellular 
targets F0F1-ATPase.54 
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3.4 SAR Studies and Target Revaluation  
Several other groups have investigated the cytotoxicity of apoptolidin A 
3.1 and its derivatives against different sensitive human cancer cell lines.15,19,21,57 
Both Nicolaou’s and Koert’s groups observed that apoptolidin A derivative 3.6 
without a C-27 disaccharide lost significant biological activity.19,21 These 
observations are consistent with Khosla’s hypothesis that the aglycone structure 
contributes to the biological activity and carbohydrates facilitate cellular transport 
or are directly involved in binding to the cellular target. 
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Figure 3.2 Biological activities of apoptolidin A (3.1) and C-9 
 sugar congener (3.6) 
 
 
Wender’s group devised a systematic method for the preparation of 
hydroxyl protected derivatives of apoptolidin A by semi-synthesis, and conducted 
extensive studies on the structure and biological activity relationship using both a 
cell-free mitochondria F0F1-ATPase assay and apoptolidin sensitive Ad12-3Y1 
cells.15,57 The observed biological activity in these two assays did not correlate. 
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First, isoapoptolidin A 3.7 (IC50 = 17 µM) was 24-fold less active than apoptolidin 
A 3.1 (IC50 = 0.7 µM) in the enzyme assay. Whereas, apoptolidin A 3.1  (GI50 = 
0.0065 µM) and isoapoptolidin A 3.7 (GI50 = 0.009 µM) are equally potent in the 
cell assay, which is consistent with the facile isomerization between these two 
compounds under the assay conditions. Second, apoptolidin A 3.1 (GI50 = 6.5 
nM) induces cell death at sub-micromolar concentration. However, it’s potency 
decreased by 2 orders of magnitude in the cell free enzyme assay (IC50 = 0.7 
µM). Third, apoptolidin derivatives displayed different potencies in the cell free 
mitochondria F0F1-ATPase assay and antiproliferative cell assay. Based on these 
observations Wender suggested a different cellular target exists or apoptolidin’s 
mechanism of action is significantly more complex.15 
 
Table 3.1 In vitro and In vivo biological activities of apoptolidin A 3.1 and 
isoapoptolidin A 3.7 
 
 
Apoptolidin A (3.1)                0.7 + 0.25                              0.0065
Isoapoptolidin A (3.7)            17 + 0.25                               0.009
Compounds IC50(µM)(F0F1-ATPase) GI50(µM) (Ad12-3Y1)
 
 
3.5 Application of Probes Derived from Apoptolidin A to Target 
Identification 
 As the in vivo cell cytotoxicity of apoptolidin A 3.1 and various analogues 
does not always correlate with in vitro mitochondria F0F1-ATPase inhibition, 
Wender’s group turned their attention to the construction of photo-affinity probes 
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of apoptolidin A for the identification of alternate protein targets.58 Photoaffinity 
techniques were developed for the identification of protein targets by 
photochemical labeling of interacting sites by the interacting ligand (small 
molecule).59,60 A photoaffinity probe is composed of three general elements: a 
binding group that promotes interactions with the active sites of specific classes 
of proteins, a reactive group (photoaffinity label) that covalently labels these 
active sites via photoreactions, and a reporter group (e.g., radioactive fluorophore 
or biotin) for the visualization and affinity purification of probe-labeled proteins. As 
natural products are protective weapons produced by organisms for extrogenous 
threats or stress, they can cause various biological responses. Therefore, natural 
product photoaffinity probes have been used as chemical-biological tools to 
elucidate the cellular mechanisms of such products.59,61,62,63,64,65,66 
According to Jankowski’s dissertation (Stanford University, 2004), four 
different photo-affinity label (PAL) conjugates of apoptolidin A using three 
different photo-reactive functionalities were synthesized and evaluated.58 
Specifically, ATFB-based apoptolidin PAL 3.8, one benzophenone-based PAL 
3.10, and two diazirine-based probes 3.9 and 3.11 were prepared by chemical 
synthesis. They expected that these PAL apoptolidins would form covalent bonds 
with specific protein target through C-H insertion upon irradiation; the targeted 
protein is then purified by affinity chromatography and identified using mass 
spectrometry analysis. Unfortunately, none of these four photo-affinity systems 
leads to the identification of protein targets of apoptolidin A 3.1. Since further 
biological activity screening revealed these four PAL apoptolidins maintained 
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moderate toxicity of apoptolidin A, the failure of applying PAL labeled apoptolidin 
to identify a celluar target was rationalized by Wender’s group being the following 
reasons: First, apoptolidin A 3.1 will undergo photo-isomerization to form two new 
unstable apoptolidins when exposed to light of 300 nm wavelength, the structures 
of the two apoptolidin A photoisomers were not completely assigned.67,58 
Therefore it is highly possible that PAL attached apoptoidin derivatives 
decompose and/or rearrange before binding to the cellular target; PAL may cross 
interact with cell lysates and lead to non-specific labeling; PAL on sugar units 
may affect the affinity to target.  In conclusion, PAL is not a suitable choice for 
construction of apoptolidin probe for identification of apoptolidin’s target protein. 
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Figure 3.3 Wender’s PAL probes of apoptolidin A 
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3.6 Dissertation Statement 
Since the discovery of apoptolidin A by Seto’s group in 1997, organic 
chemists have devoted significant efforts in the investigation of convergent 
strategies towards total synthesis of apoptolidin A and its analogues. In the 
parallel research, chemists in collaboration with biologists have made extensive 
contribution in the exploration of the action mechanism of apoptolidin A in various 
ways. Although mitochondrial F0F1-ATPase was proposed by Khosla’s group to 
be a promising cellular target of apoptolidin A, results from Wender’s SAR 
studies suggested the existence of a more relevant target to apoptolidin 
cytotoxicity. This dissertation describes recent efforts by Sulikowski’s group in 
construction of an apoptolidin probe towards the cellular target identification of 
apoptolidin A. 
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CHAPTER IV 
 
CHEMICAL SYNTHESES OF 6-NORMETHYL APOPTOLIDINONE A 
(APOPTOLIDINONE D), 2-NORMETHYL APOPTOLIDINONE D AND 12-OXY-
APOPTOLIDINONE D 
 
 
4.1 Introduction 
 Our group accomplished a total synthesis of apoptolidinone A 4.1 in 2004.40 
However, our interest in apoptolidin A 4.1 was not limited to the chemical 
synthesis of the aglycone of this compound, but to its use as a biological probe 
for target identification studies. In order to investigate apoptolidin A 4.1 as a 
biological probe, unnatural apoptolidinones including 6-normethyl apoptolidinone 
A 4.2, 2,6-dinormethyl apoptolidinone A 4.3, and 12-oxy-apoptolidinone D 4.4 
were selected for chemical synthesis. Comparision of 4.2-4.4 to the parent 
aglycone 4.1 reveals apoptolidinone 4.2 lacks one methyl group on C-6 position, 
4.3 lacks two methyl groups (C-2 and C-6) and 4.4 lacks a methyl group at C-6 
position and features an extra hydroxyl group at C-12 methyl terminal that we 
projected as a point of attachment to either a fluorescent or affinity tag reagent. 
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Figure 4.1  Structures of apoptolidinone A and unnatural apoptolidinones 
 
4.2 Total Synthesis of 6-Normethyl Apoptolidinone A 
 The successful synthetic strategy leading to apoptolidinone A 4.1 featured 
two Suzuki cross-coupling reactions, two aldol reactions, one chelation controlled 
Grignard addition, a Yamaguchi esterification and a cross-metathesis reaction. 
Since 6-normethyl apoptolidinone A 4.2 lacks only one methyl group on C-6 
carbon, the synthesis of 4.2 required only a change in the cross-metathesis 
partner from isopropenyl boronate to 1-propenyl boronate 4.12, which can be 
easily prepared from 1-propenyl magnesium bromide. In the course of 
assembling the 6-normethyl apoptolidinone A 4.2, we modified the synthesis of 
vinyl boronate 4.8 and carefully examined the stereoseletivity of the key 
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Mukaiyama aldol reaction, and explored an alternative route for introduction of 
the C(22)-C(23) bond connection by reversing the original sequence of two aldol 
reactions. Fragments 4.6-4.11 were prepared following the precedures 
developed by our earlier total synthesis of apoptolidinone A 4.1.24 The work 
included in this section has been published in the Journal of Organic Chemistry.68     
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Scheme 4.1 Synthetic strategy for 6-normethyl apoptolidinone A 4.2 
 
4.2.1 Preparation of Vinyl Boronate 4.8 
In our previous synthesis of vinyl boronate 4.8, a Roush crotylation 
employing (Z)-crotyl boronate 4.19 and aldehyde 4.15 provided 4.8 in 44% yield 
and 80% ee.69,70 In order to improve the enantioselectivity of the crotylation 
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process, a previous group member Dr. Qingsong Liu, compared Roush’s 4.19 
and Brown’s 4.20 crotylating agent addition to 3-iodoacrolein 4.18.71 The 
crotylation substrate 4.18 was easily accessed from methyl propiolate 4.16 
following a known procedure.72,73 The enantiomeric excess for 4.19 was only 
26% ee. On the other hand, the addition of Brown’s reagent 4.20 to 4.18 
provided the desired syn crotylation product 4.21 in superior yield (67%) and 
higher enantiomeric excess (90% ee).73,74,75  
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Scheme 4.2 Synthesis of vinyl iodide 4.21 
 
Towards the assembly of aldehyde 4.24, vinyl iodide 4.21 was converted 
to vinyl boronic acid 4.22, which was employed in situ in a Suzuki-Miyaura cross-
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coupling (SMCC) with vinyl iodide 4.23 (Scheme 4.3). However, the SMCC 
reation was proven to be irreproduceable and led to several side-reactions. 
Careful analysis of the crude 1H NMR spectra of SMCC reaction indicated that 
three products resulted the desired diene 4.24 and two by-products 4.25 and 
4.26 resulting from base-induced β-elimination of a methoxy group. For this 
reason the vinyl borate coupling partner was purified prior to the key coupling. To 
this end, vinyl iodide 4.21 was converted to 4.8 by lithium-iodine exchange 
followed by trapping with isopropyl pinacol borate 4.27 in THF. Following the 
purification of vinyl borate 4.8 by flash chromatography, the intermolecular 
Suzuki coupling reaction now consistently occurs in 70% yield in presence of 
Pd(PPh3)4 and TlOEt in a 3:1 mixture of THF and H2O. With a reliable method of 
obtaining vinyl boronate 4.8 in quantity, multi-grams quantities of aldehyde 4.24 
can be prepared under the desired SMCC conditions. 
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Scheme 4.3 Synthesis of aldehyde 4.24 and vinyl boronate 4.8 
  53 
 
4.2.2 Studies into the Mukaiyama Aldol Reaction 
After solving the problem of large-scale preparation of aldehyde 4.24, we 
focused our attention on the diastereoselectivity of the key Mukaiyama aldol 
reaction. Mukaiyama aldol partner, sily enol ether 4.9 was prepared from TES 
protected 1-hydroxy-2-butanone 4.28, which is easily accessible either from 1,2-
butane diol in a 2-step reaction sequence or one-step from commercially 
available1-hydroxy-2-butanone.76 Kinetic deprotonation of ketone 4.28 with LDA 
followed by TMSCl quench provided a mixture of isomeric silyl enol ethers E-4.9, 
E-4.29, Z-4.9 and Z-4.29 (73:12:14.7:0.3).77 The ratio of these isomers was 
determined by GC analysis, the double bond geometry of isomers 4.9 and 4.29 
were assigned by NOESY analysis.  
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Danishefsky and coworkers demonstrated that reactions between achiral 
siloxydienes and chiral aldehydes generated syn aldol products irrespective of 
the geometry of silyl enolsilanes.78 To explain the stereochemical outcome of 
Lewis acid mediated Mukaiyama reactions between silyl enol ethers and 
aldehydes, Heathcock and coworkers hypothesized the involvement of open 
transition-state structures as shown in Scheme 4.5 (synclinal and/or 
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antiperiplanar transition structures) and excluded the involvement of closed 
transition state structures, which were widely used for prediction of 
stereoselectivity in lithium enolate aldol condensations.79,80,81,82 In addition, 
Evans and coworkers proposed an extended Felkin-Anh model for 1,3-
asymmetric induction in Mukaiyama aldol additions to β-alkoxy aldehydes via 
systematic investigation into the stereoselectivity of Mukaiyama aldol reaction as 
shown in Scheme 4.6.83,84 Based on these literature precedents and proposed 
model systems, we predicted that Mukaiyama aldol reaction of aldehyde 4.24 
with silyl enol ethers E-4.9 would proceed via an antiperiplanar transition state 
T10 to minimize electrostatic repulsion between TMSO oxygen and aldehyde 
carbonyl oxygen as well as steric interactions between TESO and R’ substituents 
on the aldehyde and provide the desired anti, syn aldol adduct 4.30a as the 
major isomer. Mukaiyama reaction of the same aldehyde 4.24 with Z-4.9 was 
predicted to proceed via an antiperiplanar transition state T11 for the same 
reasons and also provide 4.30a as the major adduct (Scheme 4.7). Therefore, 
the stereoselectivity in Mukaiyama aldol reaction between aldehyde 4.24 and silyl 
enol ether 4.9 was anticipated to be independent of the double geometry of sily 
enol ether 4.9. 
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In the event, Mukaiyama aldol reaction between a mixture of silyl enol 
ethers 4.9 (cf. Scheme 4.4) and aldehyde 4.24 provided a mixture of aldol 
products consisting of two major diastereomers (4:1) determined by 1H NMR 
analysis of the crude product mixture. The major isomer was determined to be 
the desired anti,syn isomer based on the small coupling constant between H-19 
and H-20 (3.5 Hz) and model analysis.85 The minor isomers were removed in the 
late stage synthesis, and their structures were not assigned. Since a mixture of 
silyl enol ethers (Scheme 4.4) were used in the Mukaiyama aldol reaction, it was 
not known whether the isomers generated from Mukaiyama aldol reaction were 
diastereomers or regioisomers. To answer this question, in the synthesis of 6-
normethyl apoptolidinone A 4.2, the reaction mixture from Mukaiyama aldol 
condensation was further purified by Varian preparative HPLC after normal flash 
chromatography. No products corresponding to the reactions between aldehyde 
4.24 and silyl enol ethers E-4.29 and Z-4.29 were seperated. To our pleasure, 
four diastereomers resulting from the reaction between 4.24 and silyl enol ethers 
E-4.9 and Z-4.9 were separated. The ratio of isomers was determined to be 
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12:3.8:1.6:1 (Scheme 4.8). As predicted the major isomer was anti,syn-4.30a. 
The assignment of relative stereochemistry between C-19 and C-20 was based 
on the observed coupling constants between H-19 and H-20 in all four aldol 
adducts, the relative configuration across C-17 and C-19 was assigned based on 
the 1,3-asymmetric induction model proposed by Evans and coworkers as shown 
in Scheme 4.8 and confirmed by the total synthesis of apoptolidinones. These 
results proved the effectiveness of using the Heathcock open transition state 
models and the Evans 1,3-induction models for prediction of reaction 
diastereoselection in synthetic design.  
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Scheme 4.8 Diastereoselectivity in Mukaiyama aldol reaction 
 
 
4.2.3 Alternative Route for C(22)-C(23) Bond Connection 
In the previous synthesis of apoptolidinone A 4.1, the C-22 and C-23 
stereogenic centers were established by using a double diastereoselective 
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lithium enolate aldol reaction.24 Even though this reaction gave high 
diastereoselectivity, the yield of this step was modest (48%). Therefore, an 
alternative aldol strategy was investigated for the construction of C-22 and C-23 
bond formation in the progress towards the total synthesis of 6-normethyl 
apoptolidinone A 4.2. Thus, the corresponding Mukaiyama aldol addition partner 
silyl ketene acetal 4.29 was obtained from same starting material ketone 4.28. 
Thermodynamic silylation of ketone 4.28 with Et3N followed by TMSOTf quench 
gave silyl ketene acetal Z-4.29 as a single isomer.  
 
O
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OTMS
TESO
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THF, 92%
4.28 Z-4.29  
Scheme 4.9 Synthesis of silyl enol ether 4.29 
 
Previous studies by Evans’ group revealed that Mukaiyama aldol reactions 
with β-oxygen substituted aldehydes proceeded with high 1,3-anti 
diastereoselection due to electrostatic interactions between the carbonyl and 
polar β-oxygen substituent.85,86 It was also pointed out that addition of enolsilanes 
to α-alkyl substituted aldehydes proceeded with excellent 1,2-syn 
diastereoselection through the Felkin-Anh transition state model. Therefore, 
Mukaiyama aldol reactions with anti-α,β-disibstituted aldehydes could proceed 
with high diastereoselectivity, since α and β stereoinduction factors mutually 
reinforce this selectivity. However, when syn-α,β-disibstituted aldehydes were 
chosen as Mukaiyama aldol partner, such as aldehyde 4.11, the stereochemical 
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outcome was difficult to predict, since the 1,2-induction and 1,3 induction factors 
were nonreinforcing.87 Based on the above literature precedents, the 
stereoselection in Mukaiyama addition of silyl enol ether E-4.29 to aldehyde 4.11 
could not be predicted with confidence.   
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Scheme 4.10 Formation of C-22/C-23 conjunction with Mukaiyama aldol reaction 
 
To our surprise, the reaction of silyl enol ether E-4.29 and aldehyde 90 
under Mukaiyama condition generated a single diastereomer 4.31. None of the 
products corresponding to Mukaiyama aldol pathway was detected. This 
experimental result suggested that alcohol 4.31 could be generated through a 
Prins or heteroene reaction pathway.88 When Alcohol 4.31 was subjected to an 
acidic desilylation condition, a bicylic product 4.32 was obtained. From the 
NOESY spectrum of 4.32, strong NOE correlations between H-23 and H-27, and 
between H-23 and 22-Me, 24-Me were observed. Through a combination of NOE 
correlations and large coupling constants (J22-23 = 9.9 Hz, J23-24 = 9.9 Hz), the 
relative stereochemistry of 4.32 was assigned as shown in Scheme 4.8. 
Unfortunately, the coupling of aldehyde 4.11 and silyl enol ether E-4.29 did not 
led to the desired stereochemistry required for completion of the total synthesis 
of apoptolidinones. Therefore, efforts returned back to the original lithium enolate 
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aldol strategy utilized in the total synthesis of apoptolidinone A 4.1 for the 
construction of C-22/C-23 bond of 6-normethyl apoptolidinone A 4.2. 
 
4.2.4 Assembly of 6-Normethyl Apoptolidinone A 
 
OTES
OMe
TESO
O O OTBSO
OMe
TES
OTES
O
22
23
24
25
O
I
OTES
OMe
TESO
O O OTBSO
OMe
TES
OTES
O
O
I
B
O
O
B
O
O
MesN NMes
Cl
Cl
PCy3
Ph
H
TES
Pd(PPh3)4, TlOEt,THF/H2O
TESO
OMe
TESO
O
O
TESO
O OTBSO
OMe
TES
O
TES
OH
OMe
HO
O
HO
O
O
OMe
OH
OH H
OH
87%
HF•Pyr
95%
53%
TES
4.12
4.33
4.34
4.35
4.5
4.2
 
 
Scheme 4.11 Final assembly of 6-normethyl apoptolidinone A 4.2 
(apoptolidinone D) 
 
 
To assemble 6-normethyl apoptolidinone A 4.2, the cross-metathesis of 1-
propenyl boronate 4.12 with the common advanced synthetic intermediate 4.33 
in presence of the Grubbs 2nd generation catalyst 4.34 provided vinyl boronate 
4.35 as a single geometric isomer in a superior yield (53%) relative iso-propenyl 
borate (22%). Macrocylization under Suzuki cross-coupling conditions and 
exhausive desilylation completed the total synthesis of 6-normethyl 
apoptolidinone A 4.2. 6-normethyl apoptolidinone A 4.2 adopted the name of 
apoptolidinone D after it was reported by Wender’s group who isolated 
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apoptolidin D as a minor metabolite from the fermentation medium of 
Nocardiopsis sp.6 
 
4.3 Total Synthesis of 2,6-Dinormethyl Apoptolidinone A 
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Scheme 4.12 Retrosynthetic analysis for 2,6-dinormethyl apoptolidinone A 4.3 
 
 Structurely, 2,6-dinormethyl apoptolidinone A 4.3 lacks two methyl groups 
at both C-2 and C-6 positions. The total synthesis of this unnatural apoptolidin 
aglycone 4.3 requires changing both the Yamaguchi esterfication and cross-
metathesis partners while utilizing the same synthetic strategy used in the total 
synthesis of apoptolidinone A 4.1. 
 
4.3.1 Preparation of Carboxylic Acid 4.37 
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Scheme 4.13 Synthesis of carboxylic acid 4.37 
 
The synthesis of carboxylic acid 4.37 started from 2-methyl diethyl 
malonate 4.38, which was converted to allylic alcohol 4.40 via basic hydrolysis, 
decarboxylation and lithium aluminum hydride reduction.89 After PCC oxidation, 
the corresponding aldehyde then reacted with commercially available phosphine 
ylide 4.41 yielded the Wittig olefination product E-dienoate 4.42. The methyl ester 
in 4.42 was then hydrolyzed to produce the desired carboxylic acid 4.37.  
 
4.3.2 Assembly of 2,6-Dinormethyl Apoptolidinone A 4.3 
 In the synthesis of 2,6-dinormethyl apoptolidinone A 4.3, the major 
diastereomer 4.30a resulting from the key Mukaiyama aldol reaction was coupled 
with carboxylic acid 4.37 under typical Yamaguchi esterification conditions 
provided the ester 4.43, which was subsequently treated with LHMDS in 
presence of HMPA to generate the desired Z-enolate, and further reacted with 
aldehyde 4.11 to afford aldol product 4.44 as a single diastereomer.  The 
resulting alcohol was protected as a TES ether 4.45, which was subjected to a 
cross-metathesis reaction with 1-propenyl boronate 4.12 catalyzed by Grubbs 
secondary generation catalyst 4.34 to give an intra-molecular Suzuki coupling 
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precursor 4.46. The following macrocylization afforded macrolactone 4.36. In the 
final desilylation step, a less acidic reagent, H2SiF6, was used to complete the 
total synthesis of 2,6-dinormethyl apoptolidinone A 4.3. 
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Scheme 4.14 Assembly of 2,6-dinormethyl apoptolidinone A 4.3 
 
4.4 Total Synthesis of 12-Oxymethyl-Apoptolidinone D 
 In comparing apoptolidinone D 4.2 to oxy-apoptolidinone D 4.4, the latter 
incorporates one extra hydroxyl group at C-12 methyl group. Our attention was to 
incorporate a C-12 hydroxyl group as a point of attachment for probe 
development in connection with target identification. Detailed discussion of 
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apoptolidin labeling for the purpose of biological target identification is described 
in Chapter VI of this thesis.  
 The total synthesis of oxy-apoptolidinone D 4.4 was based on the same 
synthetic strategy developed by our group for the total synthesis of 
apoptolidinone A 4.1. Disconnetions with Suzuki couplings, Yamaguchi 
esterification, Mukaiyama aldol reaction, lithium enolate aldol reaction, and 
chelation-controlled Grignard addition revealed bromide 4.48, aldehyde 4.7, silyl 
keten acetal 4.9, aldehyde 4.10, carboxylic acid 4.11, vinyl borate 4.8 and 4.12 
were the building blocks for oxy-apoptolidinone D 4.4. According to this strategy, 
the synthesis of oxy-apoptolidinone D 4.4 shared six common building blocks that 
were used in the synthesis of apoptolidinone D 4.2. A new synthetic plan was 
required for the preparation of bromide 4.48. 
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Scheme 4.15 Retrosynthetic analysis for oxy-apoptolidinone D 4.4 
 
 
4.4.1 Preparation of Bromide 4.48 
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Scheme 4.16 Synthesis of bromide 4.48 
 
In the total synthesis of apoptolidinone A 4.1, apoptolidinone D 4.2 and 
2.6-dinormetyl apoptolidinone 4.3, the common building block E-vinyl tin 
compound 4.6 was prepared from 1,2-dihydrofuran utilizing Koceinski’s 
methodology.90 To prepare vinyl tin 4.48 for the synthesis of oxy-apoptolidinone 
D 4.4, a regio- and stereo-selective hydrostannylation was used to establish the 
E-geometry in vinyl tin 4.48. Starting from 3-butyn-1-ol 4.49, TBS protection 
followed by acetylation of the terminal alkyne 4.50 with chloromethyl formate 4.51 
generated the methyl ester 4.52.  The key palladium catalyzed hydrostannylation 
reaction yielded 4.53 in 93% yield with 8:1 regioselectivity.91,92 The minor 
regioisomer generated from this step was removed following the desilylation 
step. Removal of the TBS protective group under acidic conditions resulted in 
primary alcohol 4.54, which was converted into bromide 4.56 under typical 
Finkelstein reaction conditions via intermediate mesylate 4.55. Finally, DIBAl-H 
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reduction of the methyl ester 4.56 followed by TBS protection of the 
corresponding alcohol 4.57 finished the assembly of fragment 4.48.  
 
4.4.2 Assembly of 12-Oxymethyl Apoptolidinone D 
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Scheme 4.17 Assembly of oxy-apoptolidinone D 4.4 
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The synthesis of oxy-apoptolidinone D 4.4 starting from bromide 4.48 is 
shown in Scheme 4.17.  In contrast to the earlier bromide 4.6, the generation of 
the corresponding Grignard reagent from 4.48 requires higher reaction 
temperature. Therefore, tetrahydrofuran was selected in place of diethyl ether 
due to its higher boiling point. The chelation controlled Grignard addition to 
aldehyde 4.7 set the stereocenters at C16 and C17 in syn fashion and generated 
alcohol 4.58. Then iodine-tin exchange followed by TES protection of the newly 
formed secondary alcohol provided vinyl iodide 4.59.  Hydrolysis of the dithiane 
with MeI and K2CO3 afforded aldehdye 4.60, which was coupled with vinyl borate 
4.8 to provide aldehdye 4.61. The key Mukaiyama aldol reaction with silyl enol 
ether 4.9 gave a mixture of four diastereomers 4.62. To which, carboxylic acid 
4.10 was attached under Yamaguchi conditions and provided the ester 4.63. At 
this stage, four diasteromers resulted from Mukaiyama aldol reaction that could 
be separated and purified by preparative HPLC. The ratio among these four 
isomers was determined to be 27:7:3:2, which correlated well with the results 
obtained in the total synthesis of apoptolidinone D 4.2 (vide supra). The major 
isomer, featuring the desired chirality at C-19 and C-20, was then subjected to a 
double diastereoselective aldol reaction with 4.11 setting up the pyran ring 
precursor 4.64. Silylation of the secondary alcohol in 4.64 resulted in the 
intermediate 4.65 and made the cross metathesis precursor ready for further 
reactions.  Grubbs cross metathesis with 1-propenyl pinacol borate 4.12 provided 
vinyl boronate 4.66, and set the stage for macrolactonization. An intramolecular 
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Suzuki coupling reaction closed the 20-membered lactone under Roush modified 
condition and generated intermediate 4.47.  Global deprotection with fluorosilic 
acid released all the hydroxyl groups and simultaneously closed the pyran ring, 
which finished the total synthesis of oxy-apoptolidinone D 4.4.  
 
4.5 Experimental Section 
General Procedures: Unless indicated, all commercial reagents were used as 
received without further purification. All reactions were carried out under a 
nitrogen or argon atmosphere using dry glassware that had been flame-dried 
under a stream of nitrogen, unless otherwise noted. All solvents were purified 
prior to use. Tetrahydrofuran and diethyl ether were distilled from 
sodium/benzophenone; dichloromethane and benzene were distilled from 
calcium hydride. Chloroform was washed twice with water, dried over potassium 
carbonate, refluxed, and distilled from phosphorus pentoxide. All solvents were 
determined to contain less than 50 ppm water by Karl Fisher coulometric 
moisture analysis. Triethylamine was distilled from calcium hydride and stored 
over sodium hydroxide. Reactions were monitored by thin-layer chromatography 
(TLC) using 0.25-mm E. Merck precoated silica gel plates. Visualization was 
accomplished with UV light and aqueous ceric ammonium molybdate solution, 
anisaldehyde stain or KMnO4 followed by charring on a hotplate. Flash 
chromatography was performed with the indicated solvents using silica gel 60 
(particle size 230-400 mesh) with the indicated solvent. An automated 
chromatography system was also employed. Chromatography methods were 
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created based on Rf values. Yields refer to chromatographically and 
spectroscopically pure compounds unless otherwise stated. Melting points are 
uncorrected unless otherwise noted. 1H and 13C NMR spectra were recorded on 
Bruker 300, 400, 500 and 600 MHz spectrometers at ambient temperature. 1H 
and 13C NMR data are reported as δ values relative to chloroform, benzene or 
methanol. Enantionmeric excess was determined by chiral GC analysis by Varian 
3900 with chiral column (BETA DEX 120, 30 M x 0.25 mm, 0.25 µm film, column 
: # 17411-02B). High-resolution mass spectra were conducted either at Texas 
A&M University Mass Spectrometry Service Center by Dr. Shane Tichy on an 
API QSTAR Pulsar Instrument or at the Department of Chemistry and 
Biochemistry, University of Notre Dame on a JEOL AX505HA or JEOL JMS-
GCmate mass spectrometer. Infrared (IR) spectra were recorded as thin films or 
solutions in the indicated solvent. 
 
O
TESO
4.28  
 
Silyl Ether 4.28: To a solution of 1-hydroxybutan-2-one (0.021 g, 2.384 mmol) in 
dichloromethane (24 mL) cooled to 0 °C was added imidazole (0.032 g, 4.767 
mmol, 2 equiv) followed by TESCl (0.60 mL, 3.575 mmol, 1.5 equiv). The mixture 
was stirred overnight at room temperature and quenched with H2O (10 mL). The 
aqueous layer was extracted with dichloromethane (3 X 20 mL) and the 
combined organic layers were washed with brine (20 mL), dried (MgSO4), filtered 
and concentrated in vacuo. The residue was purified by flash chromatography 
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(Hexanes/EtOAc, 40:1 to 10:1) to afford 0.338 g (70%) of TES ether 4.28 as a 
colorless oil: IR (neat) 2955, 2878, 1720 cm-1; 1H NMR (500 MHz, CDCl3):  4.18 
(s, 2H), 2.54 (q, J = 7.0 Hz, 2H), 1.07 (t, J = 7.0 Hz, 3H), 0.97 (t, J = 8.0 Hz, 9H), 
0.64 (q, J = 8.0 Hz, 6H); 13C NMR (100 MHz, CDCl3):  211.7, 68.7, 31.5, 7.2, 6.6, 
4.3; HRMS (ESI) m/z 209.1571 [(M+Li)+ calculated for C10H22LiO2Si: 209.1549]. 
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Silyl Enol Ethers 4.9: To a solution of diisopropylamine (4.0 mL, 29.2 mmol) in 
THF (100 mL) was added n-BuLi (2.5 M in hexanes, 11.7 mL, 29.2 mmol) at 0 
°C. After15 min at 0 °C, the mixture was cooled to –78 °C and a solution of silyl 
ether 4.28 (4.9 g, 24.3 mmol) in THF (20 mL) was added dropwise. The resulted 
solution was stirred for 30 min at –78 °C. TMSCl (3.7 mL, 29.2 mmol) was 
added dropwise and the resulted solution was stirred for 2 h at –78 °C. The 
reaction was quenched with NaHCO3 (20 mL) and extracted with Et2O (3 X 100 
mL). The combined organic layer were dried (Na2SO4), filtered and concentrated 
in vacuo. The residue was purified by distillation under reduced pressure (85-90 
°C, 1 mm Hg) to afford 5.3 g (80%) isolated as a light yellow and mixture of silyl 
enol ethers (Z)-4.9/(E)-4.9/(Z)-4.29/(E)-4.29 (ca. 14.7:73:0.3:12 as determined 
by GC analysis: Varian 3900 with normal column from J & W Scientific, Cat. No.: 
1231012, 15 M X 0.32 mm, 0.25 micron, starting from 50 °C, hold for 10 min, 
then 1 °C/min to 100 °C, hold for 50 min, totally 60 min, major isomer showed up 
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at 22.11 min, 3 minor isomers showed at 20.88 min, 24.53 min, and 27.05 min 
respectively). The double bond geometry of (E)-4.9 and (Z)-4.29 was assigned 
by NOESY NMR analysis: IR (neat) 1266, 1162 cm-1; 1H NMR (300 MHz, C6D6):  
6.32 (s, 1H), 2.42 (q, J = 7.5 Hz, 2H), 1.17 (t, J = 7.5 Hz, 3H), 0.99 (t, J = 8.0 Hz, 
9H), 0.60 (q, J = 8.0 Hz, 6H), 0.17 (s, 9H); 13C NMR (125 MHz, CDCl3): 143.4, 
125.3, 21.9, 11.0, 6.5, 4.4, 4.3, 0.3; HRMS (ESI) m/z 281.1946 [(M+Li)+ 
calculated for C13H30LiO2Si2: 281.1944].  
 
Figure 4.2 GC chromatograph of silyl enol ethers 4.9 and 4.29 
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Aldol 4.30: To a solution of aldehyde 4.24 (0.40 g, 0.76 mmol) and silyl enol 
ethers (7:1, 4.9/4.29; 0.83 g, 3.03 mmol, 4 equiv) in dichloromethane (32 mL) at 
0 °C was added CaH2 (64 mg, 1.52 mmol, 2 equiv). After 15 min, the reaction 
was cooled to -94 °C and BF3·OEt2 (105 µL, 1.52 mmol, 2 equiv) was added. The 
reaction mixture was stirred for 45 min at -94 °C and quenched with saturated 
NaHCO3 (25 mL), and the aqueous layer was extracted with dichloromethane 
(30-50 mL). The combined organic layers were dried (MgSO4), filtered, and 
concentrated in Vacuo. The residue was purified by flash chromatography 
(hexanes/EtOAc, 20:1-15:1) to afford 0.39 g (72%) of alcohol 4.30a-d as a 
12:3.8:1.6:1 mixture of diastereoisomers (by Varian HPLC, 21.4 mm X 25 cm 
column, 49 min gradient, 0-10% ethyl acetate in hexanes). For synthetic 
purposes the mixture can be advanced to the next step without further 
purification, as the resulting mixture of Yamaguchi esterification products can be 
easily separated to afford the desired ester product. 
 
Data for 4.30a: tR 34.25 min; [α]D25 -9.1 (c 2.1, CHCl3); IR (neat) 2953, 2873, 
1724, 1462, 1244, 1091, 1018 cm-1; 1H NMR (500 MHz C6D6) δ 6.25 (d, J = 16.0 
Hz, 1H), 6.05-5.98 (m, 1H), 5.63 (dd, J = 16.0, 7.5 Hz, 1H), 5.55 (t, J = 7.0 Hz, 
1H), 5.08-5.03 (m, 2H), 4.24-4.18 (m, 1H), 4.07 (t, J = 7.5 Hz, 1H), 4.04 (d, J = 
4.0 Hz, 1H). 3.99-3.95 (m, 1H), 3.66 (ddd. J = 10.0, 4.0, 2.0 Hz, 1H), 3.30 (s, 3H), 
2.61 (d, J = 9.0 Hz, 1H), 2.53-2.38 (m, 4H), 2.25-2.16 (m, 1H), 1.95-1.89 (m, 1H), 
1.88-1.82 (m, 1H), 1.76 (s, 3H), 1.66-1.60 (m, 1H), 1.60-1.52 (m, 1H), 1.11 (d, J = 
6.5 Hz, 3H), 1.05-0.99 (m, 21H), 0.91 (t, J = 8.0 Hz, 9H), 0.68-0.62 (m, 12 H), 
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0.52 (q, J = 8.0 Hz, 6H); 13C NMR (125 MHz, C6D6) δ 213.3, 141.3, 135.7, 133.7, 
132.5, 128.6, 114.2, 81.7, 80.8, 78.1, 71.6, 70.6, 58.2, 45.2, 33.5, 32.2, 31.7, 
25.3, 15.0, 12.6, 7.3, 7.1, 7.1, 6.9, 5.4, 5.4, 5.0; HRMS (MALDI) m/z 749.5078 
[(M + Na)+ calcd for C39H78O6Si3Na, 749.5004]. 
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Data for 4.30b: tR 31.75 min; [α]D25 -2.6 (c 0.16, CHCl3); IR (neat) 2955, 2877, 
1716, 1459, 1239, 1083, 1006, 677 cm-1; 1H NMR (500 MHz C6D6) δ 6.27 (dd, J 
= 15.5, 4.5 Hz, 1H), 6.07-5.98 (m, 1H), 5.65 (dd, J = 15.5, 7 Hz, 1H), 5.56-5.50 
(m, 1H), 5.10-5.04 (m, 2H), 4.25-4.19 (m, 1H), 4.17 (d, J = 4 Hz, 1H), 4.09 (t, J = 
6.2 Hz, 1H), 3.93-3.88 (m, 1H), 3.44-3.39 (m, 1H), 3.30 (d, J = 4.5 Hz, 1H), 3.09 
(s, 3H), 2.73-2-58 (m, 2H), 2.45-2.32 (m, 2H), 2.24-2.14 (m, 1H), 2.04 (d, J = 15 
Hz, 1H), 1.83-1.73 (m, 2H), 1.76 (s, 3H), 1.59-1.52 (m, 1H), 1.15-1.09 (m, 6H), 
1.07-0.94 (m, 27H), 0.69-0.56 (m, 18H); 13C NMR (125 MHz, C6D6) δ 211.9, 
141.4, 135.7, 133.8, 132.4, 128.8, 114.3, 84.5, 81.9, 78.1, 73.8, 71.6, 57.1, 45.2, 
32.9, 31.9, 31.8, 25.2, 15.1, 12.7, 7.4, 7.2, 7.0, 5.5, 5.4, 5.2; HRMS (MALDI) m/z 
749.5020 [(M + Na)+ calcd for C39H78O6Si3Na, 749.5004]. 
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Data for 4.30c: tR 32.80 min; [α]D25 -9.3 (c 0.08, CHCl3); IR (neat) 2955, 2878, 
2361, 1714, 1459, 1238, 1096, 1008, 741 cm-1; 1H NMR (500 MHz C6D6) δ 6.26 
(d, J = 19.5 Hz, 1H), 6.08-5.97 (m, 1H), 5.65 (dd, J = 19.5, 9.2 Hz, 1H), 5.58-5.52 
(m, 1H), 5.10-5.04 (m, 2H), 4.25-4.20 (m, 1H), 4.14 (d, J = 5.8 Hz, 1H), 4.09 (t, J 
= 7.9 Hz, 1H), 4.00-3.95 (m, 1H), 3.60-3.57 (m, 1H), 3.27 (s, 3H), 3.01 (d, J = 5 
Hz, 1H), 2.62-2.47 (m, 2H), 2.45-2.32 (m, 2H), 2.27-2.15 (m, 1H), 2.00-1.92 (m, 
1H), 1.77 (s, 3H), 1.65-1.55 (m, 1H), 1.13 (d, J = 8.6 Hz, 3H), 1.08-1.00 (m, 18H), 
0.95 (t, J = 10.0 Hz, 9H), 0.66 (q, J = 9.8 Hz, 12H), 0.58 (q, J = 9.9 Hz, 6H); 13C 
NMR (150 MHz, C6D6) δ 141.4, 135.8, 133.8, 132.5, 128.7, 114.2, 84.5, 82.4, 
81.9, 78.1, 73.9, 72.4, 71.6, 71.1, 58.0, 57.1, 45.3, 32.9, 32.5, 32.0, 31.9, 25.2, 
15.1, 12.7, 7.4, 7.2, 7.0, 6.9, 5.6, 5.5, 5.4, 5.2, 5.1; HRMS (MALDI) m/z 749.5038 
[(M+ Na)+ calcd for C39H78O6Si3Na, 749.5004]. 
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Data for 4.30d: tR 36.80 min; [α]D25 -50.0 (c 0.01, CHCl3); IR (neat) 2955, 2878, 
1713, 1459, 1239, 1105, 1007, 741 cm-1; 1H NMR (500 MHz C6D6) δ 6.30 (d, J = 
19.6 Hz, 1H), 6.08-5.98 (m, 1H), 5.67 (dd, J = 19.5, 9.1 Hz, 1H), 5.56-5.50 (m, 
1H), 5.11-5.04 (m, 2H), 4.30-4.17 (m, 1H), 4.11 (t, J = 7.9 Hz, 1H), 4.07 (d, J = 
5.2 Hz, 1H), 3.94-3.89 (m, 1H), 3.48 (d, J = 12.6 Hz, 1H), 3.29 (s, 3H), 2.55-2.32 
(m, 4H), 2.22-2.12 (m, 1H), 1.91-1.85 (m, 1H), 1.78 (s, 3H), 1.71-1.59 (m, 2H), 
1.51-1.42 (m, 1H), 1.13 (d, J = 8.5 Hz, 3H), 1.10-1.00 (m, 18H), 0.94 (t, J = 9.9 
Hz, 9H), 0.75-0.62 (m, 12H), 0.56 (q, J = 9.9 Hz, 6H); 13C NMR (150 MHz, C6D6) 
δ 141.4, 135.7, 133.8, 132.2, 128.9, 114.3, 82.1, 81.5, 78.1, 72.9, 70.7, 57.9, 
45.3, 34.2, 34.0, 32.1, 25.3, 15.1, 12.7, 7.3, 7.2, 7.1, 7.0, 5.6, 5.5, 5.0; HRMS 
(MALDI) m/z 749.5030 [(M + Na)+ calcd for C39H78O6Si3Na, 749.5004]. 
 
Figure 4.3  HPLC chromatograph for purification of aldol 4.30 
 
 
  77 
OTMS
TESO
Z-4.29  
 
Silyl Enol Ether (Z)-4.29: To a solution of silyl ether 4.28 (0.54 g, 2.67 mmol) in 
THF (10 mL) at 0 °C, triethyl amine (0.6 mL, 1.6 equiv) was added dropwise 
followed by TMSOTf (0.72 mL, 1.5 equiv). Stirred at 0 °C for 30 min then 
quenched with water (10 mL). The mixture was extracted with Et2O (3 x 50 mL). 
The combined organic phase was dried over MgSO4 and the solvent was 
removed in vacuo to afford 0.67 g (92%) of (Z)-4.29 as a yellow oil: IR (neat) 
1251, 1064 cm-1; 1H NMR (300 MHz, C6D6): δ 4.90 (q, J = 6.7 Hz, 1H), 4.01 (s, 
2H), 1.62 (d, J = 6.9 Hz, 3H), 0.99 (t, J = 7.9 Hz, 9H), 0.60 (q, J = 7.8 Hz, 6H), 
0.23 (s, 9H); 13C NMR (75 MHz, CDCl3): δ 103.1, 65.1, 10.7, 7.0, 6.8, 4.8, 0.8; 
HRMS (ESI) m/z 281.1948 [(M+Li)+ calculated for C13H30LiO2Si2: 281.1944]. 
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Silyl Enol Ether 4.31: To a solution of aldehyde 4.11 (0.15 g, 0.37 mmol) in 
dichloromethane (5 mL) at 0 °C K2CO3 (77 mg, 0.56 mmol, 1.5 equiv) was 
added. The reaction mixture was cooled to -78 °C at which time BF3•OEt2 (9 µL, 
0.074 mmol, 0.2 equiv) was added dropwise followed by (Z)-4.29 silyl enol ether 
(0.2 g, 0.74 mmol, 2 equiv). The resultant solution was stirred for 3 h at -78 °C, 
quenched with saturated NaHCO3 aqueous solution (5 mL). The aqueous layer 
  78 
was extracted with dichloromethane (3 x 5 mL) and the combined organic layers 
were dried over MgSO4, filtered and concentrated in vacuo. The residue was 
purified by flash chromatography (Hexanes/Ethyl Acetate, 25/1) to afford 0.17 g 
(68%) of silyl enol ether 4.31 as a slightly yellow oil: [α]D 25 -45.5 (c 0.69, CHCl3); 
IR (neat) 2956, 2878, 1682, 1460, 1248, 1154, 1003, 837, 744 cm-1; 1H NMR 
(500 MHz, C6D6): δ 5.72 (s, 1H), 4.24 (td, J = 6.8, 2.5 Hz, 1H), 4.08 (d, J = 8.5 
Hz, 1H), 4.02-3.98 (m, 1H), 3.37-3.31 (m, 2H), 3.17 (s, 3H), 3.08 (d, J = 1.5 Hz, 
1H), 2.26 (q, J = 7 Hz, 1H), 2.05-1.95 (m, 3H), 1.44 (d, J = 6.5 Hz, 3H), 1.21 (d, J 
= 6.5 Hz, 3H), 1.05-1.02 (m, 18H), 0.98 (t, J = 8 Hz, 9H), 0.70 (q, J = 8 Hz, 6H), 
0.61 (q, J = 8 Hz, 6H), 0.33 (s, 9H), 0.22 (s, 3H), 0.20 (s, 3H); 13C NMR (100 
MHz, C6D6): δ 139.4, 120.8, 77.5, 77.1, 75.6, 69.8, 58.8, 41.2, 40.6, 38.9, 26.2, 
18.4, 16.0, 7.2, 6.8, 6.6, 5.8, 4.7, 1.1, -3.9, -4.4; HRMS (ESI) m/z 701.4455 
[(M+Na)+ calculated for C33H74NaO6Si4: 701.4460]. 
 
O
O
OH
H
Me Me
HO
OMe
4.32  
 
Pyran 4.32: A solution of silyl enol ether 4.31 (4 mg, 5.9 µmol) and p-TsOH (1 
mg, 5.2 µmol) in 1 mL MeOH was stirred overnight at room temperature. The 
solvent was removed in vacuo and the residue was purified by flash 
chromatography (CH2Cl2/MeOH, 25/1) to afford 1 mg (69%) of pyran 4.32 as a 
colorless oil: 1H NMR (600 MHz, CD3OD): δ 4.02 (t, J = 5.4 Hz, 1H), 3.95 (ddt, J 
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= 12, 5.4, 4.2 Hz, 1H), 3.59 (t, J = 9.9 Hz, 1H), 3.41 (d, J = 12 Hz, 1H), 3.36 (d, J 
= 11.4 Hz, 1H), 3.35 (s, 3H), 3.33 – 3.31 (m, 1H), 1.99 dqd, J = 10.2, 7.2, 5.4 Hz, 
1H), 1.96 (dq, J = 9.6, 6.6 Hz, 1H), 1.71 (ddd, J = 13.8, 12.6, 6 Hz, 1H), 1.64 
(ddd, J = 13.8, 3.6, 0.6 Hz, 1H), 1.05 (d, J = 6.6 Hz, 3H), 1.02 (d, J = 7.2 Hz, 3H); 
HRMS (ESI) m/z 253.1625 [(M+Li)+ calculated for C12H22LiO5: 253.1627]. 
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Vinyl Boronate 4.35: To a solution of alkene 4.33 (28.9 mg, 19.5 µmol) in 
toluene (0.2 mL) was added 1-propenyl pinacol boronic ester 4.12 (33 mg, 195 
µmol, 10 equiv) followed by Grubbs second-generation catalyst 4.34 (1.7 mg, 
1.95 µmol, 0.1 equiv). The resulting solution was stirred at 80 °C for 6 h, then 0.2 
mL toluene were added and the mixture stirred at 40 °C for 24 h. The reaction 
mixture was then cooled to room temperature and diluted with dichloromethane 
(5 mL). The resultant solution was filtered through a short silica gel plug. The 
solvent was removed in vacuo and the residue was purified by HPLC 
(Hexanes/EtOAc, 0-5% gradient over 50 min) to afford 16.6 mg (53%) vinyl 
boronate 4.35 as a colorless oil: IR (neat) 2954, 2365, 1708, 1638, 1459, 1362, 
1242, 1112, 1007 cm-1; 1H NMR (500 MHz, C6D6): δ 7.27 (s, 1H), 7.12 (d, J = 7 
Hz, 1H), 6.27 (s, 1H), 6.26 (d, J = 15.5 Hz, 1H), 5.98 (d, J = 11 Hz, 1H), 5.85 (d, 
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J = 18 Hz, 1H), 5.64 (dd, J = 15.5, 7 Hz, 1H), 5.52 (t, J = 6.8 Hz, 1H), 4.88 (d, J = 
3 Hz, 1H), 4.32 (dd, J = 8.5, 5.5 Hz, 1H), 4.22 (d, J = 8 Hz, 1H), 4.18 (t, J = 5.8 
Hz, 1H), 4.00-3.92 (m, 2H), 3.48 (q, J = 7 Hz, 1H), 3.43-3.40 (m, 2H), 3.38 (s, 
3H), 3.30 (dd, J = 11, 4 Hz, 1H), 3.21 (s, 3H), 2.49-2.36 (m, 3H), 2.26-2.15 (m, 
1H), 2.14-2.07 (m, 1H), 2.05-1.92 (m, 2H), 1.90 (s, 3H), 1.89-1.82 (m, 1H), 1.78 
(s, 3H), 1.75-1.73 (m, 1H), 1.72 (s, 3H), 1.64-1.53 (m, 1H), 1.37 (d, J = 7 Hz, 3H), 
1.20-1.00 (m, 72H), 0.99-0.89 (m, 6H), 0.88-0.82 (m, 6H), 0.79-0.73 (m, 6H), 
0.68-0.59 (m, 12H), 0.22 (s, 3H), 0.20 (s, 3H); 13C NMR (150 MHz, C6D6): δ 
209.5, 167.8, 157.2, 143.9, 139.5, 135.6, 133.9, 132.3, 128.8, 86.5, 82.9, 80.7, 
79.9, 77.6, 77.1, 74.7, 72.5, 70.9, 70.4, 70.1, 58.9, 58.3, 47.2, 47.0, 43.9, 40.7, 
31.5, 31.2, 25.4, 24.9, 24.8, 24.3, 14.4, 14.2, 12.7, 12.1, 10.2, 7.6, 7.5, 7.3, 7.2, 
6.7, 5.9, 5.8, -3.9, -4.4; HRMS (MALDI) m/z 1627.9080 [(M+Na)+ calcd for 
C78H154BINaO13Si6: 1627.9040]. 
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Macrolactone 4.5: To a solution of vinyl boronate 4.35 (16.6 mg, 10.3 µmol) in 
THF/H2O (12 mL, 3:1, degassed) was added Pd(Ph3P)4 (2.4 mg, 2.06 µmol, 0.2 
equiv). The resulting yellow solution was stirred for 5 min before Tl(OEt) (1.1 µL, 
15.45 µmol, 1.5 equiv) was added. The solution was stirred for 15 min (color 
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turns from yellow to grey). The reaction was quenched with saturated NaHCO3 (5 
mL) and the aqueous layer was extracted with dichloromethane (3 x 10 mL). The 
combined organic layers were dried (MgSO4), filtered and concentrated in vacuo. 
The residue was diluted with hexanes and filtrated through a small silica gel plug 
(washed with Hexanes until no more product eluted) to afford 13.3 mg (95%) of 
macrolactone 3.5 as a colorless oil: IR (neat) 2954, 2876, 1723, 1699, 1458, 
1239, 1110, 1007, 740 cm-1; 1H NMR (500 MHz, C6D6): δ 7.53 (s, 1H), 6.27 (d, J 
= 11 Hz, 1H), 6.05 (dd, J = 14.5, 11 Hz, 1H), 5.92 (d, J = 16 Hz, 1H), 5.75 (d, J = 
8 Hz, 1H), 5.53 (t, J = 7.3 Hz, 1H), 5.40-5.30 (m, 2H), 5.00 (d, J = 4 Hz, 1H), 4.33 
(dd, J = 8.5, 4.5 Hz, 1H), 4.27 (d, J = 8 Hz, 1H), 3.98-3.92 (m, 1H), 3.82 (t, J = 
8.5 Hz, 1H), 3.65 (t, J = 6.5 Hz, 1H), 3.57-3.51 (m, 1H), 3.54 (s, 3H), 3.43-3.39 
(m, 2H), 3.20 (s, 3H), 3.03 (t, J = 7.8 Hz, 1H), 2.54-2.46 (m, 1H), 2.41-2.34 (m, 
1H), 2.16-1.93 (m, 6H), 2.09 (s, 3H), 1.84-1.78 (m, 1H), 1.72 (s, 3H), 1.70-1.64 
(m, 1H), 1.61 (s, 3H), 1.46 (d, J = 7 Hz, 3H), 1.44-1.36 (m, 1H), 1.27 (d, J = 6.5 
Hz, 3H), 1.22-1.03 (m, 56H), 1.02-0.86 (m, 12H), 0.79-0.65 (m, 18H), 0.22 (s, 
3H), 0.19 (s, 3H); 13C NMR (150 MHz, C6D6):   209.9, 168.2, 144.9, 144.5, 140.9, 
136.2, 133.6, 132.6, 131.9, 131.0, 126.1, 123.9, 82.2, 80.6, 78.3, 77.2, 76.2, 
74.1, 73.1, 70.5, 70.1, 61.0, 58.8, 47.3, 46.7, 43.7, 40.9, 35.6, 34.9, 26.1, 24.8, 
18.6, 15.4, 14.1, 12.2, 11.3, 10.4, 7.6, 7.5, 7.4, 7.3, 7.2, 6.7, 6.0, 5.9, 5.6, 5.5, -
3.9, -4.4; HRMS (MALDI) m/z 1373.9100 [(M+Na)+ calcd for C72H142NaO11Si6: 
1373.9065]. 
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Apoptolidinone D 4.2. To solution of 19.9 mg (14.7 µMol) macrolactone 4.5 in 4 
mL of THF at -10 °C was added HF•Py (0.2 mL) dropwise. After 1 h the 
temperature was raised to 0 °C and after an additional 12 h to 10 °C. After 36 h 
the reaction mixture was diluted with Et2O, washed with water, and concentrated 
in vacuo leaving ca. 4 mL of Et2O. (It was noticed that drying over MgSO4 
significantly decreased the amount of product in the solution.) The residue was 
purified by flash chromatography (CH2Cl2/MeOH, 15:1) to afford 8.5 mg (87%) of 
apoptolidinone D 4.2 as a off-white solid: [α]D25 +67.5; IR (neat) 3382, 2927, 
2362, 1666, 1390, 1255, 1100, 1024, 965, 754 cm-1; 1H NMR (600 MHz, CD3OD) 
δ 7.39 (s, 1H), 6.27-6.22 (m, 2H), 5.99 (d, J = 15.6 Hz, 1H), 5.57 (t, J = 8.1 Hz, 
1H), 5.48-5.44 (m, 1H), 5.32-5.28 (m, 2H), 4.08 (dt, J = 8.4, 2.4 Hz, 1H), 3.78-
3.73 (m, 2H), 3.55-3.50 (m, 1H), 3.53 (d, J = 1.2 Hz, 1H), 3.42-3.35 (m, 2H), 3.37 
(s, 3H), 3.26 (s, 3H), 3-18-3.12 (m, 2H), 2.66 (dd, J = 9.6, 5.4 Hz, 1H), 2.49-2.42 
(m, 1H), 2.30-2.23 (m, 1H), 2.17-1.95 (m, 5H), 2.13 (s, 3H), 2.08 (s, 3H), 1.79-
1.72 (m, 2H), 1.72-1.53 (m, 3H), 1.64 (s, 3H), 1.43-1.22 (m, 4H), 1.18 (d, J = 6.6 
Hz, 3H), 1.02 (d, J = 6.6 Hz, 3H), 0.87 (d, J = 6.6 Hz, 3H); 13C NMR (150 MHz, 
CD3OD) δ 172.6, 147.5, 146.0, 143.0, 137.4, 135.0, 133.5, 132.2, 130.9, 126.6, 
124.2, 101.3, 84.0, 80.0, 78.5, 75.4, 74.9, 73.8, 72.5, 69.2, 68.1, 61.4, 59.4, 46.7, 
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40.9, 38.5, 38.3, 36.3, 36.1, 24.8, 18.6, 15.6, 13.9, 12.2, 12.1, 5.3; HRMS 
(MALDI) m/z 689.3881 [(M + Na)+ calcd for C36H58NaO11, 689.3877]. 
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Carboxylic Acid 4.37: To a solution of ester 4.42 (2.0 g, 7.9 mmol) in 
MeOH/H2O (7.5 mL/2.5 mL) was added lithium hydroxide hydrate (1.7 g, 39.7 
mmol). The clear solution was stirred at ambient temperature for 6.5 h.  Solvent 
was removed in vacuo and the residue was diluted with CH2Cl2 (20 mL) and 
water (10 mL). The biphasic mixture was then acidified with concentrated 
aqueous HCl to pH=3. The aqueous layer was separated and extracted with 
CH2Cl2 (3 X 50 mL). The combined organic layers were dried over Na2SO4 and 
concentrated in vacuo.  Flash chromatography of the residue (petroleum 
ether:ether: 4:1) gave 1.7 g (90%) of 4.37 as a yellow solid: IR (neat) 3049, 2917, 
1671, 1420, 1290, 976 cm-1; 1H NMR (400 MHz, CDCl3): δ 7.43 (d, J = 15.6 Hz, 
1H), 7.03 (s, 1H), 5.97 (d, J = 15.6 Hz, 1H), 2.03 (s, 3H); 13C NMR (100 MHz, 
CDCl3): δ 172.3, 146.6, 144.0, 117.4, 95.1, 19.6. 
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Ester 4.43: To a solution of aldol 4.30a (0.78 g, 1.08 mmol) and acid 4.37 (0.32 
g, 1.35 mmol) in toluene and THF (1:1 36 mL) was added DMAP (1.98 g, 16.21 
mmol) at 0 °C. After DMAP dissolved completely the mixture was cooled to -78 
°C, and Et3N (1.66 mL, 11.89 mmol) was added followed by 2,4,6-
trichlorobenzoyl chloride (1.70 mL, 10.81 mmol). The resulting slurry was slowly 
warmed to room temperature over 2.5 h. The reaction was stirred overnight at 
room temperature, quenched with saturated NaHCO3 (10 mL) and the aqueous 
layer was extracted with Et2O (3 x 25 mL). The combined organic layers were 
dried (Na2SO4), filtered and concentrated in vacuo. The residue was purified by 
flash chromatography (Hexanes/EtOAc, 50:1) to afford 0.35 g (35%) of desired 
ester diastereomer 4.43 as a colorless oil:  [α]D20 –13.7 (c 1.0, CHCl3); IR (neat) 
2954, 2877, 2362, 2342, 1718, 1622, 1458, 1284, 1107, 1007, 726 cm-1; 1HMR 
(600 MHz, C6D6): δ 7.35 (d, J = 15.6 Hz, 1H), 6.27 (d, J = 13.8 Hz, 1H),  6.26 (s, 
1H), 6.06-6.01 (m, 1H), 5.93 (d, J = 16.2 Hz, 1H), 5.90 (ddd, J = 10.8, 4.2, 1.8 
Hz, 1H), 5.65 (dd, J = 15.6, 7.2 Hz, 1H), 5.56 (t, J = 6.6 Hz, 1H), 5.09-5.06 (m, 
2H), 4.30 (d, J = 4.2 Hz, 1H), 4.09 (dd, J = 6.6, 6.6 Hz, 1H), 3.99-3.97 (m, 1H), 
3.38 (s, 3H), 3.37-3.34 (m, 1H), 2.70-2.63 (m, 1H), 2.44-2.35 (m, 3H), 2.33 -2.28 
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(m, 1H), 2.24-2.19 (m, 1H), 1.89-1.82 (m, 1H), 1.78 (s, 3H), 1.59-1.57 (m, 1H), 
1.57 (s, 3H), 1.14 (d, J = 4.2 Hz, 3H), 1.05-0.97 (m, 27H), 0.91 (t, J = 7.2 Hz, 
3H), 0.67-0.59 (m, 18H); 13C NMR (150 MHz, C6D6): δ 209.2, 166.4, 145.0, 
144.0, 141.4, 135.8, 133.9, 132.4, 128.8, 118.3, 114.3, 94.1, 80.8, 80.5, 78.2, 
72.0, 71.0, 58.3, 45.2, 32.0, 31.5, 31.0, 25.4, 19.2, 15.1, 12.8, 7.6, 7.2, 7.2, 7.0, 
5.5, 5.5, 5.1; HRMS (ESI) m/z 969.4393, [(M+Na)+ calculated for 
C45H83INaO7Si3: 969.4383]. 
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Aldol 4.44: To a solution of LHMDS (0.14 mL, 0.13 mmol, 1M in THF) in 
THF (2 mL) at -78 °C was added a solution of ketone 4.43 (0.064 g, 0.068 
mmol) and HMPA (0.034 mL, 0.20 mmol) in THF (2 mL). The reaction mixture 
was stirred at -78 °C for 2 h before a solution of aldehyde 4.11 (0.081 g, 0.20 
mmol) in THF (1 mL) was added dropwise. The solution was stirred at -78 °C for 
3 h, quenched with saturated NH4Cl (5 mL) and warmed to room temperature.  
The aqueous layer was extracted with Et2O (3 x 10 mL) and the combined 
organic layers were dried (Na2SO4), filtered and concentrated in vacuo. The 
residue was purified by HPLC: 21.4 mm x 25 cm column, 49 min gradient, 0–5% 
ethyl acetate in hexanes to afford 0.016 g (18%) of aldol 4.44 as a colorless oil: 
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[α]D20 –22.37 (c 0.8, CHCl3); IR (neat) 3474, 2955, 2877, 1716, 1622, 1459, 
1283, 1109, 1005, 742 cm-1; 1H NMR (600 MHz, C6D6): δ 7.37 (d, J = 15.6 Hz, 
1H), 6.31 (s, 1H), 6.27 (d, J = 15.6 Hz, 1H), 6.10-6.07 (m, 1H), 6.06-6.00 (m, 
1H), 5.96 (d, J = 15.6 Hz, 1H), 5.65 (dd, J = 15.6, 7.2 Hz, 1H), 5.54 (t, J = 7.2 
Hz, 1H), 5.09-5.06 (m, 2H), 4.92 (d, J = 3.6 Hz, 1H), 4.44 (d, J = 9.6 Hz, 1H), 
4.36-4.33 (m, 1H),  4.12-4.08 (m, 2H), 4.04 (s, 1H), 4.02-3.97 (m, 1H), 3.43 (s, 
3H), 3.39-3.35 (m, 1H), 3.32-3.28 (m, 1H), 3.27 (d, J = 4.8 Hz, 1H), 3.09 (s, 3H), 
2.45-2.35 (m, 3H), 2.26-2.18 (m, 1H), 2.09-2.05 (m, 1H), 1.99-1.83 (m, 4H), 1.78 
(s, 3H), 1.61 (s, 3H), 1.61-1.56 (m, 1H), 1.34 (d, J = 6.6 Hz, 3H), 1.13 (d, J = 6.6 
Hz, 3H), 1.10-1.00 (m, 45H), 0.94 (d, J = 7.2 Hz, 3H), 0.80-0.74 (m, 6H), 0.70-
0.62 (m, 18H), 0.23 (s, 3H), 0.20 (s, 3H);  13C NMR (150 MHz, C6D6): δ 209.9, 
166.6, 145.1, 144.1, 141.4, 135.8, 133.8, 132.5, 128.7, 118.5, 114.3, 94.2, 81.0, 
79.4, 78.2, 73.5, 72.9, 72.3, 71.1, 70.1, 58.4, 58.3, 45.4, 45.2, 41.0, 39.0, 31.6, 
31.4,  26.2, 25.4, 19.2, 18.6, 15.1, 12.8, 12.2, 7.7, 7.6, 7.3, 7.3, 7.2, 7.2, 7.1, 5.7, 
5.5, 5.4, -3.3, -4.5; HRMS (ESI) m/z 1373.7184, [(M+Na)+ calculated for 
C65H127INaO11Si5: 1373.7162]. 
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Silyl Ether 4.45: To a solution of alcohol 4.44 (0.08 g, 0.05 mmol) in 
dichloromethane (11 mL) at -78 °C was added 2,6-lutidine (0.05 mL, 0.46 mmol) 
followed by TESOTf (0.08 mL, 0.35 mmol). The mixture was stirred for 30 min at 
-78 °C, then 30 min at 0 °C and quenched with H2O (10 mL).  The aqueous layer 
was extracted with dichloromethane (3 x 10 mL) and the combined organic layers 
were dried (Na2SO4), filtered and concentrated in vacuo.  The residue was 
purified by flash chromatography (Hexanes:EtOAc = 50:1) to afford 0.12 g 
quantative yield of TES ether 4.45 as a colorless oil:  [α]D20 –51.67 (c 1.2, 
CHCl3); IR (neat)  2954, 2877, 1717, 1622, 1459, 1283, 1109, 1006, 740 cm-1; 
1HMR (600 MHz, C6D6): δ 7.35 (d, J = 15.6 Hz, 1H), 6.30 (s, 1H), 6.20 (d, J = 
15.6 Hz, 1H), 6.07-5.99 (m, 2H), 5.94 (d, J = 15.6 Hz, 1H), 5.65 (dd, J = 15.6, 7.2 
Hz, 1H), 5.56 (t, J = 7.2 Hz, 1H), 5.10-5.06 (m, 2H), 4.93 (d, J = 3.0 Hz, 1H), 4.33 
(ddd, J = 8.4, 5.4, 1.2 Hz, 1H), 4.23 (dd, J = 8.4, 1.2 Hz, 1H), 4.09 (t, J = 7.2 Hz, 
1H), 4.01-3.98 (m, 1H), 3.95-3.93 (m, 1H), 3.56 (dq, J = 6.6, 1.2 Hz, 1H), 3.41 (s, 
3H), 3.30 (ddd, J = 10.8, 4.2, 0 Hz, 1H), 3.21 (s, 3H), 2.48-2.39 (m, 3H), 2.26-
2.19 (m, 1H), 2.14-2.09 (m, 1H), 2.05-2.00 (m, 1H), 1.95-1.85 (m, 2H), 1.78 (s, 
3H), 1.78-1.74 (m, 1H), 1.62-1.57 (m, 1H), 1.60 (s, 3H), 1.41 (d, J = 7.2 Hz, 1H), 
1.19-1.15 (m, 18H), 1.13 (d, J = 6.6 Hz, 3H), 1.10-1.01 (m, 39H), 0.99-0.90 (m, 
6H), 0.86 (q, J = 7.8 Hz, 6H), 0.76 (q, J = 7.8 Hz, 6H), 0.70-0.62 (m, 12H), 0.21 
(s, 3H), 0.19 (s, 3H);  13C NMR (150 MHz, C6D6): δ 208.9 166.2, 144.9, 143.8, 
141.2, 135.5, 133.6, 132.2, 128.7, 118.0, 114.0, 94.1, 80.4, 77.9, 76.8, 74.7, 
71.8, 70.6, 70.2, 69.8, 58.7, 58.0, 47.0, 45.0, 43.7, 40.4, 31.2, 25.9, 25.2, 18.9,  
18.1, 14.9, 12.6, 11.9, 10.0, 7.3, 7.3, 7.1, 7.0, 6.9, 6.5, 5.7, 5.3, -4.2, -4.6; HRMS 
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(ESI) m/z 1487.8015 [(M+Na)+ calculated for C71H141INaO11Si6: 1487.8026]. 
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Vinyl Boronate 4.46: To a solution of alkene 4.45 (120.0 mg, 57.7 µmol) in 
dichloromethane (11.0 mL) was added 1-propenyl pinacol boronic ester 4.12 (89 
mg, 576 µmol) followed by Grubbs second-generation catalyst 4.34 (5 mg, 5.77 
µmol) at room temperature. The resulting solution was stirred at 50 °C for 46 h, 
cooled to room temperature and diluted with dichloromethane (10 mL). The 
resultant solution was filtered through a short silica gel plug.  The solvent was 
removed in vacuo and the residue was purified by HPLC (Hexanes/EtOAc, 0-5% 
gradient over 50 min) to afford 25 mg (25%) vinyl boronate 4.46 as a colorless 
oil: [α]D20 42.76 (c 1.3, CHCl3); IR (neat) 2955, 2877, 1718, 1623, 1459, 1243, 
1109, 1007, 741 cm-1; 1HMR (600 MHz, C6D6): δ 7.36 (d, J = 15.6 Hz, 1H), 6.29 
(s, 1H), 6.26 (d, J = 15.6 Hz, 1H), 6.07-6.05 (m, 1H), 5.94 (d, J = 15.6 Hz, 1H), 
5.85 (d, J = 18.0, Hz, 1H), 5.63 (dd, J = 15.6, 6.6 Hz, 1H), 5.53 (t, J = 6.6 Hz, 
1H), 4.34-4.31 (m, 1H), 4.24 (dd, J = 8.4, 1.8 Hz, 1H), 4.18 (dd, J = 6.6, 5.4 Hz, 
1H), 4.00-3.97 (m, 1H), 3.96-3.92 (m, 1H), 3.56 (dq, J = 6.6, 1.8 Hz, 1H), 3.41 (s, 
3H), 3.41 (d, J = 3.0 Hz, 2H), 3.30 (ddd, J = 11.4, 4.2, 0 Hz, 1H), 3.21 (s, 3H), 
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2.49-2.39 (m, 3H), 2.24-2.17 (m, 1H), 2.14-2.07 (m, 1H), 2.05-2.00 (m, 1H), 1.95-
1.84 (m, 2H), 1.79-1.74 (m, 1H), 1.72 (s, 3H), 1.62-1.57 (m, 1H), 1.60 (s, 3H), 
1.41 (d, J = 7.2 Hz, 3H), 1.19-1.15 (m, 21H), 1.14-1.07 (m, 24H), 1.06-1.01 (m, 
27H), 1.00-0.91 (m, 6H), 0.87 (q, J = 7.8 Hz, 6H), 0.76 (q, J = 6.6 Hz, 6H), 0.67-
0.62 (m, 12H), 0.21 (s, 3H), 0.19 (s, 3H);  13C NMR (150 MHz, C6D6): δ 209.0, 
166.2, 156.9, 144.9, 143.8, 135.4, 133.7, 132.0, 128.5, 118.0, 94.0, 82.6, 80.4, 
77.4, 76.8, 74.7, 71.8, 70.5, 70.1, 69.8, 58.7, 58.0, 47.1, 46.7, 43.7, 40.4, 31.3, 
31.2, 25.9, 25.2, 24.7, 24.6, 18.9, 18.1, 14.0, 12.5, 11.9, 9.8, 7.3, 7.3, 7.2, 7.1, 
7.0, 7.0, 6.5, 5.7, 5.3, 5.2, -4.2, -4.6; HRMS (ESI) m/z 1613.8924, [(M+Na)+ 
calculated for C77H152BINaO13Si6: 1613.8878]. 
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Macrolactone 4.36: To a solution of vinyl boronate 4.46 (26 mg, 15.9 µmol) in 
THF/H2O (8 mL, 3:1, degassed) was added Pd(PPh3)4 (1.8 mg, 1.59 µmol) at 
room temperature. The resulting yellow solution was stirred for 10 min, then 
TlOEt (1.3 µL, 18.8 µmol) was added. The reaction mixture was stirred for 
another 20 min (color turns from yellow to grey) at room temperature. The 
reaction was quenched with saturated NaHCO3 (5 mL) and the aqueous layer 
was extracted with ethyl acetate (3 x 10 mL).  The combined organic layers were 
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dried (Na2SO4), filtered and concentrated in vacuo.  The residue was purified by 
flash chromatography (Hexanes/EtOAc, 25:1) to afford 11 mg (52%) of lactone 
4.36 as a colorless oil: [α]D20 -16 (c 0.45, CHCl3); IR (neat) 2955, 2877, 2360, 
1709, 1459, 1243, 1121, 1077, 1008, 740; 1HMR (600 MHz, C6D6): δ 7.50 (d, J = 
15.6 Hz, 1H), 6.15 (d, J = 10.8 Hz, 1H), 5.91 (dd, J = 15.0, 10.8 Hz, 1H), 5.94-
5.86 (m, 1H), 5.83 (d, J = 15.6 Hz, 1H), 5.79 (d, J = 16.2 Hz, 1H), 5.46 (t, J = 7.2 
Hz, 1H), 5.28-5.21 (m, 2H), 4.97 (d, J = 3.6 Hz, 1H), 4.35-4.26 (m, 2H), 3.98-3.93 
(m, 1H), 3.75 (dt, J = 8.4, 0, 1H), 3.68 (dt, J = 7.8, 3.0 Hz, 1H), 3.62-3.58 (m, 1H), 
3.60 (s, 3H), 3.41 (d, J = 4.8 Hz, 2H), 3.20 (s, 3H), 3.06-3.3.03 (m, 1H), 2.49-2.42 
(m, 1H), 2.31-2.26 (m, 1H), 2.18-2.06 (m, 3H), 2.05-2.01 (m, 2H), 1.84-1.78 (m, 
1H), 1.72-1.66 (m, 1H), 1.64 (s, 3H), 1.62-1.57 (m, 1H), 1.57 (s, 3H), 1.45 (d, J = 
7.2 Hz, 3H), 1.42 (s, 3H), 1.25 (d, J = 6.6 Hz, 3H), 1.20-1.17 (m, 18H), 1.12-1.02 
(m, 30H), 1.02-0.82 (m, 21 H), 0.80-0.65 (m, 18H), 0.22 (s, 3H), 0.19 (s, 3H); 13C 
NMR (150 MHz, C6D6): δ 209.8, 165.7, 150.5, 145.7, 140.8, 136.1, 133.7, 131.8, 
131.1, 129.0, 126.7, 115.9, 82.0, 80.6, 77.2, 76.2, 72.5, 70.5, 70.1, 68.0, 60.8, 
58.8, 46.8, 43.8, 39.2, 35.0, 30.8, 29.3, 26.1, 24.7, 24.1, 18.1, 12.2, 11.8, 10.4, 
7.6, 7.5, 7.4, 7.3, 7.1, 6.7, 6.1, 6.0, 5.6, 5.5, -3.9, -4.4; HRMS (ESI) m/z 
1359.8911 [(M+Na)+ calculated for C71H140NaO11Si6: 1359.8903]. 
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2,6-Dinormethyl Apoptolidinone A 4.3: To solution of 11.0 mg (8.21 µmol) 
macrolactone 4.36 in 6 mL THF and 6 mL acetonitrile at -10 °C, 0.2 mL H2SiF6 
(20-25% wt in H2O) was added dropwise. After stirred for 24 h at -10 °C, the 
reaction mixture was quenched with saturated NaHCO3 solution and the aqueous 
layer was extracted with ethyl acetate (3 x 10 mL).  The combined organic layers 
were dried (Na2SO4), filtered and concentrated in vacuo. The residue was 
purified by flash chromatography (CH2Cl2/MeOH, 20:1) to afford 4.0 mg (75%) of 
2,6-Dinormethylapoptolidinone A 4.3 as a white solid: [α]D20 57.5 (c 0.40, CHCl3); 
IR (neat) 3399, 2925, 1674, 1601, 1456, 1271, 1097, 1026 cm-1; 1H NMR (400 
MHz, CD3OD): δ 7.47 (d, J = 10.4 Hz, 1H), 6.32-6.21 (m, 2H), 5.97 (d, J = 10.4 
Hz, 1H), 5.76 (d, J = 10.4 Hz, 1H), 5.57-5.52 (m, 2H), 5.35 (dt, J = 7.6, 0 Hz, 1H), 
5.28 (dd, J = 10.4, 6.0 Hz, 1H), 4.12 (dt, J = 4.8, 1.6 Hz, 1H), 3.80-3.74 (m, 2H), 
3.68-3.64 (m, 1H), 3.55 (d, J = 1.2 Hz, 1H), 3.43 (s, 3H), 3.41-3.37 (m, 1H), 3.25 
(s, 3H), 3.17-3.10 (m, 2H), 2.64 (ddd, J = 5.6, 4.4, 0.0 Hz, 1H), 2.51-2.45 (m, 1H), 
2.30-2.25 (m, 1H), 2.13 (dd, J = 10.0, 7.6 Hz, 1H), 2.05 (dd, J = 7.6, 4.4 Hz, 1H), 
2.08-2.02 (m, 1H), 1.97-1.91 (m, 1H), 1.85 (s, 3H), 1.76-1.73 (m, 1H), 1.65-1.56 
(m, 5H), 1.62 (s, 3H), 1.51-1.46 (m, 1H), 1.25-1.21 (m, 1H), 1.20 (d, J = 4.4 Hz, 
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3H), 1.03 (d, J = 4.4 Hz, 3H), 0.88 (d, J = 4.4 Hz, 3H); 13C NMR (150 MHz, 
CD3OD): δ 170.3, 153.6, 147.8, 143.2, 137.5, 134.9, 132.3, 132.2, 130.9, 126.9, 
115.8, 101.3, 84.1, 80.1, 78.7, 75.5, 75.1, 73.7, 72.1, 69.1, 68.0, 61.3, 59.4, 54.8, 
46.7, 41.0, 38.4, 38.2, 36.3, 35.7, 25.1, 18.3, 12.1, 12.0, 5.3; HRMS (ESI) m/z 
675.3723 [(M+Na)+ calculated for C35H56NaO11: 675.3715]. 
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Ester 4.53: To a solution of alkyne 4.52 (300 mg, 1.24 mmol) and 
Pd(PPh3)4 (71 mg, 0.06 mmol) in THF (6 mL) at 0°C was added (n-Bu)3SnH (1 
mL, 3.71 mmol) dropwise.  The resulted solution was continued to stir for 3 h at 
0°C and concentrated in vacuo. The residue was purified by flash 
chromatography (Hexanes/Et3N, 100:0.01) to afford 614 mg (93%) of ester 4.53 
and its regioisomer (>16:1) as a colorless oil: IR (neat) 2926, 1710, 1192,1092, 
834, 776 cm-1; 1H NMR (300 MHz, C6D6): δ 6.44 (t, J = 7.0 Hz, 1H), 3.63 (t, J = 
6.0 Hz, 2H), 3.43 (s, 3H), 2.85 (dd, J = 6.0, 12.9 Hz, 2H), 1.73-1.50 (m, 6H), 
1.44-1.32 (m, 6H), 1.07 (t, J = 7.8 Hz, 6H), 1.00-0.91 (m, 18H), 0.03 (s, 6H); 13C 
NMR (75 MHz, C6D6): δ 170.7, 151.6, 137.5, 62.6, 50.8, 36.0, 29.4, 27.7, 26.1, 
18.4, 13.9, 10.6, -5.2; HRMS (ESI) m/z  541.2718, [(M+Li)+ calculated for 
C24H50LiO3SiSn:  541.2711]. 
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Alcohol 4.54: To a solution of ester 4.53 (300 mg, 0.56 mmol) in THF (12 
mL) at 0°C was added HF·Pyridine (4.3 mL), and stirred for 10 min at 0°C.  The 
reaction mixture was quenched with NaHCO3 (10 mL) and 3 M NaOH aqueous 
solution was used to adjust the pH to 7. The resulted aqueous layer was 
extracted with diethyl ether (3 X 15 mL). The combined organic layers were 
washed with brine (15 mL), dried (Na2SO4), filtered and concentrated in vacuo.  
The residue was purified by flash chromatography (Hexanes/EtOAc/Et3N, 
8:1:0.01 to 4:1:0.01) to afford 174 mg (83%) of alcohol 4.54 as a colorless oil: IR 
(neat) 2923, 1709, 1461, 1194, 1046, 666 cm-1; 1H NMR (300 MHz, C6D6): δ 6.24 
(t, J = 7.5 Hz, 1H), 3.52 (dd, J = 11.7, 6.0 Hz, 2H), 3.40 (s, 3H), 2.66-2.59 (m, 
2H), 1.85 (t, J = 5.1 Hz, 1H), 1.72-1.45 (m, 6H), 1.41-1.29 (m, 6H), 1.03 (t, J = 
7.8 Hz, 6H), 0.92 (t, J = 7.2 Hz, 9H); 13C NMR (75 MHz, C6D6): δ 171.5, 150.6, 
138.3, 61.5, 51.0, 36.0, 29.3, 27.6, 13.9, 10.5; HRMS (ESI) m/z  427.1847, 
[(M+Li)+ calculated for C18H36LiO3Sn:  427.1846]. 
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Mesylate 4.55: To a solution of alcohol 4.54 (216 mg, 0.51 mmol) in 
CH2Cl2 (11 mL) at 0°C was added Et3N (0.11 mL, 0.77 mmol) followed by MsCl 
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(47 µL, 0.62 mmol).  The reaction mixture was stirred for 5 h at ambient 
temperature, and quenched with H2O (10 mL). The aqueous layer was extracted 
with CH2Cl2 (3 X 15 mL).  The combined organic layers were washed with brine 
(15 mL), dried (Na2SO4), filtered and concentrated in vacuo. The residue was 
purified by flash chromatography (Hexanes/EtOAc/Et3N, 8:1:0.01 to 4:1:0.01) to 
afford 235 mg (91%) of mesylate 4.55 as a colorless oil: IR (neat) 2925, 1704, 
1357, 1175, 961, 528 cm-1; 1H NMR (300 MHz, C6D6): δ 6.07 (t, J = 6.9 Hz, 1H), 
3.92 (t, J = 6.3 Hz, 2H), 3.40 (s, 3H), 2.69 (dd, J = 13.2, 6.6 Hz, 2H), 2.23 (s, 3H), 
1.60-1.50 (m, 6H), 1.40-1.27 (m, 6H), 1.00 (t, J = 8.1 Hz, 6H), 0.91 (t, J = 7.2 Hz, 
9H); 13C NMR (75 MHz, C6D6): δ 170.5, 147.4, 140.3, 68.4, 51.0, 36.7, 32.0, 
29.3, 27.6, 13.9, 10.5; HRMS (ESI) m/z  505.1260, [(M+Li)+ calculated for 
C19H38LiO5SSn:  505.1622]. 
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Bromide 4.56: To a solution of mesylate 4.55 (230 mg, 0.46 mmol) in 
acetone (10 mL) at 0°C was added LiBr (160 mg, 1.85 mmol).  The resultant 
mixture was refluxed at 40°C overnight, cooled down to ambient temperature, 
diluted with H2O and Hexane. The aqueous layer was extracted Hexane (3 X 15 
mL).  The combined organic layers were washed with brine (15 mL), and dried 
(Na2SO4), filtered and concentrated in vacuo.  The residue was purified by flash 
chromatography (Hexanes/EtOAc/Et3N, 8:1:0.01) to afford 200 mg (90%) of 
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bromide 4.56 as a colorless oil: IR (neat) 2926, 1707, 1462, 1196, 875, 665 cm-1; 
1H NMR (300 MHz, C6D6): δ 6.11 (t, J = 6.6 Hz, 1H), 3.38 (s, 3H), 3.02 (t, J = 6.6 
Hz, 2H), 2.87 (dd, J = 13.0, 6.3 Hz, 2H), 1.67-1.50 (m, 6H), 1.42-1.29 (m, 6H), 
1.03 (t, J = 8.1 Hz, 6H), 0.92 (t, J = 7.2 Hz, 9H); 13C NMR (75 MHz, C6D6): δ 
170.4, 150.1, 139.2, 50.9, 35.0, 32.2, 29.3, 27.6, 13.9, 10.6; HRMS (ESI) m/z 
489.1006, [(M+Li)+ calculated for C18H35BrLiO2Sn:  489.1002]. 
 
4.57
Bu3Sn
Br
HO
 
 
Alcohol 4.57: To a solution of bromide 4.56 (195 mg, 0.40 mmol) in 
dichloromethane (8 mL) at -78°C was added DIBAL-H (1 M in Hexane) (0.89 mL, 
0.89 mmol).  The resultant solution was continued to stir at -78°C for 20 min, and 
quenched with MeOH (2 mL). The resultant mixture was poured into a saturated 
Rochelle’s solution (15 mL), and continued to stir for 1 h.  The aqueous layer was 
extracted with Dichloromethane (3 X 20 mL).  The combined organic layers were 
washed with brine (20 mL), and dried (Na2SO4), filtered and concentrated in 
vacuo.  The residue was purified by flash chromatography (Hexanes/EtOAc/Et3N, 
4:1:0.01) to afford 176 mg (97%) of alcohol 4.57 as a colorless oil: IR (neat) 
2923, 1462, 1264, 1021, 657; 1H NMR (300 MHz, C6D6): δ 5.43 (t, J = 6.9 Hz, 
1H), 3.99 (s, 2H), 2.90 (t, J = 6.9 Hz, 2H), 2.22 (dd, J = 13.8, 6.9 Hz, 2H), 1.71-
1.61 (m, 6H), 1.49-1.37 (m, 6H), 1.06 (t, J = 8.4 Hz, 6H), 0.97 (t, J = 7.5 Hz, 9H); 
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13C NMR (75 MHz, C6D6): δ 150.7, 134.3, 63.5, 33.0, 32.2, 29.7, 27.8, 14.0, 10.6; 
HRMS (ESI) m/z 489.0577 [(M+Cl)- calculated for C17H35BrClOSn:  489.0582]. 
 
Bu3Sn
Br
TBSO
4.48  
 
Vinyl Tin 4.48: To a solution of alcohol 4.57 (170 mg, 0.37 mmol) in 
dimethylformate (7 mL) at 0°C was added imidazole (38 mg, 0.56 mmol) and 
TBSCl (57 mg, 0.37 mmol).  The resultant mixture was continued to stir at 
ambient temperature overnight, and quenched with H2O (10 mL).  The aqueous 
layer was extracted with Diethyl ether (3 X 15 mL).  The combined organic layers 
were washed with brine (20 mL), and dried (Na2SO4), filtered and concentrated in 
vacuo.  The residue was purified by flash chromatography (Hexanes/Et3N, 
100:0.01) to afford 169 mg (80%) of vinyl tin 4.48 as a colorless oil: IR (neat) 
2927, 1463, 1253, 1085, 835, 778; 1H NMR (300 MHz, C6D6): δ 5.48 (t, J = 6.6 
Hz, 1H), 4.38 (s, 2H), 2.93 (t, J = 6.9 Hz, 2H), 2.28 (dd, J = 13.2, 6.6 Hz, 2H), 
1.79-1.58 (m, 6H), 1.51-1.39 (m, 6H), 1.10 (t, J = 8.4 Hz, 9H), 1.01-0.93 (m, 
18H), 0.1 (s, 6H); 13C NMR (75 MHz, C6D6): δ 150.5, 134.1, 65.1, 33.0, 32.2, 
29.7, 27.9, 26.3, 18.7, 14.0, 10.7, -5.2; HRMS (ESI) m/z 575.1915, [(M+Li)+ 
calculated for C23H49BrLiOSiSn:  575.1918]. 
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Alcohol 4.58: To a suspension of freshly cut Mg (2.16 g, 90.00 mmol) in 
THF (50 mL) at room temperature was added 1,2-dibromoethane (0.46 mL, 5.40 
mmol) dropwise.  A solution of bromide 4.48 (4.1 g, 7.21 mmol) in THF (15 mL) 
was added to the resulting solution at room temperature over 1 h via syringe 
pump.  The mixture was stirred at room temperature for 1h, and then transferred 
to a solution of aldehyde 4.7 (0.74 g, 3.60 mmol) in THF (5 mL) at -78 oC via 
cannula.  The reaction mixture was stirred at -78 oC for 4.5 h and quenched with 
saturated NaHCO3. The aqueous layer was extracted with Et2O (3 X 50 mL) and 
the combined organic layer was dried (Na2SO4), filtered and concentrated in 
vacuo.  The residue was purified by flash chromatography (Hexane/EtOAc/Et3N, 
20:1:0.01) to afford 1.6 g (64%) of alcohol 4.58 as a colorless oil: [α]D20 -1.8 (c 
1.0, CHCl3); IR (neat ) 2927, 2360, 1462, 1252, 1075, 835, 778 cm-1; 1H NMR 
(300 MHz, C6D6)  δ 5.73 (t, J = 6.5 Hz, 1H), 4.60 (d, J = 6.3 Hz, 2H), 4.19 (t, J = 
7.2 Hz, 1H), 3.55-3.51 (m, 1H), 3.39 (dd, J = 11.4, 6.0 Hz, 1H), 3.22 (s, 3H), 
2.40-2.25 (m, 6H), 2.07 (t, J = 6.3 Hz, 2H), 1.78-1.67 (m, 6H), 1.54-1.41 (m, 8H), 
1.17-1.08 (m, 6H), 1.03-0.97 (m, 18H), 0.14 (s, 6H) ; 13C NMR (125 MHz, C6D6) δ 
147.7, 137.0, 80.5, 72.5, 64.7, 59.2, 43.8, 36.8, 33.3, 30.5, 30.2, 29.2, 27.4, 26.2, 
25.9, 15.2, 13.8, 10.2, -5.3 ; HRMS (ESI) m/z 703.3186, [ (M+Li)+ calculated for 
C31H64LiO3S2SiSn: 703.3248]. 
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Vinyl Iodide 4.59: To a solution of alcohol 4.58 (1.68 g, 2.41 mmol) in 
DCM (48 mL) at 0 oC was added a solution of I2 in DCM (632 mg, 2.48 mmol) 
slowly until the color persisted yellow.  After 5 min, Imidazole (493 mg, 7.24 
mmol) was added to the solution followed by TESCl (1.21 mL, 7.24 mmol).  The 
reaction mixture was allowed to warm up to room temperature and stirred for 1 h.  
The reaction was quenched with saturated Na2S2O3 (20 mL) and the aqueous 
layer was extracted with DCM (3 X 50 mL).  The combined organic layer was 
washed with brine (20 mL), dried (Na2SO4), filtered and concentrated in vacuo.  
The residue was purified by flash chromatography (Hexanes/EtOAc, 25:1) to 
afford 1.5 g (97%) of vinyl iodide 4.59 as a colorless oil: [α]D20 -3.8 (c 1.0, CHCl3); 
IR (neat ) 2953, 2363, 1240, 1098, 1004, 837, 740 cm-1; 1H NMR (400 MHz, 
C6D6)  δ 6.21 (t, J = 7.6 Hz, 1H), 4.37 (dd, J = 10.8, 4.0 Hz, 1H), 4.21 (s, 2H), 
3.82-3.77 (m, 1H), 3.66 (ddd, J = 10.0, 4.4, 2.0 Hz, 1H), 3.31 (s, 3H), 2.47-2.31 
(m, 4H), 2.26-2.19 (m, 2H), 2.02-1.90 (m, 2H), 1.64-1.51 (m, 2H), 1.44-1.40 (m, 
1H), 1.29-1.19 (m, 1H), 1.06-1.01 (m, 18H), 0.65 (q, J = 7.6 Hz, 6H), 0.13 (s, 6H) 
; 13C NMR (125 MHz, C6D6) δ 142.5, 103.3, 80.4, 71.3, 65.5, 58.3, 44.9, 35.7, 
31.1, 30.6, 30.0, 28.3, 26.2, 26.1, 18.6, 7.3, 5.5, -4.9; HRMS (ESI) m/e 653.2027, 
[ (M+Li)+ calculated for C25H51ILiO3S2Si2: 653.2023]. 
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Aldehyde 4.60: To a solution of dithiane 4.59 (1.50 g, 2.34 mmol) in 
MeCN/pH=7 buffer (90 mL. 4/1) at 0 oC was added K2CO3 (0.81 g, 5.85 mmol) 
and MeI (0.1.50 ml, 23.4 mmol) in 5 min. The reaction mixture was warmed up to 
30 oC and stirred 48 h. The reaction mixture was diluted with EtOAc (50 mL) and 
the aqueous layer was extracted with EtOAc (3 X 50 mL). The combined organic 
layers were washed with brine (30 mL), dried (Na2SO4), filtered and concentrated 
in vacuo. The residue was purified by flash chromatography (Hexane/EtOAc, 
25:1) to afford 1.0 g (77%) of aldehyde 4.60: [α]D20 –3.9 (c 1.0 , CHCl3); IR (neat) 
2954, 2878, 1728, 1461, 1375, 1097, 836 cm-1; 1H NMR (400 MHz C6D6): δ 9.51 
(s, 1H), 6.24 (t, J = 7.6 Hz, 1H), 4.21 (s, 2H), 3.73-3.64 (m, 2H), 3.09 (s, 3H), 
2.38-2.33 (m, 1H), 2.25-2.14 (m, 2H), 1.97-1.87 (m, 1H), 1.59-1.50 (m, 1H), 1.21-
1.10 (m, 1H), 1.00 (s, 9H), 0.95 (t, J = 8.0, 9H), 0.90 (t, J = 8.0 Hz, 9H), 0.54 (q, J 
= 8.0 Hz, 6H), 0.12 (s, 6H); 13C NMR (125 MHz, C6D6): δ 199.4, 142.3, 103.4, 
78.8, 71.4, 65.5, 57.7, 43.7, 31.3, 28.2, 26.1, 18.5, 7.1, 5.3, -4.9; HRMS (ESI) 
m/z 595.1532, [(M+K)+ calculated for C22H45IKO4Si2: 595.1538]. 
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Aldehyde 4.61: To a solution of aldehyde 4.60 (1.0 g, 1.8 mmol) and vinyl 
borate 4.8 (0.83 g, 2.34 mmol) in THF/H2O (90mL, 3/1, degassed) at room 
temperature was added Pd(Ph3P)4 (208 mg, 0.18 mmol). The mixture was stirred 
for 10 min, and TlOEt (0.16 mL, 2.25 mmol) was added via syringe. The reaction 
was kept at room temperature for 20 min, and then quenched with saturated 
NaHCO3. The aqueous layer was extracted with EtOAc (3 x 50 mL), and the 
combined organic layers were washed with brine (50 mL), dried (Na2SO4), 
filtered and concentrated in vacuo. The residue was purified by flash 
chromatography (Hexane/EtOAc, 30:1) to afford 0.91 g (77%) of diene 4.61 as a 
colorless oil: [α]D20 0.9 (c 1.0 , CHCl3); IR (neat) 2955, 2876, 1730, 1459, 1253, 
1079, 741 cm-1; 1H NMR (400 MHz CDCl3): δ 9.83 (s, 1H), 6.01 (d, J = 15.6 Hz, 
1H), 5.91-5.82 (m, 1H), 5.75 (dd, J = 16.0, 7.2 Hz, 1H), 5.51 (t, J = 7.2 Hz, 1H), 
5.02-4.97 (m, 2H), 4.30 (d, J = 6.0 Hz, 2H), 3.99 (t, J = 6.0 Hz, 1H), 3.91-3.86 (m, 
1H), 3.78-3.74 (m, 1H), 3.38 (s, 3H), 2.69 (ddd, J = 16.8, 3.6, 1.2 Hz, 1H), 2.53 
(dddd, J = 25.2, 16.8, 8.4, 2.4 Hz, 1H), 2.43-2.27 (m, 2H), 2.21-2.11 (m, 1H), 
1.71-1.63 (m, 1H), 1.43-1.33 (m, 1H), 1.01-0.90 (m, 30H), 0.65-0.55 (m, 12H), 
0.08 (s, 6H); 13C NMR (125 MHz, C6D6): δ 199.5, 141.4, 137.4, 133.8, 133.0, 
130.2, 114.4, 79.0, 78.2, 71.8, 58.5, 57.7, 45.2, 43.8, 32.0, 26.1, 25.4, 24.9, 15.1, 
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14.2, 7.1, 7.0, -5.1; HRMS (ESI) m/z 661.4693, [(M+Li)+ calculated for 
C35H70LiO5Si3: 661.4691]. 
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Aldol 4.62: To a solution of diene 4.61 (0.40 g, 0.61 mmol) and a 7:1 
mixture of silyl enol ethers E-4.9/Z-4.9 (0.67 g, 2.44 mmol) in dichloromethane 
(20.5 mL) was added CaH2 (190 mg) at 0 oC. After 10 min, the reaction was 
cooled to –94 oC and a solution of BF3·OEt2 in dichloromethane (0.61 mmol, 0.5 
M in dichloromethane) was added via syringe. The reaction mixture was stirred 
for 40 min, quenched with saturated NaHCO3 (20 mL) and the aqueous layer 
was extracted with EtOAc (3 x 15 mL). The combined organic layers were 
washed with brine (20 mL), dried (Na2SO4), filtered and concentrated in vacuo. 
The residue was purified by flash chromatography (Hexane/EtOAc, 30:1 to 25:1) 
to afford 0.48 g (91%) of alcohol 4.62 as a 6:2:1:0.3 mixture of 4 
diastereoisomers (by HPLC: 21.4 mm x 25 cm column, 49 min gradient, 0–5% 
ethyl acetate in hexane). For synthetic purposes the mixture can be advanced to 
the next step without further purification, as the resulting mixture of Yamaguchi 
esterification adducts can be easily separated to afford the desired ester 4.63: 
[α]D20 –1.3 (c 1.0 , CHCl3); IR (neat) 2955, 2877, 1715, 1461, 1414, 1250, 1098, 
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1006, 837, 741 cm-1; 1H NMR (500 MHz C6D6): 6.20 (dd, J = 16.0, 5.5 Hz, 1H), 
6.13-6.01 (m, 2H), 5.59 (dt, J = 6.5, 6.5 Hz, 1H), 5.13-5.08 (m, 2H), 4.45 (s, 2H), 
4.24-4.19 (m, 1H), 4.13 (t, J = 5.5 Hz, 1H), 4.06 (d, J = 3.0 Hz, 1H). 4.00-3.99 (m, 
1H), 3.70-3.67 (m, 1H), 3.33 (s, 3H), 2.62 (dd, J = 9.5, 1.5Hz, 1H), 2.59-2.39 (m, 
3H), 2.32-2.24 (m, 1H), 1.98-1.91 (m, 1H), 1.90-1.81 (m, 1H), 1.68-1.60 (m, 1H), 
1.59-1.51 (m, 1H), 1.17 (d, J = 6.5 Hz, 3H), 1.08-1.01 (m, 30H), 0.93 (t, J = 8.0 
Hz, 9H), 0.71-0.65 (m, 12 H), 0.54 (q, J = 8.0 Hz, 6H), 0.16 (s, 6H); 13C NMR 
(125 MHz, C6D6): δ 212.4, 141.5, 137.3, 133.9, 133.1, 130.2, 114.3, 81.8, 80.9, 
78.3, 71.8, 70.7, 58.6, 58.3, 45.2, 33.5, 32.3, 32.0, 26.1, 25.6, 18.5, 15.1, 7.4, 
7.3, 7.0, 5.5, 5.5, 5.1, -5.0; HRMS (MALDI) m/z 879.5834, [(M+Na)+ calculated 
for C45H92NaO7Si4: 879.5818]. 
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Ester 4.63: To a solution of aldol 4.63 (0.43 g, 0.51 mmol) and acid 4.10 
(0.18 g, 0.70 mmol) in toluene and THF (1:1 50 mL) was added DMAP (5.4 g, 
44.8 mmol) at 0 °C. After DMAP dissolved completely the mixture was cooled to -
78 °C, and Et3N (3.1 mL, 22.4 mmol) was added followed by 2,4,6-
trichlorobenzoyl chloride (1.75 mL, 11.2 mmol). The resulting slurry was slowly 
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warmed to room temperature over 2.5 h. The reaction was stirred overnight at 
room temperature, quenched with saturated NaHCO3 (50 mL) and the aqueous 
layer was extracted with Et2O (3 x 50 mL). The combined organic layers were 
dried (Na2SO4), filtered and concentrated in vacuo. The residue was purified by 
flash chromatography (Hexanes/EtOAc, 50:1) and further purified by HPLC using 
a Varian HPLC system equipped with Prostar 210 pumps and a photodiode array 
(PDA) detector. Preparative normal phase HPLC was conducted using a 0-5% 
linear gradient (Hexane/EtOAc) over 50 min at a flow rate of 12.0 mL/min with 
UV detection at 340 nm using a Varian’s Dynamax column (60 Å 250 x 21.4 mm, 
Si 83-121-0, Raiman Instrument Company, Inc., Mack Road, Woburn, MA). The 
retention time for desired diastereomer is 33.3 min. 0.50 g (36% over two steps) 
of ester 4.63 was obtained as a colorless oil:  [α]D20 –1.2 (c 1.0, CHCl3); IR (neat) 
2954, 2876, 1715, 1459, 1240, 1112, 1006, 836, 741 cm-1; 1HMR (500 MHz, 
C6D6): δ 7.27 (s, 1H), 6.22-6.18 (m, 2H), 6.14-6.01 (m, 2H), 5.84-5.81 (m, 1H), 
5.58 (dd, J = 14.0, 7.0 Hz, 1H), 5.18-5.09 (m, 2H), 4.45 (s, 2H), 4.29 (d, J = 3.5 
Hz, 1H), 4.13 (t, J =4.5 Hz, 1H), 3.99-3.96 (m, 1H), 3.35-3.32 (m, 4H), 2.66-2.54 
(m, 2H), 2.52-2.44 (m, 1H), 2.42 -2.33 (m, 1H), 2.27-2.22 (m, 2H), 1.90 (s, 3H), 
1.89-1.84 (t, J = 12.5, 2H), 1.75 (s, 3H), 1.58-1.54 (m, 1H), 1.17 (d, J = 6.5 Hz, 
3H), 1.07-0.96 (m, 39H), 0.70-0.57 (m, 18H), 0.16 (s, 6H); 13C NMR (125 MHz, 
C6D6): δ 209.6, 167.6, 143.9, 141.4, 139.4, 137.4, 133.8, 133.1, 130.2, 114.3, 
86.2, 80.7, 80.20, 78.3, 72.4, 71.0, 58.6, 58.2, 45.2, 32.1, 31.6, 30.4, 26.1, 25.7, 
24.3, 15.0, 14.3, 7.6, 7.5, 7.00, 5.5, 5.0, -5.05; HRMS (MALDI) m/z 1113.5378, 
[(M+Na)+ calculated for C52H99INaO8Si4: 1113.5359]. 
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Figure 4.4 HPLC chromatograph for purification of ester 4.63 
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Aldol 4.64: To a solution of LHMDS (0.40 mL, 0.37 mmol, 1M in THF) in 
THF (30 mL) at -78 °C was added a solution of ketone 4.63 (0.200 g, 0.183 
mmol) and HMPA (0.092 mL, 0.55 mmol) in THF (6 mL). The reaction mixture 
was stirred at -78 °C for 2 h before a solution of aldehyde 4.11 (0.22 g, 0.55 
mmol) in THF (4 mL) was added dropwise. The solution was stirred at -78 °C for 
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3 h, quenched with saturated NH4Cl (20 mL) and warmed to room temperature.  
The aqueous layer was extracted with Et2O (3 x 20 mL) and the combined 
organic layers were dried (Na2SO4), filtered and concentrated in vacuo. The 
residue was purified by HPLC: 21.4 mm x 25 cm column, 49 min gradient, 0–5% 
ethyl acetate in hexanes to afford 0.11 g (40%) of aldol 4.64 as colorless oil:  
[α]D20 –12.5 (c 1.0, CHCl3); IR (neat) 3568, 2955, 2879, 2365, 1702, 1459, 1245, 
1109, 1005, 738 cm-1; 1HMR (500 MHz, C6D6): δ 7.28 (s, 1H), 6.26 (s, 1H), 6.20 
(d, J = 16.0 Hz, 1H), 6.15-6.02 (m, 3H), 5.57 (t, J = 7.5 Hz, 1H), 5.14-5.09 (m, 
2H), 4.88 (d, J = 4.0 Hz, 1H), 4.45 (s, 2H), 4.15 (d, J = 10.0 Hz, 1H), 4.37-4.34 
(m, 1H),  4.16-4.13 (m, 1H), 4.12-4.08 (m, 1H), 4.04 (s, 1H), 4.00-3.97 (m, 1H), 
3.39 (s, 3H), 3.38-3.33 (m, 1H), 3.30 (d, J = 5.5 Hz, 2H), 3.27-3.20 (m, 1H), 3.11 
(s, 3H), 2.57-2.51 (m, 1H), 2.49-2.44 (m, 1H), 2.39-2.35 (m, 1H), 2.31-2.23 (m, 
1H), 2.09-2.04 (m, 1H), 2.01-1.93 (m, 3H), 1.91 (d, J = 1.0 Hz, 3H), 1.87-1.81 
(m, 1H), 1.78 (d, J = 0.5 Hz, 3H), 1.62-1.57 (m, 1H), 1.31 (d, J = 6.5 Hz, 3H), 
1.18 (d, J = 6.5 Hz, 3H), 1.10-1.00 (m, 45H), 0.91 (d, J = 7.0 Hz, 3H), 0.81-0.76 
(q, J = 7.5 Hz, 6H), 0.71-0.62 (m, 18H), 0.38 (s, 9H), 0.24 (s, 3H), 0.21 (s, 3H), 
0.17 (s, 3H),  0.17 (s, 3H); 13C NMR (150 MHz, C6D6): δ 210.3, 167.8, 143.9, 
141.4, 139.4, 137.3, 133.9, 130.2, 114.3, 86.3, 81.0, 79.3, 78.3, 78.2, 73.4, 72.8, 
72.6, 71.2, 70.1, 58.6, 58.5, 58.2, 45.3, 45.2, 41.0, 39.1, 31.7, 31.1,  26.3, 26.1, 
25.6, 24.3, 18.6, 18.5, 15.1, 14.4, 14.3, 14.2, 12.2, 7.6, 7.3, 7.2, 7.2, 7.1, 5.6, 
5.5, 5.4, -3.4, -4.4, -5.0, -5.0; HRMS (MALDI) m/z 1518.8259, [(M+Na)+ 
calculated for C72H143INaO12Si6: 1517.8138]. 
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Silyl Ether 4.65: To a solution of alcohol 4.64 (0.08 g, 0.05 mmol) in 
dichloromethane (11 mL) at -78 °C was added 2,6-lutidine (0.16 mL, 1.33 mmol) 
followed by TESOTf (0.24 mL, 1.07 mmol). The mixture was stirred for 30 min at 
-78 °C, then 30 min at 0 °C and quenched with H2O (15 mL).  The aqueous layer 
was extracted with dichloromethane (3 x 10 mL) and the combined organic 
layers were dried (Na2SO4), filtered and concentrated in vacuo. The residue was 
purified by flash chromatography (Hexanes/EtOAc 50:1) to afford 0.09 g 
quantative yield of TES ether 4.65 as a colorless oil:  [α]D20 –17.2 (c 1.0, CHCl3); 
IR (neat)  2955, 2877, 1460, 1239, 1071, 1004, 738 cm-1; 1HMR (400 MHz, 
C6D6): δ 7.28 (s, 1H), 6.28 (s, 1H), 6.20 (d, J = 15.6 Hz, 1H), 6.14-5.96 (m, 3H), 
5.59 (t, J = 7.2 Hz, 1H), 5.14-5.09 (m, 2H), 4.88 (d, J = 3.2 Hz, 1H), 4.45 (s, 2H), 
4.32 (dd, J = 8.4, 5.2 Hz, 1H), 4.21 (d, J = 8.0 Hz, 1H), 4.13 (t, J = 6.0 Hz, 1H), 
4.02-3.97 (m, 1H), 3.97-3.92 (m, 1H), 3.47 (q, J = 7.2 Hz, 1H), 3.40 (d, J = 4.4 
Hz, 2H), 3.38 (s, 3H), 3.30 (dd, J = 10.8, 4.0 Hz, 1H), 3.21 (s, 3H), 2.61-2.51 (m, 
1H), 2.49-2.37 (m, 2H), 2.33-2.23 (m, 1H), 2.14-1.94 (m, 3H), 1.90 (s, 3H), 1.90-
1.83 (m, 1H), 1.79 (s, 3H), 1.79-1.73 (m, 1H), 1.65-1.55 (m, 1H), 1.37 (d, J = 7.2 
Hz, 3H), 1.19-1.00 (m, 69H), 0.95 (q, J = 8.0 Hz, 6H), 0.84 (q, J = 8.0 Hz, 6H), 
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0.76 (q, J = 8.0 Hz, 6H), 0.71-0.62 (m, 12H), 0.22 (s, 3H), 0.20 (s, 3H), 0.17 (s, 
6H);  13C NMR (75 MHz, C6D6): δ 209.5, 167.8, 143.9, 141.4, 139.5, 137.4, 
133.8, 133.1, 130.2, 114.3, 86.5, 80.6, 79.8, 78.3, 77.1, 74.7, 72.5, 70.9, 70.4, 
70.1, 58.9, 58.6, 58.2, 47.2, 45.2, 43.9, 40.7, 31.6, 31.0, 26.1, 25.7, 24.3, 18.5,  
18.4, 15.0, 14.4, 12.0, 10.2, 7.6, 7.5, 7.3, 7.3, 7.2, 6.7, 5.9, 5.9, 5.5, -4.0, -4.4, -
5.0, -5.1; HRMS (MALDI) m/z 1632.9115 [(M+Na)+ calculated for 
C78H157INaO12Si7: 1631.9002]. 
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Vinyl Boronate 4.66: To a solution of alkene 4.65 (66.0 mg, 40.9 µmol) 
in toluene (8.0 mL) was added 1-propenyl pinacol boronic ester 4.12 (32 mg, 
205 µmol) followed by Grubbs second-generation catalyst 4.34 (35 mg, 40.9 
µmol) at room temperature. The resulting solution was stirred at 50 °C for 46 h, 
cooled to room temperature and diluted with dichloromethane (10 mL). The 
resultant solution was filtered through a short silica gel plug.  The solvent was 
removed in vacuo and the residue was purified by HPLC (Hexane/EtOAc, 0-5% 
gradient over 50 min) to afford 27 mg (38%) vinyl boronate 4.66 as a colorless 
oil: [α]D20 –32.4 (c 1.0, CHCl3); IR (neat) 2955, 2877, 1712, 1460, 1359, 1242, 
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1112, 1007, 835, 739 cm-1; 1H NMR (400 MHz, C6D6): δ 7.28 (s, 1H), 6.29 (s, 
1H), 6.19 (d, J = 15.6 Hz, 1H), 6.06-5.96 (m, 2H), 5.86 (d, J = 18.0 Hz, 1H), 5.55 
(t, J = 7.2 Hz, 1H), 4.89 (d, J = 3.2 Hz, 1H), 4.43 (s, 2H), 4.32 (dd, J = 8.8, 5.6 
Hz, 1H), 4.23-4.20 (m, 2H), 4.02-3.97 (m, 1H), 3.96-3.92 (m, 1H), 3.47 (dd, J = 
14.0, 6.8 Hz, 1H), 3.41 (d, J = 4.8 Hz, 2H), 3.82 (s, 3H), 3.31 (dd, J = 10.4, 3.6 
Hz, 1H), 3.21 (s, 3H), 2.60-2.49 (m, 1H), 2.43-2.37 (m, 1H), 2.32-2.22 (m, 1H), 
2.15-2.1.94 (m, 3H), 1.90 (s, 3H), 1.90-1.83 (m, 1H), 1.79 (s, 3H), 1.74 (t, J = 8.4 
Hz, 1H), 1.64-1.57 (m, 1H), 1.37 (d, J = 7.2 Hz, 3H), 1.21-0.99 (m, 81 H), 1.01-
0.82 (m, 12H), 0.76 (q, J = 7.6 Hz, 6H), 0.70-0.62 (m, 12H), 0.22 (s, 3H), 0.20 
(s, 9H);  13C NMR (75 MHz, C6D6): δ 209.5, 167.8, 157.1, 143.9, 139.5, 137.4, 
133.9, 133.0, 130.2, 86.5, 82.8, 80.6, 79.8, 77.8, 77.1, 74.7, 72.5, 70.9, 70.4, 
70.1, 58.9, 58.5, 58.2, 47.2, 46.9, 43.9, 40.7, 31.6, 31.0, 26.2, 26.1, 25.7, 25.0, 
24.9, 24.3, 18.5, 18.4, 14.4, 14.2, 12.0, 10.2, 7.6, 7.5, 7.3, 7.3, 6.7, 5.9, 5.9, 5.5, 
5.5, -4.0, -4.4, -4.9, -4.9; HRMS (MALDI) m/z 1759.0583, [(M+Na)+ calculated 
for C84H168BINaO14Si7: 1757.9854]. 
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Macrolactone 4.47: To a solution of vinyl boronate 4.66 (27 mg, 15.5 
µmol) in THF/H2O (4 mL, 3:1, degassed) was added Pd(Ph3P)4 (1.8 mg, 1.56 
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µmol) at room temperature. The resulting yellow solution was stirred for 10 min 
before TlOEt (1.4 µL, 19.4 µmol) was added.  The solution was stirred for 20 min 
(color turns from yellow to grey).  The reaction was quenched with saturated 
NaHCO3 (5 mL) and the aqueous layer was extracted with ethyl acetate (3 x 10 
mL). The combined organic layers were dried (Na2SO4), filtered and 
concentrated in vacuo.  The residue was purified by flash chromatography 
(Hexane/EtOAc, 25:1) to afford 19 mg (82%) of lactone 4.47 as a colorless oil: 
[α]D20 +29.5 (c 1.0, CHCl3); IR (neat) 2954, 1701, 1461, 1240, 1109, 1081, 836, 
741; 1H NMR (600 MHz, C6D6): δ 7.53 (s, 1H), 6.29 (d, J = 10.8 Hz, 1H), 6.10 
(dd, J = 15.0, 6.6 Hz, 1H), 5.86 (d, J = 16.2 Hz, 1H), 5.76-5.70 (m, 2H), 5.51 (dd, 
J = 8.4, 6.6 Hz, 1H), 5.41 (dd, J = 15.0, 10.2 Hz, 1H), 4.99 (d, J = 4.2 Hz, 1H), 
4.30 (dd, J = 81.6, 12.6 Hz, 2H), 4.35-4.29 (m, 1H), 4.28 (d, J = 7.8, 0.6 Hz, 1H), 
3.96-3.92 (m, 1H), 3.84 (t, J = 9.0 Hz, 1H), 3.61 (dt, J = 7.8, 2.4 Hz, 1H), 3.52 (s, 
3H), 3.52-3.49 (m, 1H), 3.42-3.38 (m, 2H), 3.20 (s, 3H), 2.97 (t, J = 8.4 Hz, 1H), 
2.61-2.53 (m, 1H), 2.42-2.36 (m, 1H), 2.15-2.06 (m, 5H), 2.11 (s, 3H), 2.03-1.99 
(m, 2H), 1.84-1.80 (m, 1H), 1.79 (s, 3H), 1.67-1.62 (m, 1H), 1.45 (d, J = 7.2 Hz, 
3H), 1.27 (d, J = 6.6 Hz, 3H), 1.22-1.19 (m, 18H), 1.16(d, J = 6.0 Hz, 3H), 1.14-
1.08 (m, 27H), 1.04 (s, 9H), 0.98 (s, 9H), 0.97-0.86 (m, 12H), 0.80-0.70 (m, 
18H), 0.21 (s, 3H), 0.19 (s, 3H), 0.11 (s, 6H); 13C NMR (75 MHz, C6D6): δ 209.9, 
168.2, 145.1, 144.7, 141.4, 137.2, 134.1, 133.8, 132.5, 132.0, 125.8, 123.7, 
82.4, 81.0, 78.1, 77.2, 76.2, 70.6, 70.1, 61.1, 58.8, 58.0, 47.3, 46.4, 43.7, 40.9, 
36.2, 35.0, 26.2, 26.1, 25.0, 18.7, 15.6, 14.0, 11.3, 10.4, 7.6, 7.5, 7.4, 7.4, 7.3, 
6.7, 6.0, 5.9, 5.7, 5.6, -3.9, -4.4, -5.1, -5.1; HRMS (ESI) m/z 1489.0229 [(M+Li)+ 
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calcd for C78H156O12Si7Li: 1488.0142].  
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4.4 12-oxymethyl apoptolidinone D  
 
12-Oxymethyl Apoptolidinone D 4.4: To solution of 10.0 mg (6.74 µmol) 
macrolactone 4.47 in 3 mL THF at -10 °C, H2SiF6 (0.1 mL) was added dropwise. 
After stirred for 24 h at -10 °C, the reaction mixture was quenched with saturated 
NaHCO3 solution and the aqueous layer was extracted with ethyl acetate (3 x 5 
mL).  The combined organic layers were dried (Na2SO4), filtered and 
concentrated in vacuo. The residue was purified by flash chromatography 
(CH2Cl2/MeOH, 20:1) to afford 4.1 mg (89%) of 12-oxymethyl apoptolidinone D 
4.4 as a white solid: [α]D20 19.5° (c 0.59, CHCl3); IR (neat) 3362, 2923, 1665, 
1456, 1256, 1098, 1024 cm-1; 1H NMR (600 MHz, CD3OD): δ 7.40 (s, 1H), 6.27-
6.25 (m, 2H), 5.94 (d, J = 15.6 Hz, 1H), 5.67 (dd, J = 9.6, 7.2 Hz, 1H), 5.55 (dd, J 
= 16.2, 9.0 Hz, 1H), 5.50 (dt, J = 10.2, 2.4 Hz, 1H), 5.29 (dt, J = 10.8, 0 Hz, 1H), 
4.18 (dd, J = 114, 12 Hz, 2H), 4.11-4.07 (m, 1H), 3.80-3.73 (m, 2H), 3.55-3.53 
(m, 1H), 3.55 (d, J = 1.2 Hz, 1H), 3.42-3.39 (m, 1H), 3.39 (s, 3H), 3.26 (s, 3H), 
3.19-3.12 (m, 2H), 2.66 (dd, J = 9.0, 6.0 Hz, 1H), 2.56-2.51 (m, 1H), 2.32-2.27 
(m, 1H), 2.19-2.13 (m, 1H), 2.13 (s, 3H), 2.08 (s, 3H), 2.08-1.98 (m, 2H), 1.79-
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1.74 (m, 1H), 1.68-1.61 (m, 1H), 1.60-1.55 (m, 1H), 1.51-1.44 (m, 1H), 1.36-1.21 
(m, 2H), 1.19 (d, J = 6.6 Hz, 3H), 1.02 (d, J = 6.6 Hz, 3H), 0.88 (d, J = 6.6 Hz, 
3H); 13C NMR (150 MHz, CD3OD) δ 172.7, 147.7, 146.0, 143.2, 138.4, 135.1, 
135.0, 133.7, 131.9, 126.8, 124.4, 101.4, 84.2, 80.3, 78.7, 75.5, 74.9, 73.9, 72.7, 
69.3, 68.3, 61.4, 59.5, 57.0, 46.6, 41.0, 38.6, 38.4, 36.6, 36.5, 24.9, 18.8, 15.7, 
14.0, 12.3, 5.4; HRMS (ESI) m/z  690.4176 [(M+Li)+ calculated for C36H58LiO12: 
690.4088]. 
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CHAPTER V 
 
METHODS OF PRECURSOR DIRECTED BIOSYNTHESES AND 
APPLICATION TO APOPTOLIDIN CONGENERS 
 
 
5.1 Introduction 
 Apoptolidinone A (5.1) and apoptolidinone D (5.2) prepared by chemical 
synthesis were evaluated for cytotoxicity against human lung carcinoma cells 
H292. Exposure of apoptolidinone A (5.1) and apoptolidinone D (5.2) to H292 
cells over a 72 hour period revealed minimum cytotoxic effects (LC50>10 µM) 
(see Chapter VI for details).68 Similiarly, Koert’s group (Philipps-Universität 
Marburg, Germany) tested apoptolidinone A (5.1) against breast cancer MATU 
cells (LC50>100 µM).21 In contrast, apoptolidin A (5.3) showed significant 
cytotoxicity against H292 cells (EC50=25 nM) and MATU cells (EC50=2 nM). 
Apoptolidin A (5.3) killed the cancer cells at nanomolar range. These results 
revealed the significance of the sugar fragments in relation to apoptolidin cell 
cytotoxicity, a significant observation in relation to the development of an 
apoptolidin probe for target identification. 
From the perspective of total synthesis, the challenge of assembling the 
complete molecular matrix of apoptolidin A (5.3), a complex aglycone conjugated 
to three deoxy sugar units, remains significant. In particular, the installation of 
sugar units by chemical synthesis requires the development of complex synthetic 
schemes often resulting in low overall yields. To prepare apoptolidin deoxy 
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sugars, both Nicoloau’s and Koert’s groups utilized long reaction sequence by 
modification of known natural sugar; 16,17,18,19,20,21 Crimmins’ and Roush’s groups 
developed new synthetic route requiring at least 10 steps to prepare apoptolidin 
deoxy-sugar units starting from commercially available compounds.32,35 In 
addition, the incorporation of sugar units by chemical glycosylation methods 
poses problems in stereocontrol and yield. The development of alternative 
methods of glycosylation is an area of significance. 
Recent advances in understanding the biosynthetic incorporation of deoxy 
sugars into polyketide natural products has provided new opportunities to effect 
the glycosylation of unnatural aglycones leading to new analogues with 
therapeutic value.93,94,95,96,97,98 There are primarily three methods to effect 
bioglycosylation using the enzymatic machinery of the producing organism, 
which are in vitro enzymatic glycosylation, mutasynthesis, and precursor-directed 
bioglycosylation. In vitro enzymatic glycosylation methods are usually used for 
validation of the synthetic potential of a glycosyltransferases. This method 
requires the readily availability of purified glycosyltransferases in soluble and 
active form, enzymes for the biosynthesis of specific sugar donors and access to 
aglycone substrates.94,95,96,97,98. Mutasynthesis employs engineered microbial 
with genetic inactivation of polyketide synthase modules to allow the 
bioconversion of an exogenous aglycone to natural product analogues without 
competitive interference from the endogenous (natural) aglycone.99,100,101 
Mutasynthesis presumes the knowledge of the biosynthetic gene cluster and 
well-developed methods for genetic manipulation of the producing organism, 
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which can be a slow process. 99,100,101 Precursor-directed biosynthesis is defined 
as “the derivatization of a secondary metabolite by feeding biosynthetic precursor 
analogues to the fermentation broth of producing organisms”.102 One approach to 
precursor-directed bioglycosylation, which requires no knowledge of the 
encoding biosynthetic cluster leading to the natural product, is to employ a 
selective chemical “knockdown” of the polyketide synthase. In this way, 
polyketide synthase (PKS) inhibitors may facilitate the introduction of a foreign or 
unnatural aglycone and its subsequent enzymatic glycosylation by the PKS cured 
system. This strategy has been successfully demonstrated by Omura in the early 
1980s in which the ketosynthase inhibitor cerulenin 5.4 was used to disable the 
biosynthsis of the endogenous aglycones in several polyketide antibiotics 
producing microorganisms, and allowing for glycosylation of an exogenously 
introduced aglycone protylonolide to generate various derivatives of protylonolide 
featuring different sugar units as shown in Scheme 5.1.103,104,105,106  
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Scheme 5.1 Omura's hybrid synthesis of protylonolide derivatives 
 
Since the genome of apoptolidin producing organism Nocardiopsis sp. has 
not been studied, the hypothetical biogenesis for apoptolidins presented in 
Scheme 5.2 is proposed based on a classical biosynthetic route for polyketide 
natural products. The apoptolidin polyketide synthetase (PKS) of Nocardiopsis 
sp. affords the biosynthsis of the 20-membered macrolides, apoptolidinones 5.10 
and 5.11 from starter unit 5.5. Thioesterase (TE) catalyzed the release of seco 
acids 5.8 and 5.9 presumably lead to apoptolidinones 5.10 and 5.11 from the 
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PKS respectively. It is further proposed that apoptolidinones 5.10 and 5.11 
undergo further modifications by post-PKS tailoring enzymes including 
oxygenases and glycosyltransferases. We initially hypothesized that 
glycosyltransferases catalyzed the C-9 and C-27 glycosylation, either before or 
following C-16 and C-19 oxidation and O-17 methylation to generate the unique 
structures of apoptolidins A-D (5.3, 5.12-5.14).  
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Scheme 5.2 Hypothetical biosynthesis of apoptolidin A-D 
 
Since literature precedent proved that polyketide glycosyltransferases 
have relaxed substrate specificity,103,104,105,106 we proposed to take advantage of 
the Nocardiopsis sp. machinery to effect bioglycosylation of unnatural aglycones. 
We sought to choose the convenient and relatively simple precursor directed 
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glycosylation of completely synthetic aglycones of apoptolidin 5.1, 5.2, 5.18, 5.19 
using chemical knockdown methodology developed by Omura described above, 
to produce unnatural apoptolidins 5.15-5.17 for biological evaluation and use in 
the development of molecular probes for cellular target identification. 
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Scheme 5.3 Precursor directed bioglycosylation of apoptolidinones 
 
5.2 Bioglycosylation of Synthetic Apoptolidinones  
The work included in this section has been published in the Organic 
Letters.107 
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5.2.1 Titration of Cerulenin 
 Cerulenin 5.4, an antifungal antibiotic, was isolated from the culture 
filtrates of Caephalosporium caerulens by Heta and coworkers in 1960.108 
Studies on cerulenin’s mechanism of action revealed that it could effectively 
mimic the transition state of the condensation step catalyzed by beta-ketoacyl-
acyl carrier protein synthases.109 Since beta-ketoacyl-acyl carrier protein 
synthases are common enzymes to both the biosynthesis of long chain fatty acid 
and the biosynthesis of polyketide macrolactones, it is been demonstrated that 
cerulenin 5.4 could inhibit the production of macrolides significantly when 
administered to the producing microorganisms.110   
 
O
NH2
O
O  
Figure 5.1 Structure of Cerulenin 5.4 
 
The use of cerulenin 5.4 to inhibit ketosynthase activity can be described 
as a chemical “knockout”. In order to introduce sugar units onto our synthetic 
apoptolidinones, we chose to employ precursor-directed biosynthesis using the 
apoptolidin producer (actinomycete Nocardiopsis Sp.) and cerulenin 5.4 as a 
chemical knockdown to inhibit production of endogenous apoptolidinone (natural 
aglycone). As cerulenin 5.4 is a fatty acid synthase inhibitor, the optimal 
concentration of cerulenin 5.4 needs to be identified that would inhibit apoptolidin 
5.3 production, as measured by HPLC/MS, without substantially inhibiting cell 
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growth, as measured by palliated mycelia mass. The optimized conditions 
required pulsed feeding of 0.2 mM of cerulenin 5.4 per day to a culture of the 
apoptolidin producer (Nocardiopsis sp.). At this concentration of cerulenin 5.4, 
apoptolidin 5.3 production was reduced to below 5% relative to a control cultures. 
 
5.2.2 Bioglycosylation of Apoptolidinone A 5.1 
Once conditions to effect the chemical knockdown of ketosynthase were 
determined, we began to examine the glycosylation of an unnatural 
apoptolidinone using precusor directed biosynthesis. First, we examined 
bioglycosylation of apoptolidinone A 5.1 itself to determine if apoptolidin 
production could be returned. We found that the addition of synthetic 
apoptolidinone A 5.1 accompanied with pulsed addition of cerulenin 5.4 resulted 
in only trace amounts of apoptolidin A 5.3 and apoptolidinone A 5.1. However, a 
novel apoptolidin was observed by LC-MS that corresponded to apoptolidin A 
disaccharide 5.20 (M+NH4/z = 986.6) for the first time. Notably, the equivalent 
mass corresponding to 5.20 was not observed by LC/MS in the control 
fermentation. Interestingly, this result implied that apoptolidinone A 5.1 could be 
recognized as the competent substrate for C-27 glycosyltransferases, but not for 
C-9 glycosyltransferase. One possible explaination is that the C-9 6-deoxy-4-O-
methyl-L-glucose sugar is introduced at the seco acid stage and the glycosylation 
of C-27 disaccharide proceeds after the macrolactonization in apoptolidin 
biosynthesis.111,112 
 
  120 
O
Me OH
Me
O O Me
OH
OMe
Me
Me
O
O
MeO
Me
Me
HO
O
OH
Me
OH
Me OMe
O
H
OH
HO
Me
 
Figure 5.2 Structure of apoptolidin A disaccharide 5.20 
 
5.2.3 Bioglycosylation of 6-Normethylapoptolidinone A (a.k.a. 
Apoptolidinone D) 
Once we established evidence that apoptolidinone A could be 
glycosylated by precursor directed biosynthesis, we turned our attention to the 
bioglycosylation of unnatural apoptolidinones. We examined the glycosylation of 
6-normethylapoptolidinone A 5.2 (during the course of our glycosylation studies, 
Wender’s group isolated 6-normethylapoptolidin A as a minor metabolite from 
Nocardiopsis Sp. and named it apoptolidin D) by adding 5.2 in combination with 
cerulenin 5.4 to apoptolidin producer culture. LC/MS analysis of the crude extract 
of this culture showed that the primary product was disaccharide 5.21 and 
accompanied by minor amounts of apoptolidin A 5.3 and isoapoptolidin A (see 
experimental section for HPLC analysis). Apoptolidin D disaccharide 5.21 was 
coarsely purified by flash chromatography and then carefully purified by 
preparative HPLC. The structure of 5.21 was assigned by extensive 1D and 2D 
NMR analysis.  
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Figure 5.3 Structures of apoptolidin disaccharide 5.20 and 5.21 and HPLC/MS 
detection of apoptolidins in fermentation extracts of the apoptolidin producer 
innoculated with 0.2 mM cerulenin 5.4 /day: no aglycone supplmentation (red); 
supplemented with synthetic apoptolidinone A 5.1 (blue ES+ M+NH4/z = 986.6); 
supplemented with apoptolidinone D 5.2 (green ES+ M+NH4/z = 972.6). 
 
 
5.2.4 Bioglycosylation of 12-Oxymethyl Apoptolidinone D  
Following the same method established in the precursor directed 
bioglycosylation of apoptolidinone A 5.1 and apoptolidinone D 5.2, when we fed 
the synthetic oxy-apoptolidinone D 5.17 as another apoptolidin precursor to the 
apoptolidin production medium in the presence of cerulenin 5.4 (0.2 mM per 
day), no new apoptolidin congeners were detected by LC-MS. Analysis of the 
  122 
crude extract of this culture showed the primary product to be oxy-apoptolidinone 
D 5.17 accompanied by minor amounts of apoptolidin A 5.3 and isoapoptolidin A. 
No consumption of oxy-apoptolidinone D 5.17 in the above feeding experiment 
implied that oxy-apoptolidinone D 5.17 was not a qualified substrate for both C-9 
and C-27 glycosyltransferases. One possible explaination is that the extra 
hydyroxyl group at C-12 methyl group may uniquely alter the structure rending 
the aglycone an inefficient substrate for the glycosylation transferase. A second 
explaination is that an undetermined variable of the process may render whole 
cell glycosylation a difficult method of glycosylation. 
 
5.3 Discussion 
In the above biosynthesis of apoptolidin analogues experiments, we have 
demonstrated the glycosylation of apoptolidinone A 5.1 and apoptolidinone D (6-
normethylapoptolidinone A) 5.2 by employing whole cells of the natural 
apoptolidin producer actinomycete Nocardiopsis sp. in the presence of cerulenin 
5.4 as a ketosynthase inhibitor. Such chemical knockdowns of polyketide 
biosynthesis provided rapid methods to access the glycosylation apparatus of a 
biosynthetic system. 
 Since the bioglycosylation on apoptolidinones 5.1 and 5.2 generated only 
C-27 apoptolidin disaccharides 5.20 and 5.21, and no fully glycosylated 
apoptolidins were obtained, we proposed that C-9 glycosylation happens at the 
linear polyketide stage before macrolactonization and C-27 glycosylation 
proceeds after the macrolactonization step in the biosynthetic pathway leading to 
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apoptolidins. It is generally accepted that glycosyltransferases-catalyzed 
bioglycosylation occurs after the cyclic aglycone is released from the PKS in 
polyketide biosynthesis.112 Liu’s group recently reported that linear precursor can 
be recognized by methymycin macrolide glycosyltransferases.111 Since we can 
not exclude the effects resulting from other chemical and physical conditions in 
the fermentation process, the best way to verify our proposed pathway for 
apoptolidin is to study the sequence of the whole genome of apoptolidin 
producing organism. The apoptolidin biosynthetic gene cluster need be identified 
and the corresponding genes for dedicated glycosyltransferases need to be 
verified. This study is currently conducted by Dr. Du in Bachmann’s group.  
 
5.4 Experimental Section:  
 
5.4.1 General Experimental Procedures:  
 Proton nuclear magnetic resonance (1H NMR) spectra and carbon-13 (13C 
NMR) spectra were recorded on a 600 MHz spectrometer at ambient 
temperature. 1H and 13C NMR data are reported as δ values relative to residual 
non-deuterated solvent δ 3.31 ppm from CD3OD. For 13C spectra, chemical shifts 
are reported relative to the δ 49.00 ppm resonance of CD3OD. High-resolution 
mass spectra were obtained at Texas A&M University Mass Spectrometry 
Service Center by Dr. Shane Tichy on an API QSTAR Pulsar.   
 
5.4.2 Apoptolidin Recovery Fermentation:  
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20 microliters of glycerol stock of Nocardiopsis sp. (FU40) was plated onto 
a Petri dish containing Bennett’s medium and incubated upside down at 30 oC for 
3 days. The composition of Bennett’s medium was as follows: yeast extract 1.0 g, 
beef extract 1.0 g, NZ amine A (casein digest) 2.0 g, glucose 10.0 g, agar 20.0 g 
per liter of deionized water. The pH of the medium was adjusted to 7.0 with 0.1 M 
HCl and 0.1 M NaOH. After autoclaving, the solution was cooled to room 
temperature and poured into sterile Petri dishes (30 mL/dish). Uninoculated agar 
plates could be stored in a 2~4 oC refrigerator for about 3 months if not used 
immediately.  
 
5.4.3 Apoptolidin Seed Production Fermentation:  
 The production protocol suggested by Hayakawa and coworkers was 
slightly modified.3 The production fermentation was initiated by aseptically 
inoculating one full loop of mycelia grown on Bennett’s agar plate into a sterile 50 
mL Falcon tube containing 5 mL of seed medium. The seed cultures were 
incubated for 4 days in a rotary shaker (300 rpm) at 30 °C. The composition of 
seed medium was as follows: soluble starch 10.0 g, molasses 10.0 g, peptone 
10.0 g, beef extract 10.0 g per liter of deionized water. The pH of the medium 
was adjusted to 7.2 with 1 M HCl and 1 M NaOH. After autoclaving, the solution 
was cooled to room temperature and distributed into sterile 50 mL Falcon tubes 
(5 mL/tube). 
 
5.4.4 Apoptolidin Production Fermentation:  
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The 5 mL seed culture was transferred into a 250 mL Erlenmeyer flask 
containing 50 mL of production medium. The flask was incubated for 6 days in a 
rotary shaker (300 rpm) at 30 °C. The composition of seed medium was as 
follows: glycerol 20.0 g, molasses 10.0 g, casamino acids 5.0 g, peptone 1.0 g, 
calcium carbonate (CaCO3) 4.0 g per liter of deionized water. The pH of the 
medium was adjusted to 7.2 with 0.1 M HCl and 0.1 M NaOH. The medium 
solution was distributed into 250 Erlenmeyer flasks (50 mL/flask) and autoclaved.  
 
 
Scheme 5.4 Flow chart for apoptolidin fermentation 
 
5.4.5 Feeding Experiments:  
 To determine the appropriate cerulenin concentration, 0.2 mM (4 mg/100 
mL production culture) and 0.1 mM (2 mg/100 mL production culture) were 
dissolved in 1 mL DMSO and administered separately to 100 mL production 
culture through a sterile syringe filter every 24 hours starting at the time of 
inoculation for a total of 5 times. To the control culture 1 mL DMSO (no cerulenin) 
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was added in the same manner daily. For the aglycone feeding studies, 
aglycones were added at the time of inoculation while cerulenin was pulse fed 
daily. Specifically, 7 mg apoptolidinone A was dissolved in 1 mL DMSO and 
added through a sterile syringe filter to a 100 mL production medium at the time 
of inoculation while 0.2 mM amount of cerulenin (4 mg/100 mL culture) was 
dissolved in 0.8 mL DMSO and added through a sterile syringe filter every 24 
hours for 5 days.  To the control culture 1 mL DMSO was added at the time of 
inoculation and 0.8 mL DMSO in the same manner daily.  15 mg apoptolidinone 
D were dissolved in 1 mL DMSO and added through a sterile syringe filter to a 
200 mL production medium at the time of inoculation while 0.2 mM amount of 
cerulenin (4 mg/100 mL culture) was dissolved in 1 mL DMSO and added 
through a sterile syringe filter every 24 hours for 5 days. To the control culture 1 
mL DMSO was added at the time of inoculation and 0.8 mL DMSO in the same 
manner daily.  
 
5.4.6 Apoptolidin A, Isoapoptolidin A and Apoptolidin D Disaccharide 
Purification:  
 The production culture was centrifuged at 3750 rpm for 15 min. The 
supernatant was extracted with ethyl acetate, and the mycelia were stirred with 
acetone for 1 hour and centrifuged at 3750 rpm for 15 minutes. The acetone 
supernatant was concentrated and extracted with ethyl acetate. The ethyl acetate 
extracts were combined, concentrated under reduced pressure at 36 °C after 
dried over Na2SO4. For apoptolidin production purpose, the concentrate was 
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immediately purified by flash chromatography (CH2Cl2:MeOH=15:1). For feeding 
experiment, a 1 mL CH3CN/H2O/NH4OAc solution of the concentrate was 
prepared for LC/MS analysis. 
 
5.4.7 LC/MS: 
 Mass spectrometry was performed using ThermoFinnigan (San Jose, CA) 
TSQ® Quantum triple quadrupole mass spectrometer equipped with a standard 
electrospray ionization source outfitted with a 100-µm I.D. deactivated fused Si 
capillary. Data acquisition and spectral analysis were conducted with XcaliburTM 
Software, version 1.3, from ThermoFinnigan (San Jose, CA), on a Dell Optiplex 
GX240 computer running the Microsoft® Windows 2000 operating system.  The 
source spray head was oriented at an angle of 90° to the ion-transfer tube. 
Nitrogen was used for both the sheath and auxiliary gas.  The sheath and 
auxiliary gases were set to 33 and 14 (arbitrary units) respectively.  Samples 
were introduced by HPLC.  A Surveyor® Autosampler and a Surveyor® MS 
Pump from ThermoFinnigan (San Jose, CA) were used.  The injection volume 
was 10 µL. Crude apoptolidin extracts were separated using a JupiterTM minibore 
5µm C18 column with an isocratic mobile phase consisting of 65% water, 35% 
acetonitrile and 10 mM ammonium acetate.  The flow rate was 0.2 mL/min. The 
mass spectrometer was operated in the positive ion mode and the electrospray 
needle was maintained at 4200V. The ion transfer tube was operated at 35V and 
342 °C. The tube lens voltage was set to 85V. Source CID (offset voltage 
between skimmer and the first ion guide, Q00) was used at 15V.  The mass 
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spectrometer was operated in full scan mode using Quad 1. The mass spectral 
resolution was set to a peak width of 0.70u (full width at half maximum, FWHM). 
Full scan spectra were acquired from m/z 600.0 to 1200.0 over 1.0 second.  Data 
were acquired in profile mode. The electron multiplier gain was set to 3×105. 
Apoptolidin and derivatives formed ammonium adducts and using the XcaliburTM 
Software, data was digitally filtered for the m/z of interest ([M+NH4]+).  
 
5.4.8 HPLC:  
 
Figure 5.4 HPLC chromatograph for apoptolidin A and isoapoptolidin A 
purification 
 
The fraction of apoptolidin A and isoapoptolidin A (Rf=0.23, 
CH2Cl2:MeOH=10:1) from flash chromatography purification was further purified 
by a Varian HPLC system equipped with Prostar 210 pumps and a photodiode 
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array (PDA) detector. Preparative reverse phase HPLC was conducted using a 
30-80% linear gradient (CH3CN/H2O) over 20 min at a flow rate of 21.0 mL/min 
with UV detection at 220 nm using a Varian’s Dynamax column (60 Å 250 x 21.4 
mm, C18, Walnut Creek, CA). The retention time for apoptolidin A is 9 min; for 
isoapoptolidin A is 11.5 min. 
In general, 150~200 mg of apoptolidin A and isoapoptolidin A could be 
isolated from 500 mL fermentation broth as white solids following the above 
fermentation protocol. Apoptolidin B, C, D were not detected by LC-MS analysis. 
The ratio of apoptolidin A and isoapoptolidin A varied depending on the pH of the 
fermentation medium. When CaCO3 was added into each fermentation flask 
separately from other ingredients followed by adjustment of pH of medium 
solution in every single flask, the fermentation will produce majority of apoptolidin 
A with minor isoapoptolidin A. On the other hand, when CaCO3 was distributed 
with other ingredients in the medium solution after pH adjustment, isoapoptolidin 
A was the major isomer. These results were due to the poor solubility of CaCO3. 
The varied amount of CaCO3 in each flasks resulted from distribution process will 
change the pH value of production medium, which affected the isomerization 
between apoptolidin A and isoapoptoldin A and give the observed results. 
Attempts to scale up the fermentation process by increasing the fermentation 
volume in larger fermentation flask resulted in lower fermentation yield. 4 days 
seed production time and 6 days production culture period of above stated scale 
is the optimal condition to give the highest production yield of apoptolidin A and 
isoapoptolidin A. 
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 Purification of apoptolidin D disaccharide 5.21 was carried out on the same 
Varian system equipped with Prostar 210 pumps and a photodiode array (PDA) 
detector. Preparative HPLC was conducted using a Rainin Instrument 
Company’s Dynamax column (300 Å 250 x 10 mm, Woburn, MA) eluted with a 
mobile phase comprised of 10% methanol in dichloromethane at a flow rate of 
3.0 mL/min with UV detection at 254 nm. 
 
 
Figure 5.5 HPLC chromatograph for apoptolidin D disaccharide purification 
 
 
5.4.9 Apotolidin D Disaccharide 5.21 Structure Assignment:  
1H NMR (600 MHz, CD3OD) δ 7.40 (s, 1H), 6.24-6.23 (m, 2H), 5.98 (d, J = 
15.6 Hz, 1H), 5.56 (t, J = 7.8 Hz, 1H), 5.47 (m, 1H), 5.29 (dd, J = 15.6, 8.4 Hz, 
1H), 5.27 (d, J = 11.4 Hz, 1H), 4.92 (d, J = 4.2 Hz, 1H), 4.82 (dd, J = 10.2, 1.8 
Hz, 1H), 3.94 (dd, J = 5.4, 1.8 Hz, 1H), 3.76 (t, J = 9.0 Hz, 1H), 3.71 (dd, J = 
10.8, 4.2 Hz, 1H), 3.65 (dq, J = 9.6, 6.0 Hz, 1H), 3.53 (d, J = 1.8 Hz, 1H), 3.42 
(m, 1H), 3.41 (s, 3H), 3.38 (m, 1H), 3.37 (s, 3H), 3.33 (m, 1H), 3.28 (m, 1H), 3.23 
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(s, 3H), 3.20 (dd, J = 9.2, 6.2 Hz), 3.16 (m, 1H), 2.96 (t, J = 9.3 Hz, 1H), 2.65 (dd, 
J = 9.6, 5.4 Hz, 1H), 2.46 (m, 1H), 2.43 (m, 1H), 2.26 (m, 1H), 2.14 (m, 1H), 2.13 
(s, 3H), 2.07 (s, 3H), 2.05 (m, 1H), 1.97 (m, 1H), 1.91 (m, 1H), 1.79 (m, 1H), 1.71 
(m, 1H), 1.67 (m, 1H), 1.64 (s, 3H), 1.58 (ddd, J = 14.5, 8.5, 2.6 Hz, 1H), 1.42 (m, 
1H), 1.39 (m, 1H), 1.31 (s, 3H), 1.28 (m, 1H), 1.27 (m, 2H), 1.27 (d, J = 6.6 Hz, 
3H), 1.20 (d, J = 6.6 Hz, 3H), 1.18 (d, J = 6.6 Hz, 3H), 1.02 (d, J = 6.6 Hz, 3H), 
0.88 (d, J = 7.2 Hz, 3H); 13C NMR (150 MHz, CD3OD) δ 172.8, 147.7, 146.1, 
143.1, 137.4, 135.0, 133.5, 132.2, 130.9, 126.7, 124.0, 101.9, 101.3, 99.6, 85.9, 
84.0, 82.0, 80.0, 77.2, 77.0, 76.7, 75.4, 74.9, 73.9, 73.2, 73.0, 72.7, 69.4, 67.4, 
61.3, 59.5, 57.3, 46.7, 45.5, 40.8, 38.3, 37.4, 37.2, 36.4, 36.1, 24.8, 22.8, 18.9, 
18.6, 18.3, 15.6, 14.0, 12.2, 12.1, 5.2; ; HRMS (TOF MS) m/z 961.5723 [(M+Li)+ 
calculated for C50H82LiO17: 961.5712]. 
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Table 5.1 1H (600 MHz) and 13C (150 MHz) NMR spectral data of apoptolidin D 
disaccharide 5.21 and apoptolidin D in CD3ODa 
 
 
 Apoptolidin D disaccharide Apoptolidin D  
Apoptolidin D 
disaccharide Apoptolidin D 
Number  δC δH (J=Hz) δC δH Number       δC δH (J=Hz) δC δH 
1 172.8  172.3  2-Me 14.0 2.13 13.9 2.14 
2 124.0  123.7  4-Me 15.6 2.07 15.4 2.08 
3 147.7 7.40 147.2 7.41 8-Me 18.6 1.20 (6.6) 18.6 1.20 
4 133.5  132.9  12-Me 12.2 1.64 12.2 1.65 
5 143.1 6.23 142.5 6.26 22-Me 12.1 1.02 (6.6) 12.0 1.03 
6 126.7 6.24 127.0 6.30 24-Me 5.2 0.88 (7.2) 5.0 0.90 
7 146.1 5.47 144.9 5.48 17-OMe 61.3 3.37 61.1 3.38 
8 46.7 2.26 44.5 2.52 28-OMe 59.5 3.23 59.3 3.24 
9 80.0 3.76 (9.0) 83.3 3.84 1’   96.0 4.81 
10 130.9 5.29 (15.6, 8.4) 127.5 5.21 2’   61.1 3.39 
11 137.4 5.98 (15.6) 140.5 6.08 3’   74.7 3.71 
12 135.0  134.6  4’   87.2 2.72 
13 132.2 5.56 (7.8) 132.7 5.62 5’   67.9 3.74 
14 24.8 2.46 24.4 2.48 6’   17.9 1.26 
  1.97  1.98 4’-OMe   60.9 3.58 
15 36.4 1.42 35.8 1.43 1’’ 99.6 4.92 (4.2) 99.4 4.93 
  1.39  1.33 2’’ 45.5 1.91 45.2 1.93 
16 74.9 3.38 74.1 3.40   1.79  1.80 
17 84.0 2.65 (9.6, 5.4) 83.6 2.66 3’’ 73.0  72.9  
18 38.3 2.14 37.8 2.14 4’’ 85.9 3.33 85.5 3.33 
  1.67  1.66 5’’ 67.4 3.65 (9.6, 6.0) 67.2 3.66 
19 72.7 5.27 (11.4) 72.3 5.28 6’’ 18.9 1.18 (6.6) 18.6 1.21 
20 75.4 3.53 75.1 3.53 3’’-Me 22.8 1.31 22.5 1.32 
21 101.3  100.8  1’’’ 101.9 4.82 (10.2, 
1.8) 
101.7 4.83 
22 36.1 2.05 36.2 2.05 2’’’ 37.4 2.43 37.0 2.43 
23 73.9 3.71 (10.8, 4.2) 74.0 3.72   1.28  1.28 
24 40.8 1.71 40.6 1.71 3’’’ 82.0 3.16 81.7 3.16 
25 69.4 3.93 (5.4, 1.8) 69.2 3.95 4’’’ 77.2 2.96 76.9 2.97 
26 37.2 1.58 (14.5, 8.5, 
2.6) 
37.1 1.59 5’’’ 73.2 3.20 (9.2, 6.2) 73.0 3.20 
  1.27  1.43 6’’’ 18.3 1.27 (6.6) 17.9 1.27 
27 77.0 3.42 76.6 3.42 3’’’-OMe 57.3 3.41 57.1 3.42 
28 76.7 3.28 76.5 3.28      
a 1H NMR for apoptolidin D was referenced from Ref 6 
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CHAPTER VI 
 
BIOLOGICAL EFFECTS OF APOPTOLIDIN A AND CONGENERS 
AGAINST HUMAN LUNG CANCER H292 CELLS AND PROGRESS TOWARDS 
THE SYNTHESIS OF APOPTOLIDIN PROBES FOR TARGET 
IDENTIFICATION  
 
 
6.1 Introduction 
Natural products are a group of small molecules synthesized by 
organisms in response to various environmental stress.113 These small 
molecules natural products are known to exhibit various degrees of biological 
activity.114 Previous studies have demonstrated that many of these natural 
products elicit their biological activity upon binding to various protein targets.113 A 
wide range of technologies, including genetic and proteomic methods, have been 
developed for target identification.115,116,117,118,119 The activity of proteins has also 
been shown to be dependent upon the widespread in vivo post-translational 
regulation of the current physiological states of the cells.115,116 Hence, direct 
identification of protein targets by the studying the binding events between 
natural products and their targets in the whole proteome is desired. Compared to 
the genome, the proteome is a much more complex system which consists of a 
larger set of proteins rather than genes. Classical genetic methods developed 
through the sequencing of the human genome have encountered multiple 
problems such as consistency of experimental results and low throughputs. 
Recently, rapid advances in proteomics techniques, such as 2-D gels, liquid 
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chromatography, mass spectrometry, have facilitated protein seperation and 
analysis. Profound advances in bioinformatics technology have also facilited the 
analysis of large data sets that can be evaluated for the study of whole proteome. 
The strategies involved in protein profiling and identification of target proteins for 
natural products rely primarily on biochemical methods including 
photocrosslinking, radiolabeled ligand binding, and affinity chromatography.117 
Since most of these methods are labor intensive and time consuming, application 
of an integrative technique that incorporates both proteomics and genomics such 
as a three-hybrid system, which includes protein sequencing followed by 
subsequent cloning of the cDNAs coding for in vivo target proteins, is valuable in 
providing optimal efficiency in protein profiling.117,120,121  
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Figure 6.1 Structures of apoptolidin A 6.1, isoapoptolidin A 6.2, apoptolidinone A 
6.3, apoptolidinone D 6.4, and apoptolidin D disaccharide 6.5 
 
Apoptolidin A 6.1 was identified as a specific apoptosis inducing agent by 
screening against phenotype transformed glia cells,3 and screening of this lead 
compound may help to find an effective anticancer agent for the treatment of 
various types of cancer without significant side effects. To develop apoptolidin 
into a drug that can be clinically used, one of the key requirements is to 
understand its action mechanism and identify the cellular target(s). Khosla’s 
action mechanism was developed from pharmaceutical assay analysis and 
compared to compounds of similar structure with known action targets. Results of 
these studies suggest that apoptolidin A is an inhibitor of mitochondria F0F1 
ATPase. 3,12,13 However, results from Wender’s SAR studies using both 
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mitochondria F0F1 ATPase assay and cell assay suggest that there is a more 
relevant cellular target other than mitochondria F0F1 ATPase or a more complex 
action mechanism for apoptolidin.15 In order to understand the action mechanism 
of apoptolidin in more detail, we planned to synthesize an apoptolidin probe to 
identify the protein target(s) using protein-profiling techniques. We investigated 
the cytotoxicity of apoptolidin against several cell lines including human lung 
adenocarcinoma epithelial A549 cells, human lung mucoepidermoid carcinoma 
H292 cells, and human colon carcinoma HCT116 cells in a collaboration with Dr. 
Marnett’s group. Results of this study suggest that human lung cancer H292 cell 
line is the most sensitive towards apoptolidin A treatment. Our study also reveals 
some interesting data with regard to the biological activity associated with 
apoptolidin A 6.1. Cytotoxicity results for synthetic apoptolidinone A 6.3, 
apoptolidinone D 6.4 and biosynthetic apoptolidin D disaccharide 6.5 against 
H292 cells emphasized the importance of the biological role of individual sugar 
units in the structure of apoptolidin A 6.1. These significant results suggest a new 
direction for the synthesis of apoptolidin probes with regard to target 
identification.  
 
6.2 Biological Effects of Apoptolidin A, Isoapoptolidin A on H292 cells 
Apoptolidin A 6.1 has been reported to exhibit anti-proliferative effects and 
cause apoptotic cell death in gene transformed cells and various human cancer 
lines. In our study, H292 cell line was selected and utilized for the evaluation of 
the biological effects of apoptolidin A 6.1 and its congeners.  
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We first examined the effects of apoptolidin A 6.1 on H292 cells with time- 
and concentration-dependent methods, and then assessed its effects on the cell 
viability of H292 with Calcein-AM fluorescence assay. In Wender’s study, 
cytostasis effects that lasted over 2-3 days (ca. 72 h) were reported along with 
GI50 values for apoptolidin A 6.1 (32 nM), apoptolidin B (7 nM), apoptolidin C (24 
nM), and apoptolidin D (110 nM) when screened against H292 (human lung 
carcinoma) cells.5,6,122 In our study, we observed that treatment of H292 lung 
carcinoma cells with apoptolidin A 6.1 resulted in growth arrest for the first two 
days. We also found that extended exposure of H292 cells to apoptolidin A 6.1 
resulted in delayed toxicity, which has not been reported by other groups. The 
effect was drastic, resulting in >95% cell death after 7 days in culture with 
apoptolidin A 6.1 with concentrations as low as 30 nM (Figure 6.1). In contrast, 
treatment of lung carcinoma H292 cells with apoptolidin A 6.1 in a concentration 
as low as 10 nM only resulted in only growth arrest even after maintaining the 
culture for 7 days.  
As apoptolidin A 6.1 can isomerize into its ring expanded isomer 
isoapoptolidin A 6.2 in aqueous solution (cell assay condition). In order to 
determine which isomer is the compound with the noted biological effects, we 
also evaluated the biological activity of isoapoptolidin A 6.2 against H292 cells in 
comparison with apoptolidin A 6.1. When H292 cells were treated with 
isoapoptolidin A 6.2 at 30 nM, all cells succumbed to death in a similar manner 
as was displayed by apoptolidin A 6.1 after 7 days of co-culture. These results 
validated the hypothesis that apoptolidin A 6.1 and isoapoptolidin A 6.2 are 
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equally potent apoptosis inducing agents when added to human lung cancer 
cells. This finding is in agreement with the results initially reported by Wender’s 
group who used E1A transformed glia cells to examine the cytotoxicity of both 
apoptolidin A 6.1 and isoapoptolidin A 6.2.15  
 
  
10 nM 30 nM 
 
Figure 6.2 Cytotoxicity of apoptolidins to H292 cells (cell density: 500/well) 
 
 In general, cancer cells have 200 times higher glycolytic rates than normal 
cells. Decreased supply of glucose results in a slowdown in metablolism resulting 
detrimental biological effects. In view of the cell reponses caused by decreased 
glucose supply during the treatment of apoptolidin A 6.1, H292 cells were 
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cultured in three different medium MEM, DMEM and RPMI, in which MEM 
contained 1000 mg/L D-glucose; DMEM contained 4500 mg/L D-glucose; and 
RPMI contained 2000 mg/L D-glucose. We observed that cells cultured in MEM 
exhibited higher sensitivity to apoptolidin A 6.1 treatment than cells cultured in 
higher glucose supply RPMI medium and cells cultured in DMEM medium. These 
results suggest that glucose deprivation may increase apoptolidin A’s 6.1 
cytotoxicity against H292 cells, which indicates that insufficient glucose supply 
may excert an exogeneous force on mitochondria with regard to ATP production, 
thus triggering cell death by an unknown mechanism. 
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Figure 6.3 Glucose starvation effect on apoptolidin A cytotoxicity  
 
 Cell density is another exogeneous parameter that can influence cells 
function and their interaction with various substances.123 To investigate whether 
an increase in cell density can affect sensitivity of H292 cells to apoptolidin, we 
cultured H292 cells in MEM medium with cell densities of 500/well and 5000/well, 
and examined cell response to apoptolidin A 6.1 and isoapoptolidin A 6.2 at 
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different concentrations. To our surprise, cell death was both observed within 3 
days when being treated with either apoptolidin A 6.1 or isoapoptolidin A 6.2 at 
25 nM. These results suggest that cells may be able to survive via an unkown 
self-protection mechanism (such as autophage) at low cell density, whereas 
under crowded conditions, cells may undergo apoptosis under internal stress.  
 
 
Figure 6.4 Cytotoxicity of apoptolidins to H292 cells (cell density: 5000/well) 
 
 In summary, apoptolidin A 6.1 and isoapoptlidin A 6.2 are equally potent 
cytotoxic agents. Cell death induced by apoptolidin was observed with delayed 
effect, glucose starvation effect and density effect in H292 cell line.  Although cell 
vability has been evaluated for apoptolidin cytotoxicity, further observation in 
physiological changes in response to different exogeneous environmental 
changes will provide more useful information for understanding apoptolidin A 6.1 
cytotoxicity with regard to types of cell death (apoptosis or autophage). As 
cancers are considered to be caused by mutations in the genome of the cells, 
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and genes or their protein products are usually involved in various signaling 
pathways to execute cell death, further studies using genetic and proteomic 
techniques are necessary to provide further information to help determining the 
molecular mechanisms for apoptolidin A induced cell death, delayed effect, 
glucose starvation effect and density effect. 
 
6.3 Biological Role of Sugar Units in Apoptolidin A 
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Figure 6.5 Cytotoxicity of apoptolidin sugar congencers 
 
 The biological role of sugar units in the structure of natural products is 
important to several functions including maintaining structural integrity, serving as 
solubilising auxiliaries, modulating protein functions, providing ligands for specific 
binding events mediating protein targeting, chemical defensing, as well as storing 
  142 
and transfering information or energy.94,124 Apoptolidin A 6.1 features a C-9 
monosaccharide and a C-27 disaccharide, the study on the biological roles of 
individual sugar units in apoptolidin A 6.1 cytotoxicity requires apoptolidin A 
glycoconjugates featuring different sugar moieties. Due to its the instability, 
apoptolidin A 6.1 can only tolerate limited reaction conditions. Even though acidic 
methanolysis of apoptolidin A 6.1 can provide apoptolidin A C-9 glycoconjugate 
6.7, extended hydrolysis under acidic conditions may cause massive 
decomposition. Our group has obtained apoptolidinone A 6.3 and apoptolidinone 
D 6.4 via total synthesis, and apoptolidin D C-27 disaccharide 6.5 via chemical 
and biological hybrid synthesis. Hence, it is possible to determine the importance 
of different sugar moieties in apoptolidin cytotoxicity using H292 cell assays.  
In our study, H292 cells were exposed to different concentrations of 
apoptolidinone A 6.3, apoptolidinone D 6.4 and apoptolidin D disaccharide 6.5 in 
RMPI culture medium. Toxicity effects of these compounds were evaluated 
based on the cell viability of H292 cells via Calcein-AM fluorescence assay. We 
found that the synthetic aglycones apoptolidonone A 6.3 and apoptolidinone D 
6.4 were inactive in this cell assay, inhibiting neither cell growth nor viability at 
the concentrations tested (EC50>100 µM). Apoptolidin D disaccharide 6.5 
inhibited cell growth in the submicromolar range (EC50=200 nM), showing less 
than one order loss of activity relative to apoptolidin A (Sulikowski group: 
EC50=30 nM in H292 cell assay) and similar potency relative to apoptolidin D 
(Wender group: EC50=110 nM in H292 assay). Notably, the observed significant 
recovery of cytotoxicity in the incorporation of the C-27 disaccharide 6.5 is 
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consistant with earlier indications of the biological significance of this sugar 
residue.14,19,21 In the previous studies by both Nicolaou and Koert groups, 
apoptolidin A C-9 monosugar glycoconjugate 6.7 cytotoxicity (Koert group: 
LC50=3 µM in MATU Breast Cancer Cells; Nicolaou group: LC50=20 µM in Human 
Ovarian Carcinoma) decreased by 1000 fold relative to apoptolidin A 6.1 (Koert 
group: LC50=2 nM in MATU Breast Cancer Cells; Nicolaou group: LC50=240 nM 
in Human Ovarian Carcinoma).19,21 This result indicated that the biological role of 
C-27 disaccharide is more crucial than C-9 monosaccharide, and the C-27 
disaccharide may mediate or interfere with an unknown specific target 
recognition event in the signaling pathway of apoptolidin-induced apoptosis. 
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Figure 6.6 Cytotoxicity of apoptolidinones to H292 cells 
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Figure 6.7  Cytotoxicity of apoptolidin D O-27 disaccharide to H292 cells 
 
 
Similar biological role of sugar moieties in apoptolidin was reflected in 
another structurely similar 20-membered polyketide natural product, ammocidin 
A 6.8.125 Ammocidin A 6.8 was isolated from the culture broth of a soil bacteria 
Saccharothrix sp. AJ9571 in 2001 by Hayakawa and co-workers, the same group 
who discovered apoptolidin A 6.1.126 They reported that ammocidin A 6.8 could 
induce apoptosis in Ras dependent Ba/F3-V12 transformed hematopoietic cells 
with an IC50 of 66 ng/mL.126 Even though the stereochemistry of ammocidin A 6.8 
was not completely assigned, ammocidin A 6.8 shared many structural 
similarities with apoptolidin A 6.1.127 Specifically, both ammocidin A 6.8 and 
apoptolidin A 6.1 feature a 20 membered macrolactone, a pyran ring, a 
monosaccharide on C-9 position and a disccharide. The disccharide in 
apoptolidin A 6.1 resides at C-27, while in ammocidin A 6.8, the disaccharide 
resides at C-24 on the pyran ring.  Recently, the Hayakawa group isolated three 
minor ammocidin congeners including ammocidin B-D 6.9-6.11 from the culture 
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broth of ammocidin A-producing strain Saccharothrix sp. AJ9571.125 Comparing 
to ammocidin A 6.8, ammocidin B 6.9 features an extra methyl group at C-3’’ 
position of C-24 disaccharide, ammocidin C 6.10 lacks a hydroxyl group at C-16 
postion and features a monosaccharide instead of a disaccharide at C-24 
position, ammodicin D 6.11 lacks a disaccharide at C-24 position.  Evaluation of 
the biological effects of these ammocidins 6.8-6.11 against A549 human lung 
carcinoma cells, MCF-7 human breast carcinoma cells and HCT116 human 
colon carcinoma cells revealed that both ammocidin C 6.10 and ammocidin D 
6.11 without O-24 disaccharide lost significant cytotoxicity against all above 
cancer cell lines (Table 6.1).125  
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Figure 6.8 Structures of Ammocidin A-D and apoptolidin A 
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 Table 6.1 Antiproliferative activities of ammocidins 
 
A549 (IC50 (µM)) MCF-7 (IC50 (µM)) HCT116(IC50 (µM))
Ammocidin A
Ammodicin B
Ammocidin C
Ammocidin D
0.058 0.14 0.11
0.073 0.10 0.38
2.1 1.8 8.4
6.4 5.0 23
 
 
 
Although the exact cellular action mechanism is still unknown, the 
important role of disaccharides displayed in both apoptolidin A 6.1 and 
ammocidin A 6.8 cytotoxicity has suggested that disaccharide is a crucial 
structural feature for their anti-tumor activity.  This result is an important basis for 
future design of apoptolidin probes to study both the action mechanism and 
structure optimization to improve desired biological effects. 
 
6.4 Apoptolidin Probe Design and Future Directions 
  In order to identify the cellular target of apoptolidin A, Wender’s group 
synthesized several biotinylated photoaffinity apoptolidin probes (See details in 
Chapter III).58 Since apoptolidin A is not stable under photo irradiation conditions, 
the reactive species generated from irradiation with specific wavelength (λ = 254 
nm) result in extensive and apoptolidin independent lableling of proteins in cell 
lysate. This finding suggests that apoptolidin photoaffinity conjugates are not 
suitable for elucidation of the specific protein binding in apoptolidin biological 
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activity.58 There are two contributors to the success of target identification using 
an affinity chromatography: strong affinity in natural product-protein interaction 
and high abundance of the target protein(s).118 Considering the trienoate moiety 
in apoptolidin A may act as a Michael receptor to covalently bind to the target 
protein with sufficient strength, fluorescent tag labeled apoptolidin and a three-
hybrid system of apoptolidin may be used for target identification. 
Several factors need to be taken into consideration when designing a 
apoptolidin probe.128,129,130 First, the tag should have no effect or minimal effect 
on apoptolidin’s biological activity (i.e. apoptosis). Second, the linker that 
connects the tag and apoptolidin, should be stable enough to tolerate the assay 
conditions. Third, the tag should be readily available either commercially or by 
simple chemical synthesis. Fourth, the tag should be readily conjugated to 
apoptolidin under mild reaction conditions.  
To minimize the effects on apoptolidin biological activity, choosing a right 
site for tag attachment is very important. Based on previous SAR studies 
conducted by several groups,14,15,19 we assumed that all sugar moieties in 
apoptolidin A are equally important for target recognition. Therefore, initial 
experiments were designed to incorporate a rhodamine based fluorescent tag at 
the C-12 methyl group of apopotlidin as shown in Scheme 6.1. This strategy 
required functionalization of the methyl group at C-12 position of apoptolidin with 
a hydroxyl functionality, oxy-apoptolidin 6.13. Although apoptolidin A 6.1 can be 
isolated from fermentation broth of Nocardiopsis sp. in moderate yield, due to the 
instability of apoptolidin, modification of its structure by chemical method, 
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especially on the macrolide core structure, was thought to be difficult.  Therefore, 
oxy-apoptolidinone D 6.14 were synthesized based on our previous successful 
experience in the total synthesis of apoptolidinone A and relied on precusor 
directed bioglycosylation using apoptolidin producer (Nocardiopsis sp.) to attach 
the sugars to oxy-aglycone 6.14 and prepare oxy-apoptolidin 6.13. As described 
in Chapter V, installation of sugar units using biological method was not 
suceeded, which led us to seek an alternative method to synthesize apoptolidin 
probe. 
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Scheme 6.1 Initial apoptolidin probe design 
 
In the bioglycosylation experiments, we found that the fermentation yield 
of apoptolidin A 6.1 could be increased significantly from 110 mg/L (as reported 
by Seto’s goup) to 250-300 mg/L by scaling down the fermentation volume to 50 
mL in 250 mL erlenmeyer flask and elongating the time of production 
fermentation from 5 days to 6 day (See Chapter V for details). Therefore, 
attention was turned to developing apoptolidin probes from natural apoptolidin A 
6.1 via semi-synthesis. 
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Scheme 6.2 Synthesis of apoptolidin derivatives 6.16, 6.17 and 6.18 
 
 In Wender’s SAR study, a series of hydroxyl group derivatives were 
synthesized from apoptolidin A.57 Their work demonstrated that C-2’ alcohol is 
the most reactive among eight hydroxyl groups in apoptolidin A. Based on this 
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finding, we decided to incorporate a fluorescent tag or a hybrid system at the C-2’ 
position of apoptolidin A 6.1 with the hope that the tag attachment at this postion 
would not interfere with the binding to the cellular target. Towards this goal, 
apoptolidin derivative 6.16 was synthesized via esterification of apoptolidin A 6.1 
with azido acid 6.15 in the presence of PyBrop, Hunig’s base, and DMAP. Azido 
acid 6.15 was prepared from methyl 5-bromopentanoate in two steps.131 
Apoptolidin derivative 6.17 was synthesized via esterification of apoptolidin A 6.1 
with glutaric anhydride and catalytic amount of DMAP in dichloromethane. 
Further methylation of apoptolidin derivative 6.17 with trimethylsilyldiazomethane 
provided apoptolidin derivative 6.18. From the HMBC spectrum of 6.18, strong 
correlation between H-2’ and C-29 was observed. Abeit with NMR analysis of 
HSQC, COSY, 1H and 13C spectra, the position of esterification was confirmed at 
C-2’ position. The terminal carboxylic acid functionality in 6.17 and terminal azide 
functionality in 6.16 could be further derivatized and conjugated with pre-defined 
tags.  
At this stage, the cytotoxicity of apoptolidin derivative 6.18 was screened 
against H292 cell line. The results showed that 6.18 (EC50=125 nM) retained 
most of the cytotoxicity of apoptolidin A (EC50=25 nM) in H292 cells, which 
indicated that modification at C-2’ position did not block the binding with target 
protein(s). Since modification on C-2’ position did not affect apoptolidin 
cytotoxicity significantly, we then tried to construct apoptolidin probes with tags 
attached on C-2’ postion. Apoptolidin fluorescent probe 6.19 and MTX probe 6.20 
are promising options for further investigation. 
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Figure 6.9 Cytotoxicity of apoptolidin derivative 6.18 in H292 cells 
 
 Because of the high absorption and emission, rhodamine dyes have been 
successfully used for imaging of living cells and live animals.132 Thus, we 
anticipated that 5-carboxy-X-rhodamine apoptolidin conjugate 6.19 would reveal 
the cellular location of apoptolidin. Three-hybrid systems were recently 
developed for efficient identification of interactions between small molecules and 
protein receptors.120,121 The MTX (methotrexate) three-hybrid system has been 
proven to be a powerful tool for target identification.133,134,135,136 There are three 
compotents in the three-hybrid system including a DNA-binding domain fused to 
a ligand-binding domain (i.e. DHFR), a ligand molecule (i. e. MTX) linked to a 
small molecule (i.e. natural products), and a transcriptional activation domain 
fused to a protein from a cDNA library. The interaction between small molecule 
and protein target(s) results in the formation of a trimeric complex, which can 
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activate the expression of reporter gene(s). Taking advantage the efficiency of 
MTX three-hybrid system in target identification, a MTX-apoptolidin dimerizer 
6.20 will be synthesized. 
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Figure 6.10 Structures of apoptolidin probes 6.19 and 6.20  
 
6.5 Summary 
 Apoptolidin A can selectively induce apoptosis in E1A transformed glia 
cells with minimal effects on normal glia cells. This distinguished feature makes 
apoptolidin A a promising lead for the development of new anticancer agents. In 
order to understand the action mechanism of apoptolidin A and identify its protein 
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target, the synthesis of an effective apoptolidin probe was explored. In this 
progress, 3 unnatural apoptolidinones including 6-normethyl apoptolidinone A, 
2,6-dinormethyl apoptolidinone A and oxy-apoptolidinone D were synthesized via 
modifying the synthetic routes for several small building fragments based on our 
convergent synthetic strategy developed for the total synthesis of apoptolidinone 
A in 2004. Since apoptolidinones without sugar units displayed no cytotoxity, 
precursor directed bioglycosylation was employed for the installation of sugar 
units. In this biotransformation process, we successfully purifed and identified a 
new partially glycosylated apoptolidin congener, apoptolidin D C-27 disaccharide, 
which is only 10 fold less active than apoptolidin A.  However, oxy-apoptolidinone 
D, featured a hydroxyl group at C-12 methyl position, was not a competitive 
substrate for this bioglycosylation. The C-12 hydroxyl group in oxy-
apoptolidinone D was initially designed as an attachment point of a fluorescent or 
affinity reagent to synthesize a biological probe of apoptolidin. In the 
bioglycosylation study, we found that the production yield of apoptolidin A could 
be significantly increased by 2 to 3 folds by decreasing the fermentation volume 
and elongating the fermentation time. As SAR studies of sugars of apoptolidin A 
revealed that the C-9 monosaccharide was not important to apoptolidin 
cytotoxicity, and esterification at C-2’ hydroxyl group was proven to have minimal 
effects on apoptolidin cytotoxicity, future direction in the construction of an 
apoptolidin probe will concentrate on the attachment of a fluorescent or affinity 
reagent on C-2’ position. 
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6.6 Experimental Section 
General Procedures: Unless indicated, all commercial reagents were used as 
received without further purification. All reactions were carried out under a 
nitrogen or argon atmosphere using dry glassware that had been flame-dried 
under a stream of nitrogen, unless otherwise noted. All solvents were purified 
prior to use. Dichloromethane was distilled from calcium hydride. Reactions were 
monitored by thin-layer chromatography (TLC) using 0.25-mm E. Merck 
precoated silica gel plates. Visualization was accomplished with UV light (λ = 254 
nm) and aqueous anisaldehyde stain or KMnO4 followed by charring on a silica 
gel 60 (particle size 230-400 hotplate. Flash chromatography was performed with 
the indicated solvents using mesh) with the indicated solvent. An automated 
chromatography system was also employed. Chromatography methods were 
created based on Rf values. Yields refer to chromatographically and 
spectroscopically pure compounds unless otherwise stated. Melting points are 
uncorrected unless otherwise noted. 
1
H and 
13
C NMR data are reported as δ 
values relative to residual non-deuterated solvent δ 3.31 ppm from CH3OD.  For 
13C spectra, chemical shifts are reported relative to the δ 49.0 ppm resonance of 
CD3OD. High-resolution mass spectra were conducted at the Department of 
Chemistry and Biochemistry, University of Notre Dame on a JEOL AX505HA or 
JEOL JMS-GCmate mass spectrometer. Infrared (IR) spectra were recorded as 
thin films or solutions in the indicated solvent. 
 
  155 
Me
Me
O
O
MeO
OHMe
Me
O
O
O
HO
OMe
Me
HO
O
OH
Me
OH
Me OMe
O
O
Me
OH
Me
O
O
Me
HO
MeO
H
Me
ON3
6.16  
 
Azidoapoptolidin A 6.16: To a solution of azido acid 6.15 (50 mg, 44.30 µmol) 
in dichloromethane (8.8 mL) was added diisopropylethylamine (77 µL, 443.0 
µmol) and PyBroP (61.9 mg, 132.9 µmol) at room temperature. The resulted 
solution was stirred for 10 min at room temperature and then transferred to a 
solution of 6.1 (19 mg, 132.9 µmol) and DMAP (3.78 mg, 31.0 µmol) in 
dichloromethane (1.5 mL) in a separate flask. After being stirred for 1 hour at 
room temperature, the reaction mixture was poured into aqueous 5% HCl (4 mL), 
and extracted with dichloromethane (3 X 10 mL). The organic fractions were 
washed with saturated aqueous NaHCO3 (1 X 10 mL) and further washed with 
brine (1 X 10 mL). The organic layer was dried (Na2SO4), filtered and 
concentrated in vacuo. The residue was purified by Biotage chromatography 
(2%-18% methanol in dichloromethane) to afford azidoapoptolidin A 6.16 (28.4 
mg, 52%) as a white solid: IR (neat) 3408, 2931, 2098, 1736, 1666, 1387, 1258, 
1079, 846; 1H NMR (500 MHz, CD3OD): δ 7.38 (s, 1H), 6.19 (s, 1H), 6.14 (d, J = 
16.0 Hz, 1H), 5.65 (t, J = 7.5 Hz, 1H), 5.29 (dt, J = 11.0, 0.0 Hz, 1H), 5.21 (d, J = 
10.5 Hz, 1H), 5.05 (dd, J = 16.0, 9.0 Hz, 1H), 4.98 (d, J = 4.0 Hz, 1H), 4.94 (d, J 
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= 4.5 Hz, 1H), 4.83 (dd, J = 10.0, 1.5 Hz, 1H), 4.55 (dd, J = 10.0, 4.0 Hz, 1H), 
3.95-3.93 (m, 1H), 3.92-3.74 (m, 3H), 3.71 (dd, J = 11.5, 5.0 Hz, 1H), 3.67 (dd, J 
= 9.5, 6.0 Hz, 1H), 3.60 (s, 3H), 3.58 (d, J = 3.5 Hz, 1H), 3.48-3.44 (m, 1H), 3.42 
(s, 3H), 3.42-3.38 (m, 1H), 3.36 (s, 3H), 3.34-3.32 (m, 3H), 3.27 (s, 3H), 3.24-
3.15 (m, 2H), 2.97 (t, J = 9.0 Hz, 1H), 2.81 (t, J = 9.0 Hz, 1H), 2.71 (dd, J = 9.5, 
4.5 Hz, 1H), 2.68-2.64 (m, 1H), 2.47-2.39 (m, 4H), 2.19 (s, 3H), 2.11 (s, 3H), 
2.10-2.01 (m, 3H), 1.95 (s, 3H), 1.94-1.87 (m, 1H), 1.82-1.63 (m, 8H), 1.65 (s, 
3H), 1.63-1.55 (m, 2H), 1.54-1.43 (m, 2H), 1.32 (s, 3H), 1.30-1.27 (m, 1H), 1.28 
(d, J = 6.0 Hz, 3H), 1.27 (d, J = 6.0 Hz, 3H), 1.21 (d, J = 6.5 Hz, 3H), 1.13 (d, J = 
6.5 Hz, 3H), 1.02 (d, J = 6.5 Hz, 3H), 0.89 (d, J = 7.0 Hz, 3H). 
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Carboxylic Acid 6.17: To a solution of apoptolidin A 6.1 (50 mg, 44.70 µmol) in 
dichloromethane (8.8 mL) was added glutaric anhydride (15.1 mg, 132.9 µmol) 
and DMAP (5.9 mg, 48.73 µmol) at room temperature. The resulted solution was 
continuously stirred for 48 hours at room temperature and then concentrated in 
vacuo. The residue was purified by Biotage chromatography (5%-25% methanol 
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in dichloromethane) to afford carboxylic acid 6.17 (20.7 mg, 37%) as a white 
solid: 1H NMR (400 MHz, CD3OD): δ 7.38 (s, 1H), 6.19 (s, 1H), 6.14 (d, J = 16.0 
Hz, 1H), 5.65 (t, J = 8.0 Hz, 1H), 5.32 (dt, J = 11.4, 0.0 Hz, 1H), 5.21 (d, J = 8.0 
Hz, 1H), 5.06 (dd, J = 16.0, 8.0 Hz, 1H), 4.99 (d, J = 4.0 Hz, 1H), 4.94 (d, J = 4.0 
Hz, 1H), 4.83-4.82 (m, 1H), 4.55 (dd, J = 12.0, 4.0 Hz, 1H), 3.95-3.92 (m, 1H), 
3.92 (dd, J = 8.0, 0 Hz, 1H), 3.82 (dd, J = 8.0, 0 Hz, 1H), 3.80-3.63 (m, 3H), 3.60 
(s, 3H), 3.59 (d, J = 4.0 Hz, 1H), 3.48-3.44 (m, 1H), 3.42 (s, 3H), 3.42-3.38 (m, 
1H), 3.36 (s, 3H), 3.34-3.32 (m, 3H), 3.27 (s, 3H), 3.22-3.15 (m, 2H), 2.97 (t, J = 
8.0 Hz, 1H), 2.82 (t, J = 8.0 Hz, 1H), 2.71 (dd, J = 8.0, 4.0 Hz, 1H), 2.70-2.64 (m, 
1H), 2.47-2.39 (m, 5H), 2.39-2.33 (m, 1H), 2.35 (t, J = 8.0 Hz, 2H), 2.18 (s, 3H), 
2.10 (s, 3H), 2.10-2.01 (m, 3H), 1.94 (s, 3H), 1.94-1.87 (m, 1H), 1.82-1.67 (m, 
3H), 1.65 (s, 3H), 1.62-1.55 (m, 2H), 1.54-1.45 (m, 2H), 1.32 (s, 3H), 1.30-1.27 
(m, 1H), 1.28 (d, J = 6.0 Hz, 3H), 1.27 (d, J = 6.0 Hz, 3H), 1.22 (d, J = 4.0 Hz, 
3H), 1.13 (d, J = 4.0 Hz, 3H), 1.02 (d, J = 8.0 Hz, 3H), 0.89 (d, J = 8.0 Hz, 3H); 
13C NMR (150 MHz, CD3OD) δ 175.5, 174.5, 172.7, 172.7, 149.3, 147.0, 142.7, 
141.4, 134.6, 133.8, 133.7, 133.1, 125.5, 123.8, 101.9, 101.3, 99.5, 93.6, 87.3, 
85.9, 84.4, 83.9, 82.0, 77.1, 76.9, 76.8, 75.4, 75.2, 74.6, 73.9, 73.2, 73.0, 72.4, 
72.2, 69.4, 68.2, 67.4, 61.3, 61.2, 59.5, 57.3, 52.0, 45.5, 40.6, 39.1, 38.4, 37.2, 
36.4, 34.4, 34.1, 24.6, 22.8, 22.1, 18.9, 18.3, 18.2, 18.1, 17.9, 16.5, 14.5, 12.2, 
12.1, 5.2. 
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Methyl Ester 6.18: To a solution of apoptolidin A 6.1 (15 mg, 13.29 µmol) in 
dichloromethane (2.5 mL) was added glutaric anhydride (3.1 mg, 25.58 µmol) 
and DMAP (1.7 mg, 13.29 µmol) at room temperature. After the resulted solution 
was stirred for 48 hours at room temperature, 2M trimethylsilyldiazomethane in 
diethyl ether (13 µL, 25.58 µmol) was added. The reaction mixture was stirred for 
another 2 hours and then quenched with H2O, extracted with dichloromethane (3 
X 4 mL). The organic layer was dried (Na2SO4), filtered and concentrated in 
vacuo. The residue was purified by flash chromatography 
(dichloromethane/methanol 10:1) to afford methyl ester 6.18 (4.5 mg, 36% over 2 
steps) as a white solid: IR (neat) 3428, 2931, 1738, 1668, 1385, 1252, 1102, 
1066, 1008; 1H NMR (600 MHz, CD3OD): δ 7.38 (s, 1H), 6.19 (s, 1H), 6.14 (d, J = 
15.6 Hz, 1H), 5.65 (t, J = 7.8 Hz, 1H), 5.25 (dt, J = 11.4, 0.0 Hz, 1H), 5.21 (d, J = 
9.6 Hz, 1H), 5.06 (dd, J = 15.6, 9.0 Hz, 1H), 4.99 (d, J = 4.2 Hz, 1H), 4.94 (d, J = 
4.2 Hz, 1H), 4.83 (dd, J = 9.6, 1.8 Hz, 1H), 4.55 (dd, J = 10.2, 3.6 Hz, 1H), 3.95 
(ddd, J = 8.4, 4.2, 2.4 Hz, 1H), 3.92-3.89 (m, 1H), 3.90 (dd, J = 9.0, 0 Hz, 1H), 
3.83 (dd, J = 8.4 Hz, 1H), 3.78-3.74 (m, 1H), 3.76 (dd, J = 9.6, 6.6 Hz, 1H), 3.71 
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(dd, J = 10.8, 4.8 Hz, 1H), 3.66 (s, 3H), 3.60 (s, 3H), 3.58 (d, J = 3.6 Hz, 1H), 
3.55-3.53 (m, 1H), 3.42 (s, 3H), 3.42-3.39 (m, 1H), 3.36 (s, 3H), 3.34-3.32 (m, 
3H), 3.27 (s, 3H), 3.22-3.15 (m, 2H), 2.97 (t, J = 9.0 Hz, 1H), 2.81 (t, J = 9.0 Hz, 
1H), 2.71 (dd, J = 9.6, 4.8 Hz, 1H), 2.68-2.64 (m, 1H), 2.46-2.37 (m, 8H), 2.19 (s, 
3H), 2.10 (s, 3H), 2.10-2.03 (m, 3H), 1.94 (s, 3H), 1.94-1.87 (m, 1H), 1.82-1.67 
(m, 3H), 1.65 (s, 3H), 1.62-1.55 (m, 2H), 1.54-1.45 (m, 2H), 1.32 (s, 3H), 1.30-
1.27 (m, 1H), 1.28 (d, J = 6.0 Hz, 3H), 1.27 (d, J = 6.0 Hz, 3H), 1.22 (d, J = 6.0 
Hz, 3H), 1.13 (d, J = 6.6 Hz, 3H), 1.02 (d, J = 7.2 Hz, 3H), 0.89 (d, J = 7.2 Hz, 
3H); 13C NMR (150 MHz, CD3OD) δ 175.0, 174.2, 172.7, 149.3, 147.0, 142.7, 
141.4, 134.6, 133.8, 133.7, 133.1, 125.5, 123.8, 101.9, 101.3, 99.5, 93.5, 87.4, 
85.9, 84.3, 83.9, 82.0, 77.1, 76.9, 76.8, 75.4, 75.2, 74.6, 73.9, 73.2, 73.0, 72.4, 
72.3, 69.4, 68.2, 67.4, 61.3, 61.2, 59.5, 57.3, 52.1, 52.0, 45.5, 40.6, 39.1, 38.4, 
37.2, 36.4, 34.2, 34.0, 33.8, 24.6, 22.8, 21.3, 18.9, 18.3, 18.2, 18.1, 17.9, 16.5, 
14.5, 12.2, 12.1, 5.2.  
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Table 6.2 NMR spectroscopic data for apoptolidin A congeners in CD3ODa 
Apop A 6.16 6.17 6.18  
δH δH, (J in Hz) δH, (J in Hz) δH, (J in Hz) 
3 7.41 s, 7.38 s, 7.38 s, 7.38 
5 6.23 s, 6.19 s, 6.19 s, 6.19 
7 5.27 d, 5.21 (10.5) d, 5.21 (8.0) d, 5.21 (9.6) 
8 2.79 m, 2.68-2.64 m, 2.70-2.64 m, 2.68-2.64 
9 3.87 m, 3.86-3.81 m, 3.92-3.89 dd, 3.83 (8.4, 0) 
10 5.26 dd, 5.05 (16.0, 9.0) dd, 5.06 (16.0, 8.0) dd, 5.06 (15.6, 9.0) 
11 6.21 d, 6.14 (16.0) d, 6.14 (16.0) d, 6.14 (15.6) 
13 5.71 t, 5.65 (7.5) t, 5.65 (8.0) t, 5.65 (7.8) 
14 2.50,2.09 m, 2.47-2.41, 2.10-2.01 m, 2.47-2.40, 2.10-2.06 m, 2.47-2.40, 2.10-2.06 
15 1.52,1.44 m, 1.63-1.55, 1.48-1.43 m, 1.61-1.54, 1.51-1.41 m, 1.61-1.54, 1.51-1.41 
16 3.47 m, 3.48-3.40 m, 3.42-3.39 m, 3.42-3.39 
17 2.75 dd, 2.71 (9.5, 4.5) dd, 2.71 (8.0, 4.0)  dd, 2.71 (9.6, 4.8)  
18 2.20,1.78 m, 2.12-2.03, 1.82-1.78 m, 2.06-2.03, 1.82-1.78 m, 2.06-2.03, 1.82-1.78 
19 5.32 dt, 5.29 (11.0, 0) dt, 5.32 (12.0, 0) dt, 5.25 (11.4, 0) 
20 3.57 d, 3.58 (3.5) d, 3.59 (4.0) d, 3.58 (3.6) 
22 2.08 m, 2.71-2.01 m, 2.07-2.05 m, 2.07-2.05 
23 3.76 m, 3.80-3.75  m, 3.78-3.74 m, 3.78-3.74 
24 1.76 m, 1.75-1.69 m, 1.75-1.73 m, 1.75-1.73 
25 3.99 m, 3.95-3.93 m, 3.95-3.92 ddd, 3.95 (8.4, 4.2, 2.4) 
26 1.62,1.49 m, 1.67-1.63, 1.54-1.47 m, 1.61-1.54, 1.53-1.51 m, 1.61-1.54, 1.53-1.51 
27 3.48 m, 3.56-3.53 m, 3.48-3.44 m, 3.55-3.53 
28 3.36 m, 3.34-3.31 m, 3.34-3.32  m, 3.34-3.32  
2-Me 2.14 s, 2.11 s, 2.11 s, 2.11 
4-Me 2.21 s, 2.19 s, 2.18 s, 2.19 
6-Me 1.97 s, 1.95 s, 1.94 s, 1.94 
8-Me 1.17 d, 1.13 (6.5) d, 1.13 (4.0) d, 1.13 (6.6) 
12-Me 1.71 s, 1.65 s, 1.65 s, 1.65 
22-Me 1.06 d, 1.02 (6.5) d, 1.02 (8.0) d, 1.02 (7.2) 
24-Me 0.92 d, 0.89 (7.0) d, 0.89 (8.0) d, 0.89 (7.2) 
1’ 4.85 d, 4.98 (4.0) d, 4.99 (4.0) d, 4.99 (4.2) 
2’ 3.44 dd, 4.55 (10.0, 4.0) dd, 4.55 (12.0, 4.0) dd, 4.55 (10.2, 3.6) 
3’ 3.76 m, 3.83 (9.0) t, 3.92 (8.0) dd, 3.91 (9.0, 0) 
4’ 2.76 t, 2.81 (9.0) t, 2.82 (8.0) t, 2.81 (9.0) 
5’ 3.73 dd, 3.67 (9.5, 6.0) m, 3.78-3.74 dd, 3.76 (9.6, 6.6) 
6’ 1.25 d, 1.27 (6.0) d, 1.27 (6.0) d, 1.27 (6.0) 
1’’ 4.97 d, 4.94 (4.5) d, 4.94 (4.0) d, 4.94 (4.2) 
2’’ 1.96,1.84 m, 1.97-1.90, 1.70-1.65 m, 1.95-1.90, 1.77-1.74 m, 1.95-1.90, 1.77-1.74 
4’’ 3.37 m, 3.34-3.31 m, 3.34-3.32 m, 3.34-3.32 
5’’ 3.70 dd, 3.71 (11.5, 5.0) dd, 3.71 (12.0, 4.0) dd, 3.71 (10.8, 4.8) 
6’’ 1.22 d, 1.21 (6.5) d, 1.22 (4.0) d, 1.22 (6.0) 
3’’-Me 1.36 s, 1.32 s, 1.32 s, 1.32 
1’’’ 4.86 dd, 4.83 (10.0, 1.5) m, 4.83-4.82  dd, 4.83 (9.6, 1.8) 
2’’’ 2.47,1.32 m, 2.46-2.42, 1.30-1.26 m, 2.46-2.42, 1.30-1.26 m, 2.46-2.42, 1.30-1.26 
3’’’ 3.21 m, 3.24-3.15 m, 3.22-3.19 m, 3.22-3.19 
4’’’ 3.01 t, 2.97 (9.0) t, 2.97 (8.0) t, 2.97 (9.0) 
5’’’ 3.24 m, 3.24-3.15 m, 3.22-3.19 m, 3.22-3.19 
6’’’ 1.27 d, 1.27 (6.0) d, 1.28 (8.0) d, 1.28 (6.0) 
4’-OMe 3.61 s, 3.60 s, 3.59 s, 3.59 
3’’’-OMe 3.46 s, 3.42 s, 3.42 s, 3.42 
17-OMe 3.40 s, 3.36 s, 3.36 s, 3.36 
28-OMe 3.30 s, 3.27 s, 3.27 s, 3.27 
OMe    s, 3.66 
30-33 CH2  m, 2.46-2.37, 1.76-1.69 m, 2.47-2.43, t, 2.35 (8.0) m, 2.46-2.37  
 
a 1H NMR for congener 6.16 was obtained on 500 MHz NMR spectrometer; 1H NMR for congener 
6.17 was obtained on 400 MHz NMR spectrometer; 1H NMR for congener 6.18 was obtained on 
600 MHz NMR spectrometer; 1H NMR data for apoptolidin A was modified from ref 3. 
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6.7 Materials and Methods for Biological Activity Studies 
 
6.7.1 Synthesis of Apoptolidin Sugar Analogues:  
The synthesis of apoptolidinone A 6.3 and apoptolidinone D 6.4 was 
described in Chapter III and IV. Biosynthesis of apoptolidinone D disaccharide 
6.5 was described in Chapter V. Apoptolidin A 6.1 and isoapoptolidin A 6.2 were 
isolated from fermentation broth of Nocardiopsis sp. as descried in Chapter V. 
Stock solutions were prepared by using DMSO as solvent. It was further diluted 
in DMSO to the desired concentrations for experimental use. 
 
6.7.2 Cell Assay:  
In our study, we used H292 lung carcinoma cells assay, which were 
purchased from ATCC (CRL-1848). H292 cells were cultured at 37 °C, 5% CO2 
in air in a humidified incubator. Generally, H292 cells were maintained in RPMI 
1640 medium supplemented with 10% fetal bovine serum (FBS) and 1% (1:100 
dilution) of antibiotic-antimycotic (Invitrogen, 15240-062) for compounds activity 
screening. MEM and DMEM medium were chose for observation of glucose-
starvation effects and density effect.  
 
6.7.3 Cell Viability Analysis:  
H292 cells were plated at a density of 500/well or 5000/well in 96-well 
plates, and cell viability was measured after 7 or 3 days by adding 2 µM Calcein-
AM, and measuring fluorescence on a Spectramax (Molecular Dynamics) plate 
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reader, λabs = 494; λem = 517. Effective concentration 50 (EC50) values are 
defined as the concentration of compound at which Calcein-AM fluorescence is 
inhibited by 50%. 
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APPENDIX 
SPECTRA RELEVANT TO CHAPTER IV AND CHAPTER V 
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Figure A1a The 500 MHz 1H NMR spectrum of silyl enol ether 4.9 in C6D6 
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Figure A1b The 125 MHz 13C NMR spectrum of silyl enol ether 4.9 in CDCl3 
 166 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A1c The 600 MHz NOESY NMR spectrum of silyl enol ether 4.9 in C6D6 
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Figure A2a The 500 MHz NOESY NMR spectrum of silyl enol ether 4.29 in 
CDCl3 
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Figure A3a The 600 MHz NOESY NMR spectrum of pyran 4.32 in CD3OD 
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Figure A4a The 400 MHz 1H NMR spectrum of carboxylic acid 4.37 in CDCl3 
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Figure A4b The 100 MHz 13C NMR spectrum of carboxylic acid 4.37 in CDCl3 
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Figure A5a  The 600 MHz 1H NMR spectrum of ester 4.43 in C6D6 
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Figure A5b The 150 MHz 13C NMR Spectrum of Ester 4.43 in C6D6 
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Figure A6a The 600 MHz 1H NMR spectrum of alcohol 4.44 in C6D6 
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Figure A6b  The 150 MHz 13C NMR spectrum of alcohol 4.44 in C6D6 
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Figure A7a The 600 MHz 1H NMR spectrum of TES ether 4.45 in C6D6 
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Figure A7b The 150 MHz 13C NMR spectrum of TES ether 4.45 in C6D6 
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Figure A8a The 600 MHz 1H NMR spectrum of vinyl borate 4.46 in C6D6 
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Figure A8b The 150 MHz 13C NMR spectrum of vinyl borate 4.46 in C6D6 
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Figure A9a The 600 MHz 1H NMR spectrum of macrolactone 4.36 in C6D6 
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Figure A9b The 150 MHz 13C NMR spectrum of macrolactone 4.36 in C6D6 
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Figure A10a The 600 MHz 1H NMR spectrum of 2,6 normethyl apoptolidinone A 
4.3 in CD3OD 
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Figure A10b The 150 MHz 13C NMR spectrum of 2,6 normethyl apoptolidinone A 
4.3 in CD3OD 
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Figure A11a The 300 MHz 1H NMR spectrum of vinyl tin 4.53 in C6D6 
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Figure A11b The 75 MHz 13C NMR spectrum of vinyl tin 4.53 in C6D6 
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Figure A12a The 300 MHz 1H NMR spectrum of alcohol 4.54 in C6D6 
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Figure A12b The 75 MHz 13C NMR spectrum of alcohol 4.54 in C6D6 
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Figure A13a The 400 MHz 1H NMR spectrum of alcohol 4.54b in C6D6 
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Figure A13b The 75 MHz 13C NMR spectrum of alcohol 4.54b in C6D6 
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Figure A14a The 400 MHz 1H NMR spectrum of mesylate 4.55 in C6D6 
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Figure A14b The 75 MHz 13C NMR Spectrum of mesylate 4.55 in C6D6 
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Figure A15a The 300 MHz 1H NMR spectrum of bromide 4.56 in C6D6 
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Figure A15b The 75 MHz 13C NMR spectrum of bromide 4.56 in C6D6 
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Figure A16a The 300 MHz 1H NMR spectrum of alcohol 4.57 in C6D6 
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Figure A16b The 75 MHz 13C NMR spectrum of alcohol 4.57 in C6D6 
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Figure A17a The 300 MHz 1H NMR spectrum of bromide 4.48 in C6D6 
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Figure A17b The 75 MHz 13C NMR spectrum of bromide 4.48 in C6D6 
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Figure A18a The 300 MHz 1H NMR spectrum of alcohol 4.58 in C6D6 
S
n
B
u
3
T
B
S
O
O
H
O
M
e
S
S
 198 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A18b The 125 MHz 13C NMR spectrum of alcohol 4.58 in CDCl3 
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Figure A19a The 400 MHz 1H NMR spectrum of vinyl iodide 4.59 in C6D6 
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Figure A19b The 125 MHz 13C NMR spectrum of vinyl iodide 4.59 in C6D6 
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Figure A20a The 400 MHz 1H NMR spectrum of aldehyde 4.60 in C6D6 
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Figure A20b The 125 MHz 13C NMR spectrum of aldehyde 4.60 in C6D6 
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Figure A21a The 400 MHz 1H NMR spectrum of triene 4.61 in CDCl3 
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Figure A21b The 75 MHz 13C NMR spectrum of triene 4.61 in C6D6 
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Figure A22a The 500 MHz 1H NMR spectrum of aldol 4.62 in C6D6 
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Figure A22b The 125 MHz 13C NMR spectrum of aldol 4.62 in C6D6 
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Figure A23a The 300 MHz 1H NMR spectrum of ester 4.63 in C6D6 
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Figure A23b The 125 MHz 13C NMR spectrum of ester 4.63 in C6D6 
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Figure A24a The 500 MHz 1H NMR spectrum of alcohol 4.64 in C6D6 
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Figure A24b The 100 MHz 13C NMR spectrum of alcohol 4.64 in C6D6 
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Figure A25a The 400 MHz 1H NMR spectrum of TES ether 4.65 in C6D6 
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Figure A25b The 75 MHz 13C NMR spectrum of TES ether 4.65 in C6D6 
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Figure A26a The 400 MHz 1H NMR spectrum of vinyl borate 4.66 in C6D6 
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Figure A26b The 75 MHz 13C NMR Spectrum of vinyl borate 4.66 in C6D6 
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Figure A27a The 600 MHz 1H NMR spectrum of macrolactone 4.47 in C6D6 
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Figure A27b The 75 MHz 13C NMR spectrum of macrolactone 4.47 in C6D6 
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Figure A28a The 600 MHz 1H NMR spectrum of oxy-apoptolidinone D 4.4 in 
CD3OD 
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Figure A28b The 150 MHz 13C NMR spectrum of oxy-apoptolidinone D 4.4 in 
CD3OD 
O
H
O
M
e
M
e
H
O
O
H
O
O O
O
H
O
M
e
O
H
H
O
H
H
O
 219 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A29a The 500 MHz 1H NMR spectrum of apoptolidin A congener 6.16 in          
CD3OD 
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Figure A29b The 500 MHz COSY NMR spectrum of apoptolidin A congener 6.16 
in CD3OD 
 221 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A29c The 500 MHz HSQC NMR spectrum of apoptolidin A congener 6.16 
in CD3OD 
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Figure A30a The 400 MHz 1H NMR spectrum of apoptolidin A congener 6.17 in          
CD3OD 
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Figure A30b The 125 MHz 13C NMR spectrum of apoptolidin A congener 6.17 in          
CD3OD 
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Figure A31a The 600 MHz 1H NMR spectrum of apoptolidin A congener 6.18 in          
CD3OD 
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Figure A31b The 125 MHz 1H NMR spectrum of apoptolidin A congener 6.18 in          
CD3OD 
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Figure A31c The 600 MHz COSY NMR spectrum of apoptolidin A congener 6.18 
in CD3OD 
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Figure A31d The 600 MHz HSQC NMR spectrum of apoptolidin A congener 6.18 
in CD3OD 
 228 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A31e The 600 MHz HMBC NMR spectrum of apoptolidin A congener 6.18 
in CD3OD 
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